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ABSTRACT 
 
Cancer cells reprogram their metabolism to supply biosynthetic and 
bioenergetic demands of rapid proliferation. Microenvironmental changes, 
such as hypoxia, further influence tumour metabolism, driving malignancy. 
Recent identification of cancer-associated mutations in succinate 
dehydrogenase (SDH), fumarate hydratase and isocitrate dehydrogenase (IDH) 
have shown that genetic alterations can directly alter tumour cell metabolism, 
and may be required for malignant transformation. Mutations in these 
metabolic enzymes promote tumorigenesis by hijacking the adaptive response 
to hypoxia. Understanding the metabolic vulnerabilities associated with these 
mutations may therefore elicit the design of more selective therapies.  
 
Employing a combination of analytical approaches to study metabolism, the 
research objectives were to characterise metabolic vulnerabilities associated 
with cells mutated in SDHB and IDH1. Results show that cells deficient in SDH 
activity maintain proliferation and viability by increasing dependency on 
pyruvate carboxylase for de novo aspartate synthesis. Mutations in IDH1 have 
a complex role in the metabolic adaptation to hypoxia, partially compromising 
this hypoxic response, yet also demonstrating aspects of pseudohypoxia, such 
as increased proline anabolism. This thesis reveals a metabolic vulnerability 
that could be therapeutically targeted to treat SDH-mutated tumours, and a 
novel redox-sensitive metabolic pathway, exhibited by both pseudohypoxic 
SDH and IDH1 mutated tumours, used to retain metabolic plasticity.  
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Chapter 1 REVIEW OF THE LITERATURE 
 
Introduction to Cancer Metabolism 
 
Cancers are highly complex heterogeneous diseases, conventionally categorised by 
cell type or tissue of origin (Greaves & Maley 2012). Recent advances in technology, 
such as large-scale DNA sequencing (Wong et al. 2011), has further permitted the 
clustering of cancer into molecular subtypes, which vary in terms of treatment and 
prognosis. It is becoming increasingly clear from these studies that not only are 
genomic abnormalities not necessarily confined to cell type, but high levels of 
phenotypic variability are observed among cells within a single tumour population 
(Gerlinger et al. 2012; Marusyk et al. 2012). To help comprehend this complexity, 
certain hallmarks have been proposed as essential for the progression and 
development of cancer (Hanahan & Weinberg 2000). For example, the 
reprogramming of energy metabolism is now recognised as 1 of the 10 hallmarks of 
cancer (Hanahan & Weinberg 2011) and can occur as a direct consequence of 
various tumour suppressors or oncogenes, where it may be selected or required for 
malignant transformation. Tumour metabolism is also influenced by changes in the 
microenvironment, such as the development of hypoxia. Hypoxia is a phenotype 
common to many cancers, which reprograms tumour metabolism, often resulting in a 
more malignant and therapy resistant phenotype (Cairns et al. 2011).  
 
Otto Warburg first observed altered tumour metabolism in the 1920’s (Warburg 1925; 
Warburg 1956b). Unlike most normal differentiated cells that use mitochondrial 
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oxidative phosphorylation to generate much of the ATP required for cellular 
processes, rapidly proliferating tumour cells were found to consume higher rates of 
glucose and secrete most of this carbon as lactate rather than oxidising it completely 
in the mitochondria. This phenotype, described today as the Warburg effect, has 
since been observed across most tumour types and can be clinically imaged using 
18F-deoxyglucose-positron emission tomography (FDG-PET) (Groves et al. 2007). 
Warburg postulated that the increased rates of glucose consumption was a 
consequence of impaired oxidative mitochondrial metabolism, and that this 
mitochondrial dysfunction was a root cause of all cancers (Warburg 1956a). Later 
observations confirmed that this feature was not unique to cancer cells (Hedeskov 
1968; Roos & Loos 1973; Wang et al. 1976; Brand 1985), and indeed defects in 
oxidative metabolism are not universal to all tumours (Moreno-Sánchez et al. 2007), 
although frequently observed (Guaragnella et al. 2014; Gaude & Frezza 2014).  
 
Mutations in tumour suppressors and oncogenes are the driving force behind the 
development of cancer. As changes in metabolism are fundamental to malignant 
phenotypes, it is therefore not surprising that oncogenic mutations also directly (and 
indirectly) alter cellular metabolism. For example, activating mutations in the 
oncogene, phosphoinositol 3-kinase (PI3K), and its downstream effector 
serine/threonine protein kinase B (AKT), directly stimulate glycolysis by increasing 
the expression and translocation of glucose transporters to the plasma membrane 
and activating key glycolytic enzymes such as hexokinase (HK) and 
phosphofructokinase 2 (PFK-2) (Elstrom 2004; Cairns et al. 2011). The transcription 
factor p53 also participates in metabolic control and can, in some contexts, act as a 
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tumour suppressor. For example, p53 decreases glycolytic metabolism through 
activation of TP53-induced glycolysis and apoptosis regulator (TIGAR), which blocks 
PFK-1 (Bensaad et al. 2006). In addition, glutamine uptake and catabolism is 
stimulated by the oncogenic transcription factor v-myc avian myelocytomatosis viral 
oncogene homolog (MYC) through up-regulation of glutamine transporters and 
glutaminase (Wise et al. 2008; Gao et al. 2009). Mutations in tumour suppressors or 
oncogenes rarely occur in isolation, where the combination of mutations results in 
further rewiring of the metabolic network.  
 
Understanding the mechanisms through which specific mutations influence cellular 
metabolism may reveal metabolic dependencies and/or deficiencies that can be 
exploited therapeutically. As most oncogenic mutations lead to similar patterns of 
altered metabolism, targeting the metabolism rather than the oncogene may in some 
contexts be more successful. In the case for oncogenic mutations in V-Ki-ras2 Kisten 
rat sarcoma viral oncogene homolog (KRAS), which are the signature event in the 
progression of ~95% pancreatic ductal adenocarcinoma (PDAC) (Jones et al. 2008; 
Biankin et al. 2012), no effective treatments to target this protein have reached the 
clinic to date, owing to therapeutic escape by unforeseen compensatory 
mechanisms. As mutationally activated KRAS orchestrates a number of metabolic 
changes; such as reprogrammed glutamine metabolism (Son et al. 2013), increased 
autophagy (Fujii et al. 2008; Yang et al. 2011; Guo et al. 2011), and 
macropinocytosis (Commisso et al. 2013), targeting these metabolic pathways may 
therefore provide more promise in PDAC treatments. 
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Recently, oncogenic mutations in metabolic enzymes succinate dehydrogenase 
(SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) have been 
identified. Common to all three genes is that they are either situated directly within 
the mitochondrion (SDH, FH and IDH2) or their metabolic activity directly affects that 
of the mitochondrion (IDH1). Mutations in such central metabolic enzymes are likely 
to require extensive metabolic remodelling for efficient cell proliferation and survival. 
The impact of these oncogenic mutations on tumour metabolism are subject to 
further discussion in this review and supplemental information can be found in 
Appendix A. 
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Cancer Metabolism Supports Anabolism and Cellular Redox 
 
Glucose metabolism 
The significant and preferential production of lactate from glucose in the presence of 
oxygen, known as aerobic glycolysis, is in some respects a less efficient way for 
highly proliferative cells to make ATP compared to oxidative phosphorylation. While 
glycolysis produces 2 moles ATP/mole glucose, oxidative phosphorylation can 
synthesise as much as 38 moles ATP/mole glucose. Although, It has been postulated 
that glycolytic rates occur at high enough rates to exceed ATP production from 
oxidative phosphorylation (Guppy et al. 1993; Warburg 1956b), it has been 
suggested that this increase in glycolysis and subsequent decrease in glucose 
oxidation facilitates accumulation of glycolytic intermediates required for biosynthesis 
(Lunt & Vander Heiden 2011). During replication, the cell must double its cellular 
contents, including nucleotides, proteins, lipids and ATP, to produce two viable 
daughter cells (Tennant et al. 2010). This increase in biomass involves huge 
metabolic investment, where in addition to ATP, synthesis of these macromolecules 
requires carbon and nitrogen (Lunt & Vander Heiden 2011), along with necessary 
reducing equivalents to maintain redox balance (Sullivan et al. 2015) (Figure 1.1). 
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Figure 1.1 Cancer cells reprogram their metabolism support cellular anabolism and 
redox. The metabolic diagram highlights some of the characterised changes in central 
carbon metabolism included in the text to support biomass production and maintenance of 
cellular redox. Key enzymes involved in controlling these pathway activities are shown in red. 
Abbreviations: ACO 1/2, aconitase 1/2;, AcCoA, acetyl CoA; ACLY, ATP citrate lyase; Ala, 
alanine; ALT, alanine aminotransferase; Asp, aspartate; BCAAs, branched chain amino 
acids; Cit, citrate; Cys, cysteine; DHP, dihydroxyphosphate;, F6P, fructose 6-phosphate; 
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Fum, fumarate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; G3P, glycerol 3-
phosphate; GOT2, aspartate aminotransferase; GSH, reduced glutathione; G6P, glucose 6-
phosphate; Glu, glutamate; GLUT, glucose transporter; Gly, glycine; HK, hexokinase; 
IDH1/2/3, isocitrate dehydrogenase 1/2/3; Lac, lactate; LDHA, lactate dehydrogenase A; Mal, 
malate; ME1, malic enzyme 1; MDH, malate dehydrogenase; OAA, oxaloacetate; PC, 
pyruvate carboxylase; PDH, pyruvate dehydrogenase; Pro, proline; Pyr, pyruvate; PHGDH, 
phosphoglycerate dehydrogenase; PSAT, phosphoserine aminotransferasae; PFK2, 
phosphofructokinase 2; R5P, ribose 5-phosphate; Suc, succinate; Ser, serine; SHMT1/2, 
serine hydroxymethyltransferase 1/2; aKG, α-ketoglutarate and aKGDH, α-ketoglutarate 
dehydrogenase. 
	
	
	
Glucose is imported into the cell through a family of plasma membrane transporters 
(GLUT; SLC2A), and is phosphorylated by HK to form glucose 6-phosphate (G6P). 
During glycolysis, G6P is oxidatively split into 3-carbon molecules, releasing ATP and 
culminating in the production of pyruvate. G6P can also be fed into the oxidative arm 
of the pentose phosphate pathway (PPP) to produce reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) for reductive biosynthetic reactions and/or 
protection against oxidative stress, and ribose 5-phosphate (R5P) for nucleotide 
synthesis. R5P is also formed from glycolytic intermediates fructose 6-phopsphate 
(F6P) and glyceraldehyde 3-phosphate (G3P), which are shunted into the non-
oxidative arm of the PPP (Cantor & Sabatini 2012). The lower glycolytic intermediate 
3-phosphoglycerate (3PG) can also be shunted into the serine synthesis pathway 
(SSP), providing carbon for the synthesis of non-essential amino acids (NEAA) serine 
and glycine required for lipid and nucleotide synthesis (Chaneton et al. 2012). 
 
Glucose-derived pyruvate has a large number of potential fates depending on the 
metabolic needs of a cell. A significant proportion of pyruvate is used for the 
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production of lactate by lactate dehydrogenase (LDH), which regenerates oxidised 
nicotinamide dinucleotide (NAD+) from reduced nicotinamide dinucleotide (NADH) 
that can be reused by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to 
maintain glycolytic flux (Le et al. 2010). However, it can also be transaminated to 
produce alanine for protein synthesis. In the mitochondria, pyruvate is oxidised to 
acetyl coenzyme A (CoA) by pyruvate dehydrogenase (PDH), which then condenses 
with oxaloacetate to produce citrate. Citrate supports lipid synthesis on export to the 
cytoplasm and conversion back to acetyl CoA by acetyl CoA citrate lyase (ACLY). 
The activity of pyruvate carboxylase (PC), a mitochondrial enzyme traditionally 
involved in gluconeogenesis, can also support nucleotide synthesis, although this 
anaplerotic reaction does not appear to be universal to all cell types. PC carboxylates 
pyruvate to form oxaloacetate, which can then be transaminated to aspartate and 
exported out of the mitochondria for nucleotide synthesis. Equally, it can condense 
with acetyl CoA to form citrate for lipid synthesis.  
 
Glutamine metabolism 
Cancer cells are also highly dependent on glutamine as a source of carbon and 
nitrogen required to support biosynthesis, energetics and cellular homeostasis to 
ultimately drive tumour growth (Figure 1.1). Glutamine is imported into the cell 
through neutral amino acid transporters, such as alanine/serine/cysteine/threonine 
transporter 2 (ASCT2; SLC1A5) (DeBerardinis & Cheng 2010). In the cytosol, 
imported glutamine can either be used for biosynthesis or exported back out of the 
cell through antiporters, such as the L-type amino acid transporter (LAT1; SLC7A5) 
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(Nicklin et al. 2009), which extrudes glutamine in exchange for import of branched-
chain amino acids (BCAA) such as leucine, required for protein synthesis.  
 
Intracellular glutamine can be converted to glutamate through the loss of an amide 
group by enzymes involved in nucleotide and hexosamine biosynthesis, or through 
the action of glutaminases (GLS). Glutamate is then used either as an amino acid, or 
as an amino donor for the synthesis of nucleotides and NEAAs. The synthesis of 
NEAAs occurs through the activity of transaminases, which catalyse the transfer of 
the glutamate amine group to  α-ketoacids such as pyruvate, 3PG, OAA and 
glutamate γ-semialdehyde, to synthesise alanine, serine, aspartate and ornithine, 
respectively (Wise & Thompson 2010). Serine is a precursor for glycine; ornithine a 
precursor for arginine; and aspartate a precursor for asparagine biosynthesis. 
Glutamate is also essential for the biosynthesis of NEAA proline, although proline 
synthesis occurs in a two-step enzyme-catalysed reduction reaction and does not 
require the transaminase activity. Glutamate additionally has an important 
contribution in the synthesis of the antioxidant reduced glutathione (GSH) - a 
tripeptide produced from cysteine, glutamate and glycine residues, which has a 
pivotal role in maintaining cellular redox by acting as an electron donor to reduce 
reactive oxygen species (ROS). 
 
Glutamate can be converted to α-ketoglutarate (αKG) by both transaminase activity, 
and through the activity of glutamate dehydrogenase (GDH). Glutamine-derived αKG 
can feed into the TCA cycle to produce energy by supporting the function of the 
electron transport chain (ETC). In the absence of sufficient glucose oxidation, this 
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anaplerotic pathway becomes increasingly important for energy production in 
proliferating cells. Glutamine can therefore be oxidised to support the function of the 
electron transport chain (ETC). Within the ETC, electrons derived from NADH and 
reduced flavin adenine dinucleotide (FADH2) are passed through successive 
electronegative acceptors, losing energy in the process that is used to pump protons 
across the inner mitochondrial membrane. The final electron acceptor, oxygen, is 
reduced to water, and the resulting proton gradient is then used to drive the 
phosphorylation of ADP to form ATP through complex V.  
 
In addition to producing ATP, oxidation of glutamine-derived αKG in the TCA cycle 
(along with the activity of transaminases), can supply the cell with aspartate, which 
has a crucial role in purine and pyrimidine biosynthesis to support cell division 
(Sullivan et al. 2015; Birsoy et al. 2015). Glutamine-derived αKG can also fuel lipid 
synthesis, and in certain conditions occurs without using oxidative TCA cycle 
metabolism. Reductive carboxylation of glutamine-derived αKG describes the 
synthesis of citrate for de novo lipogenesis using the reducing potential of NADPH via 
the enzymes IDH1 and 2, and aconitase (ACO) 1 and 2. Reductive carboxylation was 
first described in brown adipocytes (Yoo et al. 2008) and has since been shown to 
occur in hypoxia (Metallo et al. 2011; Wise et al. 2011; Filipp et al. 2012), and in 
conditions where oxidative phosphorylation machinery is defective (Mullen et al. 
2011).  
 
It has been recently recognised that proliferating cells incorporate most of the 
glutamine they use for biomass for building protein and nucleotides (Hosios et al. 
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2016). In some tumour cells, a portion of glutamine-derived malate exits the TCA 
cycle, and through the activity of malic enzyme (ME), produces pyruvate. This is 
unlikely to be an energy-generating process (DeBerardinis et al. 2007; Son et al. 
2013) but used to produce necessary NADPH to support cellular redox and reductive 
biosynthetic reactions. 
 
Non-essential amino acid metabolism 
In addition to changes in glucose and glutamine metabolism, alterations in the 
requirement for, and synthesis of NEAAs is becoming more appreciated in cancer 
metabolism, such as increased biosynthesis of serine from glucose (Locasale 2013; 
Zogg 2014). Serine is a central precursor in folate-mediated one carbon metabolism, 
generating intermediates that support nucleotide and lipid biosynthesis, redox 
homeostasis, and epigenetic regulation. Serine is transported into the cell by one of 
three systems; alanine/serine/cysteine/threonine transporters ASCT1 and ASCT2 
(SLC1A4 and SLC1A5, respectively), the system A transporters SAT1 and SAT2 
(SLC38A1 and SLC38A2, respectively) and neutral amino acid 
alanine/serine/cysteine (ASC) transporter system (El-Hattab 2016).  
 
Phosphoglycerate dehydrogenase (PHGDH), the rate limiting step in serine 
biosynthesis, employs NAD+ as a cofactor to convert 3PG to 3-
phosphohydroxypyruvate (3PHP) and is found to be overexpressed in numerous 
cancers including melanoma, colorectal and breast cancer (Mullarky et al. 2011; 
Yoon et al. 2015; Possemato et al. 2011). Interestingly, PHGDH expression has been 
shown to be up-regulated by MYC (Nilsson et al. 2012). Increased PHGDH activity is 
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often observed with an increase in the mitochondrial serine hydroxymethyltransferase 
(SHMT2). This catabolises serine to glycine, thereby supplying one-carbon units that 
support nucleotide biosynthesis, which yields the production of NAD(P)H, and S-
adenosylmethionine (SAM) pools necessary for epigenetic regulation. SHMT2 is also 
found to be overexpressed in numerous cancers and associated with an adverse 
outcome (Ye et al. 2014; Lee et al. 2014). In some cases, the availability of serine 
itself is limiting for cancer cell proliferation (Maddocks et al. 2012), where use of this 
metabolic pathway has been shown to be regulated by p53 during conditions of 
serine starvation to promote cell-cycle arrest and replenish GSH stores.  
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Hypoxia and HIF biology 
 
Hypoxia inducible transcription factors 
Owing to the rapid proliferation of cancer cells, the huge metabolic demand for 
biomass production in tumours can often occur and even result in challenging 
environments, where the availability of nutrients and oxygen become limiting. Indeed, 
many cancers are shown to exhibit areas of intratumoural low oxygenation (hypoxia), 
and are associated with an increased risk of mortality and metastasis (Vaupel et al. 
2004). Rapid adaptive responses are therefore induced and required for cell survival 
and vascularisation of the tumour mass. 
 
Much of the cellular transcriptional response to hypoxia is thought to be mediated by 
a family of heterodimeric transcription factor complexes known as hypoxia-inducible 
factors (HIFs). These consist of dynamically regulated α subunits (HIF1α, 2α, 3α) and 
constitutively active β subunit (HIF1β/aryl hydrocarbon receptor nuclear translocator 
[ARNT] and ARNT2). In conditions of low oxygen, HIFα subunits stabilise and 
translocate to the nucleus to heterodimerise with the HIFβ subunit. The heterodimer 
binds to a co-activator (p300/CBP [cyclic AMP responsive element-binding (CREB) 
protein]), which de-condenses chromatin to permit the transcription of a number of 
target genes (Jiang et al. 1996; Schodel et al. 2011) involved in angiogenesis, 
metabolic adaptation, migration and survival (Liao & Johnson 2007; Luo & Semenza 
2011; Semenza 2012).  
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The majority of HIF transcriptional responses have been attributed to HIF1α and 
HIF2α, and increased expression of these subunits is associated with a higher risk of 
mortality in many human cancers (Semenza 2010). The structure of HIF1α and 
HIF2α consists of an N-terminal basic helix loop helix (bHLH) domain required for 
DNA binding, a central Per-ARNT-Sim (PAS) domain to facilitate heterodimerisation, 
and a C-terminal regulatory domain, which recruits transcriptional co-regulatory 
proteins (Figure 1.2A). The active HIF heterodimer complex initiates transcription by 
binding to hypoxia-response elements (HREs) containing a conserved 5’-RCGTG-3’ 
core sequence in the promoter or enhancer regions of HIF-regulated genes. HIF is 
thought to regulate hundreds of genes, with over 500 HIF binding sites have been 
identified in the human genome (Schödel et al. 2013).  
 
HIF hydroxylases regulate transcriptional activity 
HIFα subunits 1 and 2 are co-ordinately regulated by a family of αKG dependent non-
haem iron(II)-dioxygenases known as HIF prolyl hydroxylases (PHDs) and factor 
inhibiting HIF (FIH), the activity of which are dependent on the presence of iron and 
ascorbate. Three PHD isozymes exist: PHD 1, 2 and 3, are coded for by the Egl nine 
homologue (EGLN) genes 2, 1 and 3, respectively. PHDs and FIH use one atom of 
molecular oxygen to hydroxylate prolyl and asparaginyl residues, respectively. The 
second atom of oxygen is used in the oxidative decarboxylation of αKG to form 
carbon dioxide and succinate. In the presence of sufficient oxygen, PHDs hydroxylate 
prolyl residues in the C- and N- terminal of the oxygen-dependent degradation 
domain (ODDD) of HIFα (Pro 403/564 HIF1α; Pro 405/531 HIF2α) (Figure 1.3A) 
(Epstein et al. 2001; Bruick 2001). This post-translational modification promotes 
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recognition by the E3 ubiquitin ligase complex containing the von Hippel-Lindau 
(pVHL) tumour suppressor protein, targeting HIFα for polyubiquitylation and 
subsequent proteasomal degradation (Maxwell et al. 2001; Jaakkola et al. 2001). FIH 
hydroxylates an asparaginyl residue in the C-terminal HIFα transactivation domain 
(TAD) (Asn 803 HIF1α; Asn 851 HIF2α), which impairs the interaction with 
coactivator p300 required for full transcriptional activity (Lando 2002; McNeil et al. 
2002), therefore regulating HIF activity rather than stability (Figure 1.3A). PHD2 
(EGLN1) is considered to be the major HIF1α hydroxylase in normoxia, whereas 
PHD3 (EGLN3) and PHD1 (EGLN2) are thought to be the major HIF2α hydroxylases 
(Huang et al. 2002). 
 
The HIF hydroxylases become progressively inactive with a reduction in oxygen 
tension. Although they have a relatively low affinity for oxygen, their Michaelis 
constant (KM) is much higher than the partial pressure of oxygen in tissues, allowing 
cells to adapt to low oxygen conditions before oxygen is completely absent, which 
would otherwise result in cell death (Gnaiger et al. 1998). PHDs and FIH enzymes 
vary in their affinity for oxygen (KM 100-250 µM for PHDs; 90 µM for FIH), where FIH 
appears less sensitive to hypoxia and may remain active at lower oxygen tensions 
(Figure 1.2B) (Koivunen et al. 2004; Ehrismann et al. 2007). This enables differential 
hypoxic gene sets to be activated in response to varying degrees of hypoxia, thus 
fine-tuning the magnitude and repertoire of the hypoxic response (Koivunen et al. 
2004; Dayan et al. 2006).  
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Figure 1.2 Structure and regulation of HIFα. (A) Domain structure of HIF1α and HIF2α 
showing proline and asparagine residues involved in its regulation by prolyl hydroxylase 2 
(PHD2) and factor inducible HIF (FIH). HIFα possesses bHLH and PAS domains that are 
involved in dimerization with HIF1β and DNA binding. HIFα contains N-TAD and C-TAD 
where the N-TAD lies within the ODDD. The stability of HIFα is regulated through the ODDD 
via recognition of the hydroxylation state of the Pro 402 and/or Pro 564 residues on HIF1α, 
and Pro 405 and/or Pro 531 on HIF2α. PHD2 predominately catalyses this hydroxylation on 
HIF1α. Hydroxylation of Asn 803 and Asn 847 on HIF1α and HIF2α, respectively, by FIH 
inhibits activation by preventing binding of transcriptional coactivator p300/CBP.  (B) The two 
TAD domains of HIFα differentially regulate gene expression, depending on gradient of 
oxygen within a solid tumour as PHDs require higher oxygen levels than FIH for activity. 
Adapted from Dayan et al. 2006. 
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Accumulation of mitochondrial ROS is shown to promote HIF activity, where 
treatment with hydrogen peroxide (H2O2) stabilises HIF1α, and cells with non-
functional mitochondria (and therefore decreased ROS levels) are unable to stabilise 
HIF1α in response to hypoxia (Chandel et al. 2000). This likely occurs through 
oxidation (and therefore inactivation) of the PHD iron(II) catalytic centre to iron(III), 
overwhelming the reductive capacity of cellular agents such as ascorbate and 
preventing the hydroxylation-dependent degradation of HIF1α. The activity of HIF 
hydroxylases are also thought to be modulated through the availability of αKG, where 
competitive inhibition of the HIF hydroxylases occurs in SDH and FH deficient 
tumours owing to the accumulation of structurally similar metabolites succinate and 
fumarate, respectively (Selak et al. 2005; Isaacs et al. 2005). This results in the 
constitutive activation of hypoxic pathways in the presence of oxygen – a 
phenomenon known as pseudohypoxia. 
 
HIFα expression profiles 
Although the structure and mechanism of regulation for HIF1α and 2α is highly 
similar, HIF1 and HIF2 are capable of eliciting the transcription of different sets of 
genes, resulting in a differential response between tumour types (Hu et al. 2003; 
Sowter et al. 2003; Raval et al. 2005). While expression of HIF1α is ubiquitous: 
tissue-specific responses to hypoxia are at least partially mediated through restricted 
expression of HIF2α, which has been shown in cell types such as hepatocytes and 
endothelial cells (Wiesener 2002). However, it is thought that most cancer cells 
express both isoforms (Zhong et al. 1999; Talks et al. 2000). HIF3α is the least 
understood, but is believed to act as a natural antagonist owing to a lack of C-TAD 
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and capability of binding to HIF1α to prevent transcription activation. Little is known 
about the impact of HIF3α on hypoxic tumour progression. 
 
Further adjustments to HIF signalling is through differential induction dependent on 
the type of intratumoural hypoxia. In chronic hypoxia, HIF1α is rapidly increased and 
stabilised within a few hours, but its expression subsequently decreases. This is likely 
due to HIF1-mediated increase in PHD2 and PHD3, which could hydroxylate HIF1α 
resulting in its renewed degradation (Ginouves et al. 2008). HIF2α is thought to be 
more stabilised in long-term hypoxia than HIF1α, and may therefore play a role in 
tumour progression under chronic hypoxia (Lin et al. 2011). In contrast to chronic 
hypoxia, cycling hypoxia results in enhanced activity and stabilisation of HIF1, and is 
associated with increased metastatic potential and resistance to chemo- and 
radiotherapy (Dewhirst et al. 2008).  
 
As HIFs are not directly sensitised by oxygen, there are a number of additional 
factors that can regulate HIF stability. Loss of pVHL function, reported in clear-cell 
renal cell carcinoma (Latif et al. 1993), results in constitutive HIFα activity in the 
presence of oxygen, as HIFα is no longer subjected to oxygen-dependent 
ubiquitylation and degradation (Ratcliffe et al. 1999). Interestingly, it is in this disease 
context where HIF2α is the primary HIFα isoform responsible for oncogenesis (Kondo 
et al. 2002; Raval et al. 2005). HIF activity is also regulated by oncogenes and 
tumour suppressors, for example MYC and p53, where more detail can be found in 
appendix B. 
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Hypoxia-induced changes in metabolism and cellular redox 
 
Cytosolic energy compensation 
Cells remodel their metabolism in response to hypoxia, a primary goal of which is 
likely to support oxygen-independent ATP production (Figure 1.3). HIF1 is thought to 
be the major driver of this adaptation, stimulating increased glycolytic flux in the 
majority of cell types through the targeted transcription of glucose transporters 
(GLUT1; SLC2A1 and GLUT3; SLC2A3), and almost all glycolytic enzymes (Tennant 
et al. 2010). Through up-regulation of the LDH isoform A, HIF1 also supports 
increased reduction of pyruvate to lactate in hypoxia, required to ensure continued 
glycolytic flux in the absence of efficient mitochondrial oxidation of NADH (Semenza 
et al. 1996). LDH is a reversible pentameric complex consisting of variable ratios of 
the A and B subunit. The resulting isoenzymes differ in their favoured direction of 
reaction, where LDH1 (5x LDHB) favours lactate oxidation and LDH5 (5x LDHA) 
favours pyruvate reduction (Cahn et al. 1962; Bishop et al. 1972). The up-regulation 
of LDHA appears to be a critical hypoxia-induced metabolic alteration, as silencing 
LDHA in hypoxic breast cancer models has been shown to decrease tumorigenicity 
(Fantin et al. 2006). Inhibition of LDHA has been shown to increase mitochondrial 
ROS (Le et al. 2010), induce cell death (Xie et al. 2014) and impair the growth of 
patient-derived xenografts (Rajeshkumar et al. 2015). 
 
To prevent cytosolic acidification as a result of lactate accumulation, which itself 
inhibits glycolysis, lactate must be secreted from cells by monocarboxylate 
transporters (MCTs). In hypoxia, HIF1 mediates the transcription of MCT4 in addition 
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to Na+/H+ exchangers to excrete lactate out of the cell and mediate proton efflux 
(Ullah et al. 2006; Shimoda et al. 2006). This activity is accompanied by that of 
another target of HIF1, carbonic anhydrase (CA9). CA9 is a transmembrane protein 
that regulates intracellular pH by catalysing the reversible conversion of carbon 
dioxide and water to bicarbonate and H+, and by importing extracellular bicarbonate 
into the cytosol. It promotes intracellular alkalinisation required for proliferation, and 
extracellular acidification required for tumour invasion, metastasis and immune 
evasion (Švastová et al. 2004; Moellering et al. 2008; Gatenby & Gillies 2008; Parks 
et al. 2011). Lactate production and excretion through MCT4 by tumour cells has 
been shown to be taken up by aerobic stromal cells (via MCT1, which is also highly 
expressed in cancer cells), as an external fuel to regenerate pyruvate for oxidative 
metabolism, permitting rapid tumour growth in a glucose independent mechanism 
(Sonveaux et al. 2008). 
 
Mitochondrial regulation of oxygen consumption  
In combination with cytosolic changes in glucose metabolism, HIF1 mediates 
mitochondrial metabolic remodelling on exposure to hypoxic conditions. Carbon entry 
into the TCA cycle is reduced through the HIF1-induced expression of mitochondrial 
pyruvate dehydrogenase kinase 1 (PDK1). Active PDK1 phosphorylates the E1α 
subunit of the PDH complex and inhibits PDH activity (Kim et al. 2006; Papandreou 
et al. 2006). This indirect mechanism reduces carbon influx into the TCA cycle and 
further promotes the conversion of pyruvate to lactate. As mitochondrial respiration 
relies on the availability of oxygen, this metabolic adaptation becomes vital for cell 
survival in hypoxia by reducing ROS production and stabilising ATP production (Kim 
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et al. 2006). Such cellular adaptation occurs before oxygen is limiting for 
mitochondrial respiration, as maximal HIF1 stability is thought to be ~1% O2, and 
respiration becomes proportional to oxygen tension at ~0.4 - 0.7% O2 (Gnaiger et al. 
1998) - a protective mechanism consistent with the affinity of HIF hydroxylases for 
oxygen compared to the partial pressure of oxygen in hypoxic tissues.  
 
As a consequence of the reduction in pyruvate oxidation, loss of PDH activity 
decreases carbon influx into citrate, thereby altering the citrate to αKG ratio, and is 
suggested to change the way in which glutamine is metabolised (Fendt et al. 2013; 
Gameiro et al. 2013). Increased reductive carboxylation of glutamine-derived αKG 
has been extensively described in hypoxia (Metallo et al. 2011; Wise et al. 2011; 
Filipp et al. 2012), and in conditions where oxidative phosphorylation machinery is 
defective (Mullen et al. 2011) for the provision of carbon for anabolic purposes other 
than oxidative TCA cycle metabolism. IDH1 and ACO1 are cytosolic enzymes 
involved in the pathway, whereas IDH2 and ACO2 are mitochondrial, forming two 
pathways with the same activity but distinct localisation. As mitochondrial ACO is 
susceptible to ROS-mediated inactivation through oxidation of its iron-sulphur centres 
(Gardner 2002), it would suggest that mitochondrial ACO2 activity is reduced, making 
IDH2-mediated reductive carboxylation less efficient, and perhaps IDH1 as the major 
source of reductive carboxylation, consistent with previous reports (Grassian et al. 
2014).  
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Figure 1.3 Hypoxia-induced changes in metabolism and cellular redox. Some of the 
metabolic pathways known to have altered activity or importance in hypoxia. Metabolic 
pathways described in the text are shown, as are the enzymes mentioned shown in red. 
Thicker lines represent those pathways in which hypoxic cells have been shown to increase 
flux, or rely more on their activity. Abbreviations: AcCoA, acetyl CoA; ACO1/2, aconitase 1/2; 
Asp, aspartate; Cit, citrate; DHP, dihydroxyphosphate; Fum, fumarate; G6P, glucose 6-
phosphate; G3P, glyceraldhyde 3-phosphate; GLUT1/3, glucose transporter 1/3; Glu, 
glutamate; GLS, glutaminase; Gly, glycine; HK, hexokinase; IDH1/2/3, isocitrate 
dehydrogenase 1/2/3; Lac, lactate; LDHA, lactate dehydrogenase A; Mal, malate; MDH, 
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malate dehydrogenase; ME1, malic enzyme 1; MCT4, monocarboxylate transporter 4; OAA, 
oxaloacetate; 3PG, 3-phosphoglycerate; PC, pyruvate carboxylate; PDH, pyruvate 
dehydrogenase; Ser, serine; SHMT1/2, serine hydroxymethyltransferase 1/2; aKG,  α-
ketoglutarate and aKGDH, α-ketoglutarate dehydrogenase. 
 
 
HIFs also regulate the expression of subunits of respiratory enzyme complex IV, the 
complex that transfers electrons to molecular oxygen, by inducing a switch in 
cytochrome c oxidase (COX) isoform expression from COX4-1 regulatory subunit to 
COX4-2. HIF1 induces expression of the COX4-2 transcript and the mitochondrial 
LON protease, which degrades the COX4-1 subunit (Trueblood & Poyton 1988) 
suggested to optimise respiratory efficiency at low oxygen tensions through more 
efficient electron transfer by COX-2, reducing mitochondrial ROS production 
(Waterland et al. 1991; Allen et al. 1995; Burke et al. 1997; Fukuda et al. 2007). This 
is further enhanced from the HIF1α-mediated decrease in expression of SDH subunit 
B (Dahia et al. 2005). The resulting decrease in mitochondrial ATP synthesis could 
promote hypoxia-induced autophagy, a process of “self-catabolism” whereby 
cytoplasmic organelles are broken down to provide macromolecules for energy 
generation. To this end, HIF1 induces the expression of BCL2/adenovirus E1B 
interacting protein 3 (BNIP3), encoding a protein that promotes mitochondrial-
selective autophagy to reduce oxidative metabolism (Zhang et al. 2008).  
 
Hypoxic cellular redox changes 
Hypoxia directly affects metabolism as a consequence of changes in cellular redox, 
though the mechanisms for this are not entirely clear. Reduced oxygen availability 
could elicit changes in mitochondrial redox status that directly increase lactate 
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production. Under hypoxia, the mitochondrial NADH/NAD+ ratio is thought to increase 
owing to slowing of electron transport (through reduced oxygen availability) and 
consequent reduction in the rate of NADH oxidation (Chance & Williams 1955; 
Mayevsky 1984). The resulting increased NADH/NAD+ ratio would inhibit the activity 
of the TCA cycle dehydrogenases; PDH, IDH3, αKG dehydrogenase (αKGDH) and 
malate dehydrogenase (MDH). Consequently, mitochondria would be unable to 
continue to oxidise cytosolic NADH, which in normoxic conditions enters the TCA 
cycle via the malate-aspartate or glycerol 3-phosphate shuttle. This would then 
trigger the requirement for increased pyruvate reduction in the cytosol in hypoxia to 
regenerate NAD+ for glycolysis. Neither NADH nor NADPH are thought to be able to 
physically cross the mitochondrial inner membrane. However, in addition to the 
NADH-active redox shuttles mentioned, mitochondrial nicotinamide nucleotide 
transhydrogenase (NNT) allows the transfer of reducing potential from NAD+ to 
NADP+ and vice versa. Changes in the mitochondrial NADH/NAD+ ratio in hypoxia 
could suppress this transfer.  
 
The NADP+/NADPH pyridine redox pair, although relatively low in abundance in most 
cell types, is critical for maintaining cellular ROS detoxification, allowing the 
regeneration of GSH. Mitochondrial ROS production is thought to increase in hypoxia 
(Chandel et al. 1998). The most highly reactive ROS species, the superoxide radical, 
which is created from the leakage of complex I and III electrons, causes cellular 
damage through their oxidation of proteins, lipids and DNA. There is an increased 
demand for reducing equivalents in the mitochondria to maintain genetic stability, 
protein function, lipid membrane fluidity and cell viability. Some of the enzymes within 
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the mitochondrial matrix are particularly susceptible to oxidative inactivation: complex 
I, ACO2 and αKGDH are thought to be the most vulnerable, which results in further 
loss of TCA cycle activity in hypoxia. 
 
The production of NADPH through the catabolism of serine to glycine removes 
carbon from glycolytic ATP production. However, this system is also able to cycle 
reducing potential between the mitochondria and the cytosol through transport of 
serine and glycine across the mitochondrial membrane, facilitated by the presence of 
mitochondrial isoforms of the enzymes involved in this pathway. This mechanism 
may be exploited by hypoxic cells to maintain mitochondrial redox balance and cell 
survival in hypoxia. Indeed, MYC-transformed cells induce SHMT2 when subjected to 
hypoxia in a HIF1-dependent manner, which maintains the cellular NADPH/NADP+ 
ratio, decrease ROS and ultimately avoid cell death (Ye et al. 2014). More recently, 
SHMT2 and glycine decarboxylase (GLDC), known to prevent the toxic accumulation 
of glycine in SHMT2 expressing cells, was specifically detected in hypoxic regions of 
gliomas, thereby providing them with a metabolic advantage under hypoxia (Kim et 
al. 2015).  
 
Direct regulation of metabolic pathways by oxygen availability 
Depleted oxygen levels are also likely to directly limit the activity of some metabolic 
pathways. For example, cholesterol synthesis is highly oxygen-dependent as eleven 
molecules of molecular oxygen are consumed by four enzymes during the production 
of one molecule of cholesterol from acetyl-CoA (Bloch n.d.; Summons et al. 2006). 
Greatest oxygen consumption during cholesterol biosynthesis occurs in the 
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demethylation of lanosterol, which consumes nine molecules of molecular oxygen to 
oxidatively remove three methyl groups. Hypoxic conditions have been shown to 
decrease the demethylation of lanosterol, resulting in accumulation of sterols and a 
repression of pathway activity (Song et al. 2005). Adaptive hypoxic signalling 
pathways are thought to indirectly degrade 3-hydroxy-3-methyl-glutaryl-coenzyme A 
(HMG-CoA) reductase, the rate-limiting step in cholesterol biosynthesis, mediated 
through the transcriptional activity of HIF1, to maintain cholesterol homeostasis 
(Nguyen et al. 2007). 
 
Similarly, the desaturation of fatty acids requires oxygen. Palmitate is a substrate for 
various elongation and desaturation reactions to accommodate the need for a 
diversity of fatty acids, of which the most abundant is monounsaturated oleate 
(C18:1). Oleate is produced from palmitate by elongation to stearate (C18:0) followed 
by desaturation by Δ9 stearoyl-CoA desaturase (SCD)1 (the rate-limiting enzyme in 
the production of monounsaturated fatty acids), which requires oxygen as an electron 
acceptor. A specific ratio of oleate to stearate must be maintained by cells to ensure 
proper membrane fluidity and thus cell integrity, where an imbalance can induce 
apoptosis. Hypoxia has been shown to reduce the requirement for de novo fatty acid 
synthesis and desaturation by increasing fatty acid import (Kamphorst et al. 2013). 
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Mutations of mitochondrial (and associated) metabolic enzymes in cancer 
 
SDH was the first bona fide metabolic tumour suppressor identified in paraganglioma 
(PGL) and pheochromocytoma (PCC) in 2000 (Baysal et al. 2000). The discovery of 
SDH mutations proved that there are tumours in which Warburg’s hypothesis held 
true. This finding changed our understanding of both basic cell metabolism, and that 
of cancer. Not only was a fully functional TCA cycle thought to be absolutely required 
for efficient mammalian cell proliferation, but since Warburg’s first observations over 
80 years ago, cancer metabolism was typically considered a consequence rather 
than a cause of cancer. Since this initial discovery, cancer-associated mutations in 
the mitochondrial and associated metabolic enzymes FH and IDH1 and/or 2 have 
also been identified.  
 
Inactivating mutations in tumour suppressors SDH and FH have been identified as 
causative in cancers such as PGL (Baysal et al. 2000; Niemann S 2000; Astuti et al. 
2001; Burnichon et al. 2010) and renal cell carcinoma (RCC) (Tomlinson et al. 2002), 
and result in the significant production of succinate (Selak et al. 2005) and fumarate 
(Isaacs et al. 2005), respectively. Mutations in IDH however, have been reported in a 
variety of diverse cancers, including adult gliomas (Parsons et al. 2008; Yan et al. 
2009) and acute myelogenous leukemia (AML) (Mardis et al. 2009; Ward et al. 2010), 
and unlike FH and SDH, are genetic oncogenes. A single hit is only ever observed in 
IDH and results in loss of wild-type function but also acquires a neomorphic ability to 
produce (R)-2-hydroxyglutarate (2HG) from αKG (Dang et al. 2009). Mutations in IDH 
are believed to be early genetic events, but are insufficient to induce transformation 
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on their own (Watanabe, Nobusawa, et al. 2009; Watanabe, Vital, et al. 2009; Masato 
Sasaki et al. 2012; Chaturvedi et al. 2013). 
 
Owing to the structural similarities to αKG, the production and accumulation of 
oncometabolites succinate, fumarate and (R)-2HG target αKG-dependent 
dioxygenases in cancer, resulting in the competitive inhibition of numerous αKG-
dependent hydroxylases (Selak et al. 2005; Isaacs et al. 2005; Xu et al. 2011; Xiao et 
al. 2012). They have therefore all been reported to cause global epigenetic 
remodelling and interact with the HIF system. In the case of SDH and FH mutations, 
these unequivocally result in HIFα stabilisation and the subsequent development of 
pseudohypoxia (Selak et al. 2005), whereas with IDH1 and IDH2 the case is less 
clear (Yang et al. 2013). 
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Succinate Dehydrogenase 
SDH is a highly conserved, heterotetrameric complex, where all the subunits are 
encoded entirely by the nuclear genome. The two hydrophilic subunits, subunit A and 
B protrude into the mitochondrial matrix. SDHA contains a covalently attached flavin 
adenine dinucleotide (FAD+) cofactor and provides the succinate-binding site. Iron-
sulphur subunit B tethers catalytic A to hydrophobic subunits C and D, which act as 
an anchor in the inner mitochondrial membrane and also produce the binding site for 
ubiquinone (Bardella, Pollard, et al. 2011). SDH catalyses the 2-electron oxidation of 
succinate to fumarate in the TCA cycle with the subsequent transfer of electrons 
yielding ubiquinol from ubiquinone. As an integral component in the mitochondrial 
respiratory chain and the TCA cycle, SDH has a dual function in energy production, 
contributing to both mitochondrial membrane potential and ATP synthesis. 
Interestingly, complex II is the only complex in the ETC that does not pump protons. 
Unlike many TCA cycle enzymes, SDH is unique to the mitochondrion and has no 
existing isoforms, making the mitochondrion the major source of succinate. 
 
Mutations in SDHD were the first to be identified as causative in patients with 
hereditary  PGL and subsequently in PCC (Baysal et al. 2000). Since this initial 
discovery, mutations in all the other subunits constituting the SDH complex have 
been identified in the same syndrome - SDHB and SDHC, and more recently SDHA - 
as well as the required assembly factor SDHAF2, which encodes the protein found to 
be responsible for covalent attachment of FAD+ into catalytic SDHA (Burnichon et al. 
2010; Astuti et al. 2001; Niemann S 2000; Baysal et al. 2000; Hao et al. 2009). 
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Mutations identified in all the SDH subunits may not be entirely intuitive, owing to the 
different structure and function exhibit by each SDH subunit. 
 
PCC and PGL are neuroendocrine tumours arising from chromaffin cells of the 
adrenal medulla and paraganglia of the autonomous nervous system, respectively. 
They are mainly benign, but 10% of PCCs and up to 40% PGLs become malignant 
with a 5-year survival rate below 50% (Castro-Vega et al. 2015). PGL and PCC are 
relatively rare with an annual incidence of 1 or 2 per 1 million, respectively (Baysal 
2008). Interestingly, PCC/PGLs exhibit remarkable genetic determinism, where at 
least 12 susceptibility genes have been identified (Dahia 2014). These mutations 
present in both familiar and apparently sporadic PGL/PCC where up to 40% of 
affected patients carry a germline mutation in one of these genes and the remaining 
~60% are thought to be sporadic. SDH mutations have also been reported in other 
tumour types including gastrointestinal stromal tumours, RCCs and neuroblastoma 
(Janeway et al. 2011; Ricketts et al. 2008; Schimke et al. 2010).  
 
SDH mutations are heterozygous germline mutations, where loss of protein function 
results from a ‘second hit’ or loss of the wild-type allele, resulting in neoplastic 
transformation (Gottlieb & Tomlinson 2005). Loss of any SDH subunit results in full 
loss of dehydrogenase activity and a complete block in the TCA cycle, where 
accumulation of succinate occurs at millimolar concentrations (Gimenez-Roqueplo et 
al. 2001; Gimenez-Roqueplo et al. 2002; Douwes Dekker et al. 2003; Selak et al. 
2005; Pollard 2005; Hao et al. 2009; Burnichon et al. 2010). Interestingly, it is 
mutations in SDHB that predispose to a more malignant and aggressive phenotype, 
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and are associated with a poorer prognosis (Gimenez-Roqueplo et al. 2003; Amar et 
al. 2007; Boedeker et al. 2007). It is unknown why only mutations in SDHB lead to 
this clinical observation, highlighting a incomplete understanding of SDH function.  
 
Reports to date have shown that succinate accumulation owing to a loss of SDH 
activity, imparts inhibition of all αKG-dependent dioxygenases studied to date. This 
includes histone and DNA demethylases, and results in a hypermethylated 
phenotype of the chromatin, which is thought to promote cell migration and is 
interestingly increased in cells deficient in Sdhb (Xiao et al. 2012; Letouzé et al. 
2013). Loss of SDH has also been reported to activate HIFs at normal oxygen 
tension through the inhibition of αKG-dependent PHDs, giving HIF1 and 2 
stabilisation in the presence of oxygen (Selak et al. 2005; Briere 2005). This elicits 
changes in metabolism to a more ‘hypoxic-like’ state through HIF transcriptional 
activation of downstream targets, driving increased glycolysis regardless of oxygen 
tension. This is suggested to be the primary mechanism of tumour progression as 
inhibition of HIFα expression in tumour cells with stable SDHB knockdown reduced 
their growth as xenografts (Guzy et al. 2008). It has been additionally suggested that 
SDH-deficient mitochondria may generate more superoxide owing to a block in 
electron flow (Yankovskaya 2003), which would result in further PHD inactivation. 
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Fumarate Hydratase 
Like SDH, FH is also a bona fide tumour suppressor gene, inactivation of which is 
causative in hereditary leiomyomatosis and renal cell cancer (HLRCC) (Tomlinson et 
al. 2002). Patients inherit one defective copy of the gene, and following loss of 
heterozygousity, develop leiomyomas of the skin and uterus, along with aggressive 
RCC (Tomlinson et al. 2002; Gottlieb & Tomlinson 2005). The aggressiveness of 
RCC leads to early metastasis (Grubb et al. 2007), similar to that observed in SDHB 
deficient tumours. There is evidence to suggest that FH deficiency may also 
contribute to the development of breast and bladder tumours (Lehtonen 2006). 
 
FH is a homotetrameric enzyme that catalyses the stereospecific and reversible 
hydration of fumarate to malate in the TCA cycle. Malate can then either be oxidised 
to oxaloacetate by MDH to generate NADH, or oxidatively decarboxylated to pyruvate 
by ME to form NADPH. Mitochondrial and cytosolic isoforms of FH exist, differing 
only in the translation start site used. Mutations in the FH gene may be missense, 
frameshift or deletion and are detected in 90% of HLRCC families (Kuwada et al. 
2014). 
 
Loss of the remaining wild-type allele in FH mutants gives rise to a complete deficit of 
enzyme activity and block in TCA cycle activity. This instigates the accumulation of 
fumarate, which like succinate, competitively inhibits αKG dioxygenases and results 
in a hypermethylated phenotype and a pseudohypoxic response through HIF1α 
stabilisation (Isaacs et al. 2005; Xiao et al. 2012). Loss of FH activity has been shown 
to result in significant metabolic reprogramming, which is essential for continued cell 
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viability (Figure 1.4). In addition to increased aerobic glycolysis emanating from 
HIF1α stabilisation, loss of FH activity has also been shown to increase glutamine-
dependent reductive carboxylation (Mullen et al. 2011). As fumarate is not only an 
intermediate of the TCA cycle, but also a product of the urea cycle, the accumulation 
of cytosolic fumarate stemming from FH loss, causes reversal of the urea cycle, 
whereby argininosuccinate lyase reverses its usual activity, converting fumarate to 
argininosuccinate. This has the effect of making FH-deficient cells metabolically 
sensitive to arginine depletion (Zheng et al. 2013; Adam et al. 2013). 
 
It was initially proposed that stabilisation of HIF was required for tumour formation 
(Isaacs et al. 2005; Pollard 2005), but genetic deletion of HIFs did not prevent cyst 
formation in Fh-deficient mice (Adam et al. 2011). It has since been suggested that 
the transcription factor nuclear erythroid-related factor 2 (NRF2) is the primary driver 
in oncogenesis. As an electrophilic metabolite, fumarate has been shown to 
spontaneously (albeit slowly) react and form covalent bonds with free sulphydryl 
groups in cysteine residues – a process known as succination, and a phenotype 
observed in Fh-deficient mice and HLRCC patients (Bardella, El-Bahrawy, et al. 
2011). Succination of Kelch-like ECH-associated protein 1 (KEAP1), an E3 ubiquitin 
ligase and an inhibitor of NRF2, prevents the interaction between KEAP1 and NRF2, 
resulting in nuclear translocation of NRF2 and activation and expression of 
antioxidant genes (Adam et al. 2011; Ooi et al. 2011), which could further promote 
tumourigenesis by supporting ROS detoxification. Fumarate-dependent succination, 
rather than ROS-induced oxidation of KEAP1, is thought to be the dominant 
mechanism for NRF2 activation in this system.  
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Haem oxygenase 1 (HMOX1), the first enzyme involved in haem degradation, is a 
well characterised NRF2 target gene, which has been shown to be synthetic lethal 
with FH deficiency (Frezza et al. 2011), further supporting NRF2 as a major 
contributor to pathogenesis. Accumulation of TCA cycle intermediate succinyl CoA 
from glutamine, permits the synthesis and degradation of haem in the mitochondrial 
matrix, allowing partial mitochondrial NADH production and release of biliverdin and 
bilirubin, both of which have been suggested as antioxidants (Robertson & Fridovich 
1982; Galliani et al. 1985). Interestingly, in this study, both PC and SDH are predicted 
to be synthetic lethal with FH deficiency, though no definitive experimental evidence 
exists to support this yet.  
 
The accumulation of fumarate has also been demonstrated to directly bond with the 
antioxidant GSH in vitro and in vivo, producing the novel metabolite succinated 
glutathione (GSF). GSF acts as an alternative substrate for glutathione reductase, 
resulting in a decreased NADPH/NADP+ ratio, reduced detoxification of mitochondrial 
ROS, HIF1 activation and oxidative stress (Sudarshan et al. 2009; Sullivan et al. 
2013). The oxidative stress induced by GSH succination is necessary and sufficient 
to elicit cellular senescence in non-transformed cells (Zheng et al. 2015). Ablation of 
cellular senescence results in the transformation of benign renal cysts into a 
hyperplastic lesion, suggesting that fumarate-induced senescence needs to be 
bypassed for the initiation of renal cancers in HLRCC. Succination also inhibits ACO2 
activity, at three cysteine residues required for iron-sulphur cluster binding, further 
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truncating the cycle (Ternette et al. 2013). How this inhibition of aconitase affects 
reductive carboxylation remains unclear.  
 
Figure 1.4  Metabolic remodelling in cancers with mutated fumarate hydratase. 
Known metabolic pathways that have been shown in tumours or cells containing mutations 
in fumarate hydratase are shown. Likely pathways that are not yet confirmed are marked 
with ‘?’. Abbreviations: AcCoA, acetyl CoA; ACO2, mitochondrial aconitase; a-KG; α-
ketoglutarate; Asp, aspartate; BR, bilirubin; BV, biliverdin; Cit, citrate; Fum, fumarate; Glc, 
glucose; Gln, glutamine; Glu, glutamate; GSH, reduced glutathione; Gly, glycine; Iso, 
isocitrate; Lac, lactate; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, pyruvate 
dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1; Pyr, pyruvate; Suc, succinate. 
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Isocitrate Dehydrogenase 
Recurrent somatic mutations in IDH1 were first identified in 2008, when The Cancer 
Genome Atlas (TCGA) conducted a genome-wide study characterising genetic 
abnormalities driving glioblastoma (GBM) pathogenesis. Since this initial study, a 
total of 149 tumours have been analysed, where 12% of tumours display recurrent 
somatic heterozygous missense mutations in IDH1 (Parsons et al. 2008). These 
mutations rarely present in primary GBMs but occur in the majority of secondary 
GBMs. Secondary GBMs evolve from lower-grade glioma, typically observed in 
younger patients (Ohgaki & Kleihues 2007), but are histologically identical to primary 
tumours. Deep sequencing further revealed that mutated IDH1 and IDH2 (although to 
a lesser extent) are highly prevalent in low-grade gliomas (LGG) (>70% grade II), 
including grade II-III oligodendrogliomas and/or oligoastrocytomas and grade III 
astrocytomas (Balss et al. 2008). They present in younger patients, with a median 
age of 33.2 years (compared to 55.3 years for wild-type IDH), and confer a survival 
advantage of 3.8 years (in comparison to 1.1 years for wild-type IDH) (Parsons et al. 
2008). It is unknown whether the IDH1 status alone contributes to this, or 
characteristics of secondary GBM. Interestingly, it has been suggested that IDH1 
mutant tumours are associated with higher rates of total surgical resection (Beiko et 
al. 2014).  
 
IDH enzymes catalyse the oxidative decarboxylation of isocitrate to αKG and carbon 
dioxide. Five IDH genes (1, 2, 3A/B/G) in the nuclear genome encode the three IDH 
isoforms (1, 2 and 3) expressed by eukaryotic cells (Dalziel 1980). IDH1 and 2 are 
reversible, NADP+/NADPH dependent homodimers, where interconversion of 
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isocitrate and αKG occur in the cytosol and mitochondria, respectively. These 
isoforms are highly homologous with ~70% sequence identity, almost identical 
quaternary structures and two identical enzyme active sites per homodimer (Xu et al. 
2004; Ceccarelli 2002). Cytosolic NADPH production by IDH1 is thought to be 
important for limiting cellular oxidative damage (Kim et al. 2007) and is also required 
as a reducing agent in lipid synthesis (van Roermund 1998). Although, both IDH1 
and 2 are capable of reductive carboxylation, IDH1 may be primarily involved in 
hypoxia-mediated reductive carboxylation for de novo lipid synthesis. IDH3 is an 
irreversible NAD+-dependent heterodimer, both genetically and structural unrelated to 
IDH isoforms 1 and 2. IDH3 is primarily responsible for mitochondrial isocitrate 
oxidation and therefore regulating oxidative phosphorylation and redox homeostasis. 
Interestingly, IDH3 is the only isoform not yet linked to cancer progression.  
 
All reported IDH1 mutations have a single-point mutation in an arginine residue 
located in the enzyme active site at codon 132. The most common heterozygous 
missense mutation found in IDH1, occurring in ~90% of IDH1 mutated gliomas, is the 
substitution of the arginine residue with histidine (R132H) (Parsons et al., 2008, Yan 
et al., 2009b, Gravendeel et al., 2010). The remaining R132 mutations observed 
result in a substitution of arginine with cysteine, glycine, serine, leucine and 
glutamine substitutions (Pusch et al. 2014; Molenaar et al. 2014). The number and 
variety of amino acid substitutions may suggest that it is the replacement of arginine 
that confers a tumour-supportive activity, rather than the incorporation of a new 
residue. However, the frequency of the R132H mutations argue that there may be a 
selective pressure, which could be explained by reports demonstrating that R132H is 
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associated with the lowest production of (R)-2HG (Ward et al. 2013) to potentially 
avoid cellular toxicity (Pusch et al. 2014). Interestingly, the R132C mutation occurs 
more frequently in astrocytoma than oligodendroglioma, suggesting that the type of 
IDH1 mutation may correlate to the histological types of glioma (Gravendeel et al. 
2009). Consistent with this, is the finding that different genetic alterations follow the 
IDH1 mutation, where IDH1 mutated astrocytomas exhibit loss of p53, and IDH1 
mutated oligodendrogliomas exhibit co-deletion of chromosome 1p and 19q 
(Wakimoto et al. 2014). 
 
Mutations in IDH1 and 2 are thought to be mutually exclusive (Yan et al. 2009), 
suggesting that either isoform is sufficient to confer growth or survival advantages. 
Unlike glioma, mutations in IDH2 are much more prevalent in AML than IDH1 
mutations (15-33% as compared to 9%) (Mardis et al. 2009). It is unknown why this is 
the case, but perhaps suggests the role of mutant IDH is context dependent. 
Mutations in IDH2 in gliomas occur at a much lower frequency (0-6%) than IDH1 in a 
paralogous amino acid residues R140 and R172, which are most commonly 
substituted with lysine (Yan et al. 2009). R132 and R172 in IDH1, and R140 and 
R172 in IDH2 are key residues in IDH activity as they form hydrogen bonds with the 
α-carboxyl and  β-carboxyl groups of isocitrate to facilitate isocitrate binding in the 
enzyme active site (Xu et al. 2004; Dang et al. 2009). Mutations in these residues 
reduce binding affinity for isocitrate and increase binding affinity for NADPH, resulting 
in the reduction of αKG by NADPH and the release of the (R) enantiomer 2HG 
(Rendina et al. 2013). Although (R)-2HG is physiological, produced by αKG 
reductase enzymes and oxidised back to αKG by 2HG dehydrogenases (Struys, 
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2006), cellular concentrations of (R)-2HG accumulate to extremely high millimolar 
(<35 mM) concentrations, disrupting a number of cellular functions (Dang et al. 
2009).  
 
The production of (R)-2HG requires heterozygosity, as homozygous IDH1 mutations 
have been shown to significantly reduce the production of (R)-2HG (Jin et al. 2013), 
with a KM that is approximately 11-fold lower (Brooks et al. 2014). Wild-type IDH1 
either increases the enzymatic activity of mutant IDH1 towards αKG by inducing a 
different conformational state, or the wild-type allele produces the αKG required for 
mutant IDH activity and subsequent (R)-2HG production. The latter would result in a 
redox neutral process and permit both increased and more stable (R)-2HG 
production. 
 
Owing to the structural similarity between 2HG and αKG, the effect of IDH mutations 
on the αKG-dependent dioxygenase family of enzymes has also been studied. Much 
like SDH- and FH- mutated tumours, IDH mutations have been shown to exhibit a 
hypermethylated phenotype through competitive inhibition of the ten-eleven 
translocation (TET) family of DNA demethylases and members of the Jumonji C-
domain (JmjC) histone demethylases (Figueroa et al. 2010; Xu et al. 2011; Koivunen 
et al. 2012; S et al. 2012) resulting in global epigenetic modifications.  
 
Unlike SDH and FH mutations however, the effect of (R)-2HG on PHD activity has 
been the subject of some controversy. An initial report demonstrated that (R)-2HG 
production in IDH1 mutant U87 glioma cells inhibits HIF degradation owing to lack of 
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proline hydroxylation, and occurs as a result of loss of wild-type activity and 
decreased production of αKG (Zhao et al. 2009). A subsequent study confirmed 
increased 2HG production in IDH mutants and suggested (R)-2HG could cause 
competitive inhibition of αKG-dependent PHDs, thus providing an alternative reason 
for increased HIF (Dang et al. 2009). Consistent with these findings are both 
increased HIF protein levels and transcription of target genes in the brain cells of 
IDH1 mutant mice (M. Sasaki et al. 2012).  
 
In contrast, (R)-2HG in human astrocytes expressing IDH1 R132H was later shown 
to act as an agonist or co-substrate for PHD activation, resulting in reduced HIF 
expression and increased proliferation (Koivunen et al. 2012). In an enantiomer 
specific manner, (R)-2HG was shown to act as a co-substrate by the non-enzymatic 
oxidisation of 2HG into αKG, to provide a source of normal substrate at a level 
sufficient to support PHD2 catalysis, which is ultimately decarboxylated to succinate 
during the hydroxylation reaction (Tarhonskaya et al. 2014). Analysis of IDH mutant 
astrocytomas in the TCGA data set confirmed reduced HIF activity using a previously 
defined HIF-responsive gene expression signature (Nickols et al. 2007; Verhaak et 
al. 2010).  
 
A subset of IDH mutant tumours from a cohort of 120 human gliomas showed HIF1α 
overexpression localised to areas of necrosis only (Williams et al. 2011). These 
findings may support the IDH mutant mouse model (M. Sasaki et al. 2012), which 
was associated with haemorrhage and high perinatal mortality. The role of (R)-2HG 
in hypoxia biology may be context dependent and influenced by the disease 
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environment. It should be noted that the blunted HIF response observed by Koivunen 
et al. was at a given level of hypoxia (7.5% O2), whereas the previous studies were 
all conducted in normoxia. It is likely that different oxygen tensions shift the inhibitory 
or activation potential of (R)-2HG, with a differential effect on each member of the 
dioxygenase family.  
 
In addition to the biological effects of (R)-2HG production in IDH1 mutants, the effects 
of a mutation in IDH1 itself, or a change in redox as a result of the IDH mutation may 
have intriguing effects in hypoxia. Cancer cells become more dependent on reductive 
glutamine metabolism in hypoxia, likely mediated by IDH1 (Metallo et al. 2011; Wise 
et al. 2011). Given the hypoxic nature of gliomas, and the preference for mutations in 
IDH1, there may be a requirement for IDH2 wild-type activity in hypoxic IDH1 mutant 
gliomas. However, IDH1 mutated cells, unlike their wild-type counterparts, are 
thought to retain oxidative TCA cycle metabolism in hypoxia (Grassian et al. 2014). If 
the consumption of oxygen in hypoxic IDH1 mutant cells is sustained, this would 
create a challenging environment, further exacerbating hypoxic conditions to form 
areas of necrosis. The lack of mitochondrial adaptation to low oxygen may account 
for the improved survival observed in patients harbouring gliomas with mutated IDH1. 
 
Collagen maturation and stability also requires post translation modification through 
the activity of PHDs (Myllyharju 2004). PHD enzymes hydroxylate proline residues on 
type IV collagen for formation of the collagen triple helix, which contributes to the 
integrity of the blood brain barrier (BBB). In the animal models described earlier, mice 
were found to have higher levels of immature type IV collagen (M. Sasaki et al. 
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2012). 2HG may therefore cause defects in collagen protein maturation and 
breakdown the BBB owing to 2HG-mediated inhibition of collagen prolyl and lysyl 
hydroxylases (M. Sasaki et al. 2012; Poschl 2004). Interestingly, mutations in 
collagen synthesising genes have been associated with IDH mutation in non-central 
nervous system tumours (Tarpey et al. 2013) and RNA expression array analysis of 
mutant IDH1 xenograft tumours identified alterations in type IV collagen expression 
(Rohle et al. 2013). 
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Methods to decipher cancer metabolism 
 
Metabolomics 
Progress in the field of cancer metabolism has largely been facilitated by the 
development of analytical techniques such as chromatography, mass spectrometry 
(MS) and nuclear magnetic resonance (NMR) spectroscopy. The study of the 
metabolome encompasses a phenotype that reflects changes in the genome, 
transcriptome and proteome. Metabolomics describes a broad and sensitive 
approach that provides relative intra- or extracellular metabolite levels present in a 
given biological sample, particularly effective for investigating metabolic changes 
between different states or conditions. It can be used to reveal disease biomarkers, 
that may be useful for diagnosis, prognosis and assessing treatment outcome. An 
untargeted metabolomics analysis studies hundreds (as is the case for NMR) to 
thousands (as is the case for MS) of metabolites with limited prior information 
regarding sample composition. This type of data analysis lends well to generating a 
biological hypothesis. Targeted studies, on the other hand, are typically conducted 
after a hypothesis has been generated, and tends to involve the analysis of a number 
of functionally related metabolites. 
 
Isotopic tracing 
The metabolomics approach offers limited mechanistic information, as concentration 
changes could be indicative of altered activity of connected consuming or producing 
reactions (Buescher et al. 2015). Nor does this approach provide information 
regarding flux or pathway directionality, as an increase in metabolite levels could be 
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indicative of increased activity of metabolite-producing reactions or decreased activity 
of metabolite-consuming reactions (Fendt et al. 2010). In addition, a given metabolite 
can be produced by a number of intersecting pathways, for example, glutamate is 
involved in 55 known pathways and approximately 200 reactions (Fan et al. 2012). 
Methods that therefore allow interrogation of pathway usage, or determine flux 
through it, are often more useful. These methods rely on the use of naturally 
occurring metabolites, enriched in a relatively rare heavy isotope. One of the most 
frequently used is 13C, which is particularly effective considering the prevalence of 
carbon-containing metabolites in mammalian cells. As this isotope possesses a non-
integer spin and a different mass, metabolic tracers or their products enriched in 13C 
can be traced using both NMR and MS-based methods, respectively.  
 
To perform these analysis, up to 100% 13C-enriched tracers (such as glucose or 
glutamine) are added to the culture media of cells. Metabolism of the tracer results in 
increasingly 13C-enriched downstream metabolites until a steady state is reached and 
is highly dependent on the system and metabolic pathway being studied. The 
metabolic tracer, whether it is the metabolite itself or its isotopic labelling position, 
provides information on differential pathway activities, and should therefore be 
dictated by the biological question, for example, [1,2-13C2]-glucose is thought to 
reveal most information of glycolysis and PPP activity (Metallo et al. 2009). 
 
In many cases, the direct interpretation of labelling patterns within a metabolite is 
sufficient to provide information on relative pathway activities. Qualitative changes in 
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pathway contributions and nutrient contribution to the production of different 
metabolites can also be inferred from this type of analysis. This direct interpretation is 
known as isotope tracer analysis. Metabolic flux analysis (MFA) refers to labelling 
patterns in intracellular metabolites resulting from a particular tracer, combined with 
cellular uptake and excretion rates, and an almost complete understanding of the 
biochemical reaction network to computationally estimate metabolic fluxes. This 
provides information on flux magnitudes but is however, much more time and data 
intensive.  
 
NMR Spectroscopy 
NMR spectroscopy is highly reproducible and provides accurate absolute 
quantification of metabolite concentrations with little inter-experiment variation. It can 
exploit the physical properties of any non-zero spin nuclei, which include spin-half 
nuclei such as 1H, 15N, 31P as well as 13C. NMR spectroscopy is a powerful technique 
for the elucidation of structures at the molecular level, and for this reason, is capable 
of distinguishing positional 13C enrichment (isotopomers). This enables the 
determination of labelling patterns in intracellular metabolites which have the same 
number of 13C nuclei present, but differ in position, and can provide more accurate 
conclusions on pathway activity. As the sample does not interact directly with the 
instrument, sample alteration or damage is avoided. The major limitation of NMR is 
poor sensitivity, compared to other analytical techniques such as MS, where high 
concentrations of metabolites are required for reliable detection and quantification.  
1D 1H NMR is the simplest and most sensitive NMR method. In a 1D 1H spectrum, 
the signal intensity (the area under each signal) is directly proportional to the number 
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of 1H nuclei contributing to the signal, making this approach useful for metabolite 
quantification. As no prior assumption of metabolite composition is required for 
analysis, this method can also be useful for untargeted studies. However, in 
biological mixtures such as body fluids, tissues and cell extracts, the 1D 1H spectrum 
can become highly crowded. As each proton within a metabolite resonates at a 
specific frequency, depending upon its chemical environment, and biological mixtures 
can contain hundreds of metabolites, this can make identification and quantification 
difficult.  
 
Improvements in metabolite overlap within a spectrum is achieved by the introduction 
of a second dimension such as 2D Heteronuclear Single Quantum Coherence 
(HSQC) spectroscopy. This spectroscopy correlates the resonance frequencies of 1H 
and 13C that are directly bound, where each 1H-13C pair gives rise to a signal at the 
proton chemical shift in the horizontal (direct) and the 13C chemical shift in the vertical 
(indirect) dimension. 13C-incorporation is determined by analysing signal splitting, or 
multiplet analysis, in a given metabolite, which arises from simultaneous 13C 
incorporation into neighbouring carbon nuclei. In combination with quantification of 
metabolite concentrations from analysis of 1D 1H NMR spectra, HSQC spectroscopy 
can determinate intracellular fluxes, determining the rate of substrate conversion per 
cell (metabolite amount converted/cell/time). 
 
HSQC spectra need to be acquired at high resolution to accurately interpret signal 
splitting/multiplets, which results in long and often impractical acquisition times. Non-
uniform sampling can be employed to overcome this, where only a subset of 
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increments are sampled, and the remaining is reconstructed using algorithms such 
as compressed sensing (Stanek & Koźmiński 2010; Kazimierczuk & Orekhov 2011; 
Hyberts et al. 2007). However, this requires substantial computational capacity. 
Despite the introduction of a second dimension, this approach is still limited by 
sensitivity, where the label incorporation analysis can only focus on metabolites that 
are present in sufficient abundance. Further details of other NMR spectroscopy 
methods can be found in appendix C. 
 
Mass Spectrometry 
In comparison to NMR, MS is highly sensitive, with quick-scanning times, high mass 
resolution and mass accuracy, facilitating rapid and accurate metabolite identification. 
Ion fragment detection by MS follows chromatographic separation. Gas 
chromatography mass spectrometry (GC-MS) is a widely used and well established 
technique implemented for isotopic tracing and metabolomics. Prior to 
chromatographic separation and detection, GC-MS requires the derivatisation of 
metabolites by chemical modification. This involves the addition of molecular groups 
comprised of C, H, N, O and Si atoms to polar functional groups within metabolites to 
promote vaporisation at GC temperatures and chromatographic separation. This 
limits GC-MS to volatile compounds and small mass metabolites, which lends itself 
well to targeted studies. As interference with the sample affects reproducibility, and 
derivatisation efficiency can vary greatly between metabolites (Koek et al. 2006), GC-
MS requires the use of internal and external standards.  
 
48	
	
In MS, the mass isotopologue distribution (MID) is analysed, which refers to the shift 
in mass of a metabolite that occurs due to the incorporation of isotopes, making MS 
only able to differentiate metabolites that differ in isotope composition 
(isotopologues). MIDs describe the fractional abundance of each isotoplogue 
normalised to the sum of all possible isotopologues. MS can identify isotopomers in 
specific cases of tandem MS (Choi et al. 2012; Antoniewicz 2013), or the analysis of 
multiple fragments (Antoniewicz et al. 2011). Although analysis of isotopomers 
provides more accurate conclusions on pathway activity, MIDs can be sufficient in 
some cases to draw conclusions on nutrient contributions regarding known pathway 
activities. Importantly, MS requires to correct for the presence of naturally occurring 
isotopes (Fernandez et al. 1996; Yuan et al. 2008).  
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Thesis aims 
 
Cancer cells alter their metabolism to make sufficient energy to support replication, 
support the anabolic demands of macromolecular biosynthesis, and maintain cellular 
redox homeostasis to maintain high rates of proliferation. Hypoxia is a well-described 
phenotype of most cancers, driving many aspects of malignancy, which further 
remodels metabolism to fine tune the balance between biosynthesis and 
bioenergetics. Moreover, many cancers hijack the adaptive response to hypoxia to 
promote tumorigenesis. Further understanding of the significant metabolic plasticity 
demonstrated by cancer cells, and how metabolism changes in response to hypoxic 
stimuli, may therefore elicit the design of new selective therapies.  
 
This thesis aims to investigate using primarily NMR spectroscopy and GC-MS based 
methods, how cancer-associated mutations in metabolic enzymes SDH and IDH 
reprogram mitochondrial metabolism to facilitate tumour growth and development. 
More specifically, we intend to identify how cells deficient of SDHB activity maintain 
proliferation and viability in PCC/PGL, and investigate how mutations in IDH1 affect 
the metabolic adaptation to hypoxia in glioma progression. In addressing these 
questions, we aim to further understand how metabolic perturbations are induced by 
hypoxia, how mutations in these enzymes control mitochondrial metabolism, and 
what this could mean for the biology of the cancers in which these mutations are 
observed. 
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Chapter 2 SDHB-DEFICIENT CELLS RELY ON PYRUVATE CARBOXYLASE FOR 
ASPARTATE BIOSYNTHESIS 
 
Introduction 
 
Despite being the first metabolic bona fide tumour suppressor identified in the TCA 
cycle, the direct molecular mechanisms of SDH dysfunction remain uncharacterised. 
Given the importance of the TCA cycle in supplying reducing potential for oxidative 
phosphorylation during ATP synthesis, and for providing anabolic substrates for cell 
growth, the means by which cells proliferate in the absence of a fully functional TCA 
cycle, and how this resulting phenotype is capable of sustaining oncogenic 
transformation, remains unknown. A previous steady-state metabolic profile analysis 
performed on SDH-mutated tumours (unpublished work from Judith Favier’s research 
group) provided metabolic changes, useful for biochemical identification and tumour 
stratification, but did not however permit the analysis of biochemical fluxes necessary 
for proliferation. Therefore, to define SDH-mutated metabolism, with the potential aim 
to identify cancer-specific metabolic vulnerabilities, the use of stable isotope labelling 
approaches were employed. 
 
Until recently, RNA interference-mediated (RNAi) approaches have been used to 
silence SDH subunits, permitting what may be only a partial understanding of the 
biological effect of SDH deficiency (Selak et al. 2005; Guzy et al. 2008; Xiao et al. 
2012). As a complete loss of SDH activity is not achieved using RNAi, residual 
enzyme activity remains, potentially limiting data interpretation. Furthermore, the only 
in vitro models reported to date have successfully deleted subunit B of the SDH 
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complex (Letouzé et al. 2013; Cardaci et al. 2015). We therefore sought to 
investigate how cells deleted in SDHB remodel their metabolism in order to maintain 
proliferation and viability using PGL/PCC as a genetically relevant tumour model. 
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Results 
 
Sdhb deletion induces complete block in TCA cycle and drives an aerobic 
glycolysis phenotype 
 
To define the metabolism of SDH deficient cells, two physiologically relevant in vitro 
models, carrying deletions in SDH subunit B, were employed in the study. This 
included the previously described Sdhb knock-out (KO) immortalised mouse 
chromaffin cell (imCC) model (Sdhb KO clone 6 and clone 8) (Letouzé et al. 2013) 
and a novel Sdhb KO mouse adrenal fibroblast (MAF) model. Confirmation of Sdhb 
deletion in the novel MAF cell line is shown in Figure 2.1A, which resulted in a 
complete loss in protein expression of SDHB but unchanged SDHA levels (Figure 
2.1B). Loss of Sdhb in both cell models resulted in a complete block of TCA cycle 
activity, as demonstrated by high steady-state concentrations of intracellular and 
extracellular succinate (Figure 2.1C and 2.1D, respectively).  
 
To investigate the overall metabolic changes associated with Sdhb deficiency, the 
culture media was firstly assessed from both cell line models using NMR 
spectroscopy. Extracellular lactate concentrations in Sdhb KO cells were increased 
compared to wild-type (Figure 2.2A), indicative of an increase in glycolytic 
metabolism. When cell lines were incubated with [1,2-13C2]-glucose for 24 hours, 
increased concentrations of labelled lactate, in addition to unlabelled, were observed 
in the culture media, suggesting that Sdhb loss drives Warburg-like bioenergetic 
features of aerobic glycolysis (Figure 2.2B). This enhanced glycolytic flux is 
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consistent with the pseudohypoxic phenotype previously reported in SDH deficient 
cells (Selak et al. 2005; Briere 2005).  
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Figure 2.1 Sdhb deficient cells confirm a block in SDH activity. (A) Genotyping of the 
MAF KO cell line shows homozygous deletion of Sdhb exon 2 (∆ex2) resulting in (B) 
complete loss of SDHB protein expression. Sdhblox represents the targeting vector with full 
length endogenous Sdhb exon 2 flanked by loxP sites. Sdhb is deleted by Cre-mediated 
recombination (Sdhb∆ex2). Suppression of exon 2 leads to a premature stop codon resulting 
in the translation of a truncated protein. Steady-state concentrations of succinate are 
increased in (C) cells and (D) culture medium from Sdhb KO imCC and MAF cells, as 
quantified by 1D 1H-NMR spectroscopy. Data is mean +/- S.E.M and representative of at 
least three biological replicates. Significance determined using two-tailed unpaired student’s 
t-test. Data (A) and (B) are produced by Judith Favier’s research group. 
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Figure 2.2 Sdhb deficient cells exhibit an aerobic glycolysis phenotype. Sdhb KO 
ImCC and MAF cells exhibit increased extracellular lactate concentrations as determined 
using 1D,1H-NMR Spectroscopy (A). 24 h incubation with [1,2-13C2]-glucose in Sdhb KO 
ImCC and MAF cells reveals increased 13C labelled and unlabelled (0 0 0) lactate 
concentrations in the cell culture medium (B), indicative of increased rates of glycolysis. [2,3-
13C2]- lactate (0 1 1) and [3-13C1]-lactate (0 0 1) arise from glycolytic and PPP activity, 
respectively. Increased 13C incorporation in [3-13C1]-lactate in Sdhb KO cells suggests 
increased PPP activity compared to wild-type. 
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Sdhb deficient cells exhibit altered pyruvate metabolism 
 
Given the pseudohypoxic phenotype described in cells deficient in SDH activity, 
differential glucose metabolism between wild-type and Sdhb KO cells was firstly 
assessed. Once in the mitochondria, pyruvate, the end-product of glycolysis, can 
either be oxidatively decarboxylated by PDH to form acetyl CoA, or carboxylated by 
PC to form oxaloacetate. Further metabolism of acetyl CoA and/or oxaloacetate by 
the TCA cycle results in the synthesis of αKG, which can be transaminated to form 
glutamate. The position of 13C atoms within glutamate can therefore be used as a 
read-out of relative activities of PC ([2,3-13C2]- glutamate) and PDH ([4,5-13C2]-
glutamate). NMR can be employed to investigate positional 13C incorporation by 
analysing simultaneous 13C incorporation into neighbouring carbon atoms (13C-13C 
couplings) within a given metabolite. NMR is therefore useful to deconvolute 
isotopomer mixtures such as the example above from [1,2-13C2]-glucose. A brief 
explanation of multiplet analysis by 2D 1H,13C-NMR spectroscopy using glutamate to 
differentiate PDH and PC activity by is highlighted in Figure 2.3.  
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Figure 2.3 Example multiplet analysis using glutamate to differentiate relative pathway 
activity. 2D 1H,13C-HSQC NMR analysis of 13C incorporation into glutamate from [1,2-13C2]- 
glucose can be used to assess relative flux through the activity of PDH and PC. The 
chemical structure of glutamate (A) is shown, along with the multiplet of C2 glutamate (B). 
The quantum mechanical simulation of the nuclear spin system (red line) is fitted to the 
experimental data (blue line). C2 can provide labelling information on adjacent carbons, 
which dictates the splitting of the multiplet. In the example multiplet, two doublets are 
observed corresponding to [1,2-13C2]- and [2,3-13C2]-glutamate. The doublets are 
differentiated by the J coupling constant (Jcc), which itself is dictated by the functional groups 
attached to the adjacent carbon. For example, [1,2-13C2]-glutamate has a larger coupling 
constant than [2,3-13C2]-glutamate owing to the attached COOH functional group. The 
percentage contribution of each multiplet therefore provides relative information on the 
pathway activity, where [1,2-13C2]-glutamate corresponds to two rounds of TCA cycle 
resulting from PDH activity and [2,3-13C2]-glutamate is formed directly from PC activity. 
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Figure 2.3 Example multiplet 
analysis using glutamate to 
differentiate relative pathway 
activity, continued. Spectra (C) 
for ImCC and MAF Sdhb KO cell 
lines are normalised to cell 
number. Wild-type samples show 
a small percentage contribution for 
[2,3-13C2]-glutamate (large C3 
middle peak) but a large [1,2-13C2]-
glutamate (small C2 middle peak). 
The opposite is true for SDH 
deficient cells. [4,5-13C2]-glutamate 
labelling in C4 is present in all 
samples but the contribution is 
significantly less in SDH deficient 
cells. It is assumed here that the 
middle peak is natural abundance 
only (i.e. unlabelled, and therefore 
only possible to get labelling in 
[4,5-13C2]-glutamate – this is not 
strictly true but the percentage 
contribution of C3 in lactate and 
alanine from [1,2-13C2]-glucose in 
negligible). 
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Analysis of glutamate after cells were labelled with [1,2-13C2]-glucose for 24 hours 
revealed differential isotopomer distributions between wild-type and Sdhb KO cells 
(Figure 2.4A). In wild-type cells, [4,5-13C2]-glutamate was the major isotopomer 
observed, consistent with oxidative decarboxylation of pyruvate by PDH. An 
additional round of TCA cycle activity was also observed through the identification of 
[1,2-13C2]-glutamate in wild-type cells, and its absence in Sdhb KO cells owing to the 
previously stated block in TCA cycle activity. The labelling schematic for wild-type 
cells is illustrated in Figure 2.4B. In Sdhb KO cells, however, the relative contribution 
of [4,5-13C2]-glutamate was reduced by ~50%, and instead a considerable 
percentage of [2,3-13C2]-glutamate was detected, representing the incorporation of 
labelled oxaloacetate into the TCA cycle. The same isotopomer distributions in 
glutamate were also reflected in the media (Figure 2.4C). Collectively, these data 
suggest that in Sdhb KO cells, there is an increase in oxaloacetate synthesis from 
pyruvate, likely through the activity of PC, which compensates for the reduction in 
pyruvate oxidation (Figure 2.4D). This mechanism, which presumably occurs as a 
result of HIF1α stabilisation and subsequent transcriptional activation of PDK1 to 
inhibit PDH activity, may provide necessary carbon for continued cellular anabolism 
in Sdhb KO cells. 
 
The isotopomers of aspartate, a direct metabolite produced through the 
transamination of oxaloacetate, confirmed the switch in pyruvate oxidation to 
carboxylation in Sdhb KO cells (Figure 2.4E). Although wild-type cells were observed 
to synthesise [1,2-13C2]-/[3,4-13C2]-aspartate through oxidative TCA cycle activity, 
these isotopomers were absent in SDH-deficient cells and a significant increase (~10 
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fold) in [2,3-13C2]-aspartate synthesised from PC-derived oxaloacetate was detected. 
This observation, along with the fact that mitochondrial aspartate production from 
oxidative TCA metabolism is absent in Sdhb KO cells, led to the hypothesis that 
oxaloacetate produced by PC was used primarily for aspartate synthesis, and this 
biosynthetic pathway may be essential for proliferation of Sdhb KO cells. 
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Figure 2.4 Loss of Sdhb results in increased pyruvate carboxylation. 2D 1H,13C-NMR 
spectroscopy analysis of resulting 13C incorporation from [1,2-13C2]-glucose into glutamate 
(A). Diagram (B) describes the incorporation of carbon from glucose through PDH (red) and 
PC (blue) activity into wild-type Sdhb cells. The same 13C label incorporation in glutamate is 
also reflected in the culture media (C). 
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Figure 2.4 Loss of Sdhb results in increased pyruvate carboxylation, continued. 
Reduction in the relative abundance of the [4,5-13C2]-glutamate and increase in [2,3-13C2]-
glutamate isotopomers in Sdhb KO cells suggest an increase in PC activity and relative 
decrease in PDH activity, as exemplified in diagram (D). This is confirmed by the change in 
metabolite isotopomer distribution (MID) in aspartate from cell extracts towards [2,3-13C2]-
aspartate (E). Note that MID for NMR data refer to metabolite isotopomer distributions (not 
mass isotopologue distribution). Coloured circles on each diagram represent carbons that 
are 13C labelled and white circles represent carbons that are 12C. Translucent circles 
represent those metabolites that are not detectable by NMR due to low abundance. Data is 
mean +/- S.E.M from three biological replicates. Abbreviations in metabolic diagrams: 
AcCoA, acetyl CoA; Ala, alanine; Asp, aspartate; Cit, citrate; Glc, glucose; Gln, glutamine; α-
KG, α-ketoglutarate; Lac, lactate; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, 
pyruvate dehydrogenase; Pyr, pyruvate. 
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Aspartate synthesis is dependent on pyruvate carboxylase activity in Sdhb 
deficient cells 
 
As the NMR isotopomer analysis of glutamate and aspartate suggested Sdhb KO 
cells depend upon mitochondrial PC activity, PC protein expression was assessed 
and shown to be increased in Sdhb KO imCC cells (Figure 2.5A) and in SDH-
mutated PCC (Figure 2.5B), further highlighting the potential importance of PC 
activity in the metabolism on SDH mutant cells and tissues. 
 
	
Figure 2.5 SDH deficient cells and tumours increase expression of pyruvate 
carboxylase. (A) PC protein expression is increased in imCC Sdhb KO cells compared to 
wild-type controls. (B) SDH-mutated PCC shows extensive up-regulated PC protein 
expression compared with non SDH-mutated PCC harbouring a RET mutation. Scale bar, 
50 µm. Data produced from Judith Favier’s research group. 
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As aspartate has a pivotal role in cellular anabolism to support nucleotide and protein 
synthesis, and aspartate synthesis in Sdhb KO cells is shown to be PC dependent, 
we predicted that loss of PC activity in Sdhb KO cells would affect proliferation and/or 
survival. Knock-down of PC in the imCC cell model was validated using two 
independent short interfering RNA (siRNA) sequences, achieving significant 
reduction in PC mRNA (Figure 2.6A) and protein expression (Figure 2.6B). Absence 
of PC had no effect in wild-type cells (Figure 2.6C) but a significant decline in 
proliferation and viability was observed in the Sdhb KO cells (Figure 2.6D). This 
confirmed the essential role of PC in Sdhb KO cell growth and survival. Identifying 
PC as an essential gene for SDH-deficient but not wild-type cells, unveiled a 
metabolic vulnerability that could be exploited for potential treatment.  
 
As the proliferation of Sdhb KO cells requires the mitochondrial production of 
aspartate through PC activity, aspartate must be made available for cytosolic 
biosynthetic processes, and therefore requires export across the inner mitochondrial 
membrane. The aspartate-glutamate antiporter (SLC25A13) is one example 
transporter used to export aspartate into the cytosol. Indeed, expression of 
SLC25A13 was increased in imCC KO cell lines (Figure 2.7A) and shown to be 
significantly and specifically up-regulated in SDH-deficient tumours (Figure 2.7B).  
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Figure 2.6 Expression of pyruvate carboxylase is essential for the proliferation of 
Sdhb deficient cells. Successful knockdown of PC protein and mRNA expression in both 
the wild-type (WT) and Sdhb KO clone 8 assessed by (A) RT-PCR and (B) 
immunofluorescence. Reduction in the expression of PC using two independent siRNA 
sequences, siPC #3 and #4, results in (A) unaffected proliferation of wild-type cells and 
(B) a significant reduction in proliferation of SDH deficient cells. Data produced from Judith 
Favier’s research group. 
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Figure 2.7 Increased expression of glutamate/aspartate antiporter SLC25A13 in SDH 
deficient cells and tumours. Increased protein expression of the glutamate-aspartate 
antiporter SLC25A13 is shown in (A) imCC KO cells and (B) SDHB-mutated PCC, by 
immunofluorescence and immunohistochemistry, respectively. Scale bar, 100 µm. Data 
produced from Judith Favier’s research group. 
 
Cultured cells are entirely reliant on endogenous aspartate synthesis for growth, as 
aspartate is not present in the culture medium DMEM. When cultured with 
exogenous [U-13C4]-aspartate, Sdhb KO cells were found to import (Figure 2.8A) and 
metabolise (Figure 2.8B) significantly more exogenous aspartate than their wild-type 
counterparts. These observations support the notion that Sdhb KO cells have an 
increased dependence on aspartate, as a result of a truncated TCA cycle. 
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Figure 2.8 Sdhb deficient cells have increased dependence on aspartate. (A) ImCC 
KO cells Cl6 and Cl8 demonstrate increased uptake of extracellular aspartate when 
incubated with 0.1 mM [U-13C4]-aspartate for 48 h compared to wild-type, which is further 
metabolised intracellularly, as evident from isotopomer distrubution of succinate (B), and 
is consistent with a increased requirement for aspartate to support proliferation in SDH-
deficient cells. Owing to the symmetrical nature of succinate, [1,2-13C2]-and [3,4-13C2]-
isotopomers cannot be distinguished using NMR spectroscopy and are therefore reported 
as a single combined value. Data is mean +/- S.E.M from three biological replicates. 
Significance determined using an ordinary one-way ANOVA. 
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Sdhb deficient cells elicit reductive glutamine metabolism but is insufficient to 
refill the depleted metabolite pools 
 
As a considerable amount of glucose carbon is directed towards mitochondrial 
aspartate biosynthesis mediated by PC in Sdhb KO cells, we next sought to 
investigate whether glutamine, an alternative carbon source to glucose, could be 
used for the synthesis of cytosolic aspartate through reductive glutamine metabolism. 
Glutamine is an important source of carbon for de novo nucleotide biosynthesis and 
the synthesis of almost all NEAAs. In common with other systems where oxidative 
TCA cycle metabolism is perturbed, there may be an increased reliance on reductive 
carboxylation for cellular anabolism (Mullen et al. 2011). To investigate this, cells 
were incubated with [U-13C5]-glutamine for 24 hours and the resulting polar extracts 
from the cells and culture media were obtained and analysed for 13C incorporation 
into metabolites.  
 
13C labelled carbon nuclei from glutamine were significantly enriched in malate and 
aspartate isotopomers in wild-type imCC cells, consistent with oxidative ([U-13C4]- 
and [1,2-13C2]-/[3,4-13C2]-) and reductive ([1,2,3-13C3]-/[2,3,4-13C3]-) glutamine 
metabolism (Figure 2.9A and B, respectively). Analysis of the isotopomer distribution 
in lactate synthesised from [U-13C5]-glutamine, although significantly less than 
glucose (~50-fold), confirmed the presence of oxidative glutamine metabolism ([U-
13C3]- and [1,2-13C2]-) in the wild-type cells only (Figure 2.9C). However, identification 
of [2,3-13C2]-lactate in both wild-type and Sdhb KO cells supported the activity of 
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reductive glutamine metabolism, exemplified in labelling schemes Figure 2.9D and 
2.9E.  
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Figure 2.9 SDH deficient cells exhibit dysfunctional glutamine metabolism. Glutamine 
metabolism leads to incorporation of 13C from [U-13C5]-glutamine into (A) malate and (B) 
aspartate in ImCC WT cells only, as analysed by NMR spectroscopy. However, no 
isotopomers were detected in Sdhb KO cells suggesting a lack of reductive glutamine 
metabolism in addition to oxidative glutamine metabolism. Isotopomer distributions in (C) 
lactate confirm the presence of reductive glutamine metabolism in both wild-type and Sdhb 
KO cells by the identification of [2,3-13C2]-lactate. Data is mean +/- S.E.M from three 
biological replicates. 
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Figure 2.9 SDH deficient cells exhibit dysfunctional glutamine metabolism, 
continued. Diagrammatic representation of the oxidative (red) and reductive (blue) 
metabolism of glutamine in wild-type (D) and ImCC and MAF Sdhb KO (E) cells. 
Abbreviations in metabolic diagrams: AcCoA, acetyl CoA; Asp, aspartate; Cit, citrate; Gln, 
glutamine; IC, isocitrate; α-KG, α-ketoglutarate; Lac, lactate; Mal, malate; OAA, 
oxaloacetate; Pro, proline; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; Pyr, 
pyruvate; Suc, succinate. 
 
To investigate whether the enzymes involved in reductive glutamine metabolism 
supported this activity (Figure 2.10A), a transcriptional analysis was performed, which 
suggested increased expression of cytosolic reductive glutamine enzyme activity in 
Sdhb KO cells (Figure 2.10B).  
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Figure 2.10 SDH deficient cells increase expression of enzymes involved in reductive 
glutamine metabolism. The enzymes involved in the reductive metabolism of glutamine (A) 
are differentially expressed in SDH-deficient cells (B). Noticeably, most enzymes with 
cytosolic reductase activity are up-regulated, whereas most with mitochondrial-localised 
reductive activity are down-regulated. Data is produced from Judith Favier’s research group. 
Abbreviations: ACLY, ATP citrate lyase; ACO1/2, aconitase 1/2; GLS, glutaminase; 
GLUD1/2, glutamate dehydrogenase; IDH1/2, isocitrate dehydrogenase 1/2; ME1/2/3, malic 
enzyme 1/2/3; MDH1/2, malate dehydrogenase 1/2; PCK1/2, phosphoenolpyruvate 
carboxykinase; and PKM/P/L, pyruvate kinase M/P/L. 
 
In case the absence of observable label incorporation into aspartate and malate in 
Sdhb KO cells was due to the lack of sensitivity of the NMR approach, cell samples 
were incubated with [U-13C5]-glutamine for longer incubation times of 72 hours and 
extracted for GC-MS analysis. Owing to very low steady-state concentrations, neither 
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labelling in malate, aspartate or citrate could be identified by GC-MS (Figure 2.11A, 
2.11B and 2.11C, respectively). The low steady-state concentrations of malate and 
aspartate were consistent with previous findings from the metabolomics analysis 
performed on SDH-mutated PCC (Figure 2.21D and 2.21E, respectively). However, 
isotopologues of fumarate confirmed increased proportions of M+3 in Sdhb KO cells 
from [U-13C5]-glutamine, which is consistent with the presence of reductive 
carboxylation (Figure 2.12A). 
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Figure 2.11 GC-MS data confirms depleted amino acid pools as a consequence of a 
truncated TCA cycle. ImCC incubation with [U-13C5]-glutamine for 72 h confirms a lack of 
labelling in metabolites malate (A), aspartate (B) or citrate (C), owing to low intracellular 
concentrations, which is additionally observed in SDH-mutated tumours (D) and (E). Data is 
mean +/- S.D. Statistical significance determined using ordinary one-way ANOVA. Metabolite 
abundance determined by normalising ion counts to norvaline and calculating relative to wild-
type. 
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An additional observation, was the substantial 13C incorporation into glutamate 
(Figure 2.12B) and succinate (Figure 2.12C) from [U-13C5]-glutamine in Sdhb KO 
cells. Increased expression of SLC25A13 (Fig 2.7), for transport of mitochondrial 
aspartate across the inner mitochondrial membrane to support biosynthetic purposes, 
may additionally contribute to the increase of flux into glutamate.  
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Figure 2.12 GC-MS data confirms the presence of reductive carboxylation. The 
presence of reductive carboxylation in Sdhb KO is confirmed by virtue of (A) increased M+3 
fumarate. As PC activity is high, the labelling in M+3 fumarate from reductive carboxylation is 
likely diluted by mitochondrial fumarate from glucose. High M+5 glutamate (B) and M+4 
succinate (C) from [U-13C5]-glutamine in KO cells suggest decreased oxidative IDH flux. Note 
that all GC-MS data shows the mass isotopolgues distribution (MID) from [U-13C5]-glutamine, 
presented mean +/- SD and performed in technical triplicate. Statistical significance 
determined using ordinary one-way ANOVA. 
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Non-essential amino acid metabolism is highly perturbed in Sdhb deficient 
cells 
 
In addition to differential 13C incorporation into NEAAs aspartate and glutamate, 
analysis of 13C incorporation into serine and proline revealed potential differences in 
their usage or synthesis between wild-type and Sdhb KO cells. An increase in [2,3-
13C2]-serine was observed from [1,2-13C2]-glucose (Figure 2.13A), in parallel with a 
decrease in steady-state serine concentrations (Figure 2.13B) in Sdhb imCC KO cells 
and SDH-mutated PCC (Figure 2.13C), suggesting a change in the rate of serine 
synthesis and use.  
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Figure 2.13 Loss of SDH activity increases usage of the serine synthesis pathway. 
Increased 13C incorporation is observed into [2,3-13C2]- and [3-13C1]-serine isotopomers after 
24 h incubation with [1,2-13C2]-glucose, as identified by 2D 1H,13C-NMR spectroscopy (A). [3-
13C1]-serine arises through activity of PPP. Data is mean +/- S.E.M from three biological 
replicates. Decreased steady-state values were observed in Sdhb KO imCC cells (B) and 
tumours (C) by GC-MS where data is mean +/- S.D from three technical triplicates. 
Significance determined using ordinary one-way ANOVA. Data suggestive of increased 
production and usage of serine.  
 
This was supported by the increased expression of a number of enzymes involved in 
serine biosynthetic pathway (Figure 2.14A) in SDH-mutated tumours (Figure 2.14B) 
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and Sdhb KO cells (Figure 2.14C). Most noticeably, mitochondrial SHMT2 transcripts 
were significantly up-regulated in SDH mutated tumours. 
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Figure 2.14 Loss of SDH increases expression of enzymes involved in the serine 
synthesis pathway. Expression of the serine biosynthetic enzymes (A) was assessed, and 
confirms an increase in expression if SDH-mutated tumours (B) and Sdhb KO cells (C), 
where SHMT2 was most noticeably increased in SDH-mutated tumours. Data is produced 
from Judith Favier’s research group. Abbreviations: PHGDH, phosphoglycerate 
dehydrogenase; PSAT1, phosphoserine aminotransferase 1; PSPH, phosphoserine 
phosphatase; SHMT2, serine hydroxymethyltransferase 2 and THF, tetrahydrofolate. 
 
Increased expression and activity of this enzyme is consistent with increased glycine 
concentrations in both SDH deficient cells (Figure 2.15A) and tumours (Figure 
2.15B). Collectively, the data suggests that Sdhb KO cells significantly increase the 
synthesis of serine and its subsequent catabolism potentially to support anabolism, 
redox or epigenetic regulation. 
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Figure 2.15 Increased glycine concentrations support increased usage of the serine 
synthesis pathway. Increased glycine concentrations in both cells (E) and tumours (F) 
confirmed an increase in pathway usage. Data is mean +/- S.D from three technical 
triplicates. Significance determined using ordinary one-way ANOVA. 
 
Proline, one of the major amino acids synthesised from glutamine, revealed different 
isotopomer distributions between wild-type and Sdhb KO cells from the analysis of 
both [1,2-13C2]-glucose and [U-13C5]-glutamine polar extracts. While both [U-13C5]- 
and [1,2,3-13C3]-proline isotopologues from [U-13C5]-glutamine were found in wild-
type cells, only [U-13C5]-proline was detected in Sdhb KO cells and was found to be 
increased (approximately 5% over 24 hours) (Figure 2.16A). This is consistent with 
the 13C labelled proline exported into the medium (Figure 2.16B), where almost three 
times the amount of proline (both labelled and unlabelled) was exported in Sdhb KO 
cells. Steady-state proline concentrations reflect this observation, where increased 
proline was determined in Sdhb KO cells (Figure 2.16C) (although this was 
inconsistent between the clones) and SDH-deficient tumours (Figure 2.16D). 
 
76	
	
	
A                                                    B 
Proline
P
ro
lin
e 
M
ID
 fr
om
 
[U
-1
3 C
5]
-g
lu
ta
m
in
e 
(%
)
0 0
 0 
0 0
1 1
 1 
1 1
1 1
 1 
0 0
0
20
40
60
80
100
ImCC WT
ImCC KO Cl6
ImCC KO Cl8
	
Proline
13
C
 Is
ot
op
om
er
s 
fr
om
 
[U
-1
3 C
5]
-g
lu
ta
m
in
e 
(µ
m
ol
 p
er
 1
06
 c
el
lls
 p
er
 2
4 
h)
0 0
 0 
0 0
1 1
 1 
1 1
1 1
 1 
0 0
0.0
0.5
1.0
1.5
2.0
ImCC WT
ImCC KO Cl6
ImCC KO Cl8
	
																	C																																																																				D	
im
CC
 W
T
im
CC
 C
l6
im
CC
 C
l8
0
1
2
3
Proline
M
et
ab
ol
ite
 a
bu
nd
an
ce
 
(r
el
at
iv
e 
to
 W
T)
****
*
 no
n-
SD
H 
tu
mo
ur
s
SD
H 
tu
mo
ur
s
0
2
4
6
Proline
M
et
ab
ol
ite
 a
bu
nd
an
ce
 
(r
el
at
iv
e 
to
 n
on
-S
D
H
)
	
 
Figure 2.16 Loss of SDH activity increases glutamine-derived proline biosynthesis and 
extracellular export. Proline biosynthesis from glutamine (A) shows an increase in [U-13C5]-
proline in imCC Sdhb KO cells and no [1,2,3-13C3]-proline owing to the block in TCA cycle 
activity. Significant amounts of proline (both labelled and unlabelled) are exported into the 
medium of imCC Sdhb (B). Data are mean +/- S.E.M from three biological replicates. Proline 
concentrations are increased in cells (C) although not consistent between clones, and in 
tumours (D). Data are mean +/- S.D from technical triplicates. Significance determined using 
unpaired student’s t-test. 
 
In addition, there was significant up-regulation in gene expression of pyrroline 5-
carboxylase reductase 1 (PYCR1), the principle enzyme responsible for the reduction 
of pyrroline 5-carboxylate into proline, in Sdhb KO cells and SDH-mutated tumours 
(Figure 2.17), supporting the observed increase in glutamine-derived proline 
biosynthesis. 
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                          A                                             B 
 
 
Figure 2.17 Loss of SDH activity increases glutamine-derived proline biosynthesis and 
extracellular export. The observed increase in glutamine-derived proline biosynthesis is 
supported by the increase in gene expression of pyrroline-5-carboxylate 1 (PYCR1) – the 
rate limiting step in proline biosynthesis – in Sdhb deficient cells (A) and SDH-mutated 
tumours (B). Data from Judith Favier’s research group. 
 
No isotopomers of proline were identified from [1,2-13C2]-glucose in Sdhb KO cells 
(Figure 2.18A), presumably as a considerable amount of glucose carbon is directed 
towards aspartate synthesis through the activity of PC. GC-MS data confirmed a 
decrease in labelling from glucose (Figure 2.18B), which was in accordance to that of 
glutamate (Figure 2.18C).  
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Figure 2.18 Increased proline biosynthesis from glucose is not observed in Sdhb 
deficient cells. Proline is not detected in Sdhb KO cells after 24 h incubation with [1,2-13C2]-
glucose by NMR spectroscopy (A) or GC-MS (B), which is also supported by the mass 
isotopologue distribution (MID) of glutamate (C). NMR data is mean +/- S.E.M from three 
biological replicates, whereas GC-MS data is mean +/- S.D from three technical replicates. 
 
Our results suggest that the majority of proline is synthesised from glutamine in Sdhb 
KO cells, and the increased synthesis of proline is likely to exceed biomass 
production as it is exported in significant proportions into the culture medium. 
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 Discussion 
 
PGL/PCC presents an ideal genetic model to study how cancer cells deficient in SDH 
activity reprogram mitochondrial metabolism to sustain proliferation. Inactivation of 
SDH and loss of mitochondrial function per se, along with the subsequent 
development of a pseudohypoxic phenotype as a result of succinate accumulation 
has been well established. However, the direct effects of metabolic transformation 
owing to a loss in SDH activity were as yet uncharacterised.  
 
The metabolic tracer studies demonstrate that there is considerable metabolic 
rewiring of mitochondrial pathways, as a result of a truncated TCA cycle. Sdhb 
deficient cells increase PC-dependent carboxylation of pyruvate to synthesise 
oxaloacetate for the production of aspartate (Figure 2.4). These findings are 
consistent with recent publications using a primary Sdhb-ablated epithelial kidney cell 
line (Cardaci et al. 2015). As inhibition of this biosynthetic pathway results in a loss of 
proliferation and viability, it is clear that SDH-deficient cells are highly dependent on 
mitochondrial aspartate production. Aspartate is a major precursor for protein and 
nucleotide biosynthesis, as well as the synthesis of NEAAs arginine and asparagine. 
As aspartate is among one of the least abundant amino acids circulating in human 
plasma (Mayers & Vander Heiden 2015), and is inefficiently transported into most 
mammalian cells (Birsoy et al. 2015), de novo synthesis is required for cell growth 
and proliferation. The loss of metabolic plasticity means that PC-mediated aspartate 
biosynthesis is likely to determine the anabolic and proliferative state of the cell. This 
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cellular vulnerability therefore presents as an ideal way to therapeutically target these 
tumours.  
 
Traditionally a gluconeogenic enzyme, PC is expressed in a tissue-dependent 
manner, where greatest expression occurs in the liver and kidney. It uses a 
covalently attached biotin cofactor to catalyse the ATP-dependent carboxylation of 
pyruvate to oxaloacetate in the presence of magnesium and is allosterically regulated 
by levels of acetyl CoA and aspartate. Acetyl CoA enhances the rate of biotin 
carboxylation and therefore positively regulates PC activity, whereas aspartate is 
thought to inhibit PC activity by repressing the PYC1 promoter (Jitrapakdee et al. 
2008). As the induction of PC activity is not universal to all hypoxic tissues, it may 
therefore be induced by the low intracellular levels of aspartate as identified in SDH 
deficient cells (Figure 2.11B) and tissues (Figure 2.11D) rather than the direct 
development of “pseudohypoxia” itself.  
 
For aspartate to be used for biosynthetic purposes in the cytosol, it must be exported 
out of the mitochondria. Our results suggest that the expression of the aspartate-
glutamate antiporter SLC25A13 is increased with SDHB deficiency (Figure 2.7). 
SLC25A13 is one of two solute carrier family 25 transporters responsible for 
exporting mitochondrial aspartate into the cytosol. Unlike SLC25A13, which is widely 
expressed, with greatest expression in the liver, SLC25A12 is found mainly in heart, 
skeletal muscle and brain (Del Arco et al. 2000; Palmieri et al. 2001). Use of either 
aspartate-glutamate transporter would further import glutamate into the mitochondria, 
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which would partially be removed through the increased activity of mitochondrial 
aspartate aminotransferase (GOT2) to convert PC-derived oxaloacetate to aspartate. 
 
In Sdhb deficient cells, which exhibit reduced PDH activity (Figure 2.4A), and 
therefore reduced acetyl CoA production from glucose, it may be possible that an 
alternative pool of mitochondrial acetyl CoA exists. This could be produced from an 
external source such as β-oxidation, which would yield numerous reducing 
equivalents in the mitochondria to drive ATP production under normal SDH function. 
Alternatively, Sdhb deficient cells could utilise reductive glutamine metabolism to 
produce citrate, thereby bypassing the activity of citrate synthase. Despite evidence 
to support the presence of reductive glutamine metabolism in Sdhb deficient cells 
(Figure 2.9C, 2.10, 2.12A), activity of this pathway appears to be so rapid that 
metabolite steady-state levels remain low, and therefore do not fully compensate for 
the lack of oxidative TCA cycle activity. The absence of detectable 13C incorporation 
in malate, aspartate and citrate from [U-13C5]-glutamine resulted in a suspected lack 
of sensitivity in the NMR approach, and the need for the use of GC-MS to take 
advantage of its enhanced sensitivity. Although, findings using GC-MS were 
consistent with the NMR results, with none of the above metabolites detected. 
Activity of this pathway is unlikely to exceed the reliance of Sdhb deficient cells on 
mitochondrial PC activity for endogenous aspartate synthesis. 
 
In the absence of SDH activity, there is likely to be an increase in glutamate carbon 
and nitrogen within the mitochondria, owing to both a block in TCA cycle activity and 
as a result of increased aspartate export by GOT2. Increased biosynthesis of proline 
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from glutamine may provide a means to remove excess glutamate from the 
mitochondrion. As mitochondrial proline biosynthesis from glutamine is a highly 
redox-regulated pathway that requires the use of 2 NAD(P)H, increased use of this 
pathway may also be an important way in which these cells support cellular redox 
homeostasis. Increased NADH/NAD+ is likely to occur as a result of decreased ETC 
function, as is thought to be the case for hypoxic cells. Increased use of this pathway 
could remove excess NADH from the mitochondrion, in addition to glutamate. The 
most striking observation regarding proline however, was its high extracellular export 
in Sdhb deficient cells (Figure 2.16B). Our results suggest that proline is produced in 
amounts exceeding biomass requirements and secretion may act to remove excess 
NADH and glutamate in Sdhb deficient cells.  
 
Like lactate, proline export may have a functional role within a larger system of 
metabolic cooperation and symbiosis between tumour cells and the 
microenvironment (Nakajima & Van Houten 2013). In addition to regulating redox, 
extracellular export of proline could also be used by surrounding stromal cells as a 
source of energy. This “two compartment” model of tumour metabolism may further 
stimulate tumour proliferation and metastasis, as reported in breast cancer cells and 
their neighbouring fibroblasts (Martinez-Outschoorn et al. 2011; Sotgia et al. 2011) 
and ovarian cancer cells and their neighbouring adipocytes (Nieman et al. 2011). 
Interestingly, PYCR1 has been identified as a major driver of metastatic invasive 
breast carcinoma (Possemato et al. 2011). 
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As collagen in the extracellular matrix (ECM) is primarily comprised of proline 
residues, extracellular export of proline could support increased collagen synthesis. 
Interestingly, a key step in collagen production is to ensure correct folding and 
secretion by the hydroxylation of proline residues catalysed by collagen prolyl 4-
hydroxylases (cP4H). It has been recently shown in hypoxic breast cancer cells that 
HIF1 activates the transcription of genes encoding cP4Hs, which are critical for 
collagen deposition and promotes cancer cell alignment resulting in enhanced 
invasion and metastasis (Gilkes et al. 2013). Owing to the pseudohypoxic phenotype 
reported in SDH deficient tumours, it may be interesting to see whether SDH deficient 
tumours do indeed accumulate collagen deposits, and whether this contributes to the 
invasive and metastatic phenotype reported in the majority (50-97%) of SDHB 
mutated tumours (Fliedner et al., 2010). 
 
Our metabolomics, transcriptomics and isotope tracing analyses suggest that Sdhb 
deficient cells increase de novo serine synthesis and catabolism from glucose. It is 
unlikely that the low steady-state concentrations of serine (Figure 2.13B and 2.13C) 
in Sdhb deficient cells are due to decreased or dysfunctional serine uptake from the 
culture medium, as the numerous serine antiporters that exist for extracellular serine 
uptake are thought to be active even at steady-state (DeNicola et al. 2015). In 
addition, it has been shown that cells with PHGDH amplification, as appears to be the 
case for SDH-mutated tumours (Figure 2.14B) and cells (Figure 2.14C), require flux 
through the SSP even when serine is available (Possemato et al. 2011). Usage of 
this metabolic pathway could be increased in Sdhb KO cells to sustain nucleotide 
synthesis and/or mitochondrial NAD(P)H production in the absence of a fully 
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functional TCA cycle. It could also be up-regulated to provide methyl groups required 
for biosynthesis, or even DNA and histone methylation, which is consistent with the 
hypermethylation profile observed in this tumour type (Letouzé et al. 2013). 
 
Previous studies have identified the importance of serine catabolism for supporting 
redox homeostasis in hypoxia (Ye et al. 2014). The high expression of mitochondrial 
SHMT2 identified in SDH-mutated tumours (Figure 2.14B) and cells (Figure 2.14C) 
indicates a potential requirement of mitochondrial NADPH production from serine 
catabolism to support redox homeostasis. Reports have shown that loss of SDHB 
leads to increased mitochondrial ROS production (Guzy et al. 2008), which may 
therefore create an increased demand for NADPH. The increase in PPP activity 
observed by virtue of an increase in [3-13C1]-lactate from [1,2-13C2]-glucose (Figure 
1.2C) in the culture media of Sdhb deficient cells, along with the detection of [2,3-
13C2]-lactate production from [U-13C5]-glutamine (Figure 1.9C) using the activity of 
cytosolic ME1, may be evidence of this putative increase in NADPH production. It 
could be possible that our results for increased serine synthesis and catabolism also 
support this putative increase in NADPH demand. 
 
It is becoming increasingly clear that the TCA cycle is not necessarily a cycle, but a 
series of linear reactions required by the cell for biosynthetic demands. The 
integration of diverse carbon sources and conversion of one carbon source to 
another in mitochondria means that the cells do not completely rely on exogenous 
nutrient sources for cell proliferation and repair. Collectively, these data provide 
insight into how the reprogramming of mitochondrial aspartate biosynthesis through 
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the activity of PC could be exploited to mitigate the growth of SDH-deficient tumours 
(Figure 2.19). 
 
Figure 2.19 Summary of succinate dehydrogenase deficient cell metabolism. As a 
result of a truncated TCA cycle, SDH deficient cells increase PC-mediated aspartate 
biosynthesis, which is essential for proliferation and viability. Abbreviations: AcCoA, acetyl 
CoA; Asp, aspartate; Cit, citrate, Glc, glucose; Glu, glutamate; Gln, glutamine; Iso, isocitrate; 
a-KG, α-ketoglutarate; Lac, lactate, OAA, oxaloacetate; Pyr, pyruvate; PC, pyruvate 
carboxylase; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1 and 
Suc, succinate. 
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Experimental Procedures  
 
Patient Information 
In collaboration with Judith Favier 
Tumour samples were collected prospectively by the French ‘Cortico et 
Médullosurrénale: les Tumeurs Endocrines’ (COMETE) network and ethical approval 
for the study was obtained from the institutional review board [Comité de Protection 
des Personnes (CPP) Ile de France III, June 2012]. Written informed consent for the 
sample collection and subsequent analyses was obtained from all patients. The 
procedures used for PCC/PGL diagnosis were in accordance with both internal and 
international clinical practice guidelines (Plouin PF, Gimenez-Roqueplo AP n.d.; 
Lenders et al. 2014).  
Diagnosis was confirmed by histology in each case. A total of 202 consecutive cases 
of PCC/PGL, recruited over 15 years (1993-2008), were included in the study. Fresh 
tumour samples collected during surgery were immediately frozen and stored in liquid 
nitrogen until processing. Formalin-fixed paraffin-embedded tissues were used for 
immunohistochemical analyses.  
 
Cell Lines 
Immortalised mouse chromaffin cells (imCC) and mouse adrenal fibroblast cells 
(MAF) were kindly donated by Dr Judith Favier and cultured in GIBCO® high glucose 
DMEM (Dulbecco’s modified Eagles Medium) containing 2 mM GlutaMAX and 1 mM 
pyruvate (ThermoFisher Scientific, 10569044), supplemented with 10% FBS (foetal 
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bovine serum) (Thermo Fisher Scientific, 10270-106) (Letouzé et al. 2013; Lussey-
Lepoutre et al. 2015). 
Cell lines were maintained using standard procedures in a 37oC humidified incubator, 
5% CO2 and regularly tested and excluded for mycoplasma contamination using PCR 
Mycoplasma Test kit I/C (PromKine, PK-CA91-1048). 
 
Gene expression data  
In collaboration with Judith Favier 
Gene expression profiles of 186 PPC/PGL tumours available from a previous study 
were genotyped for the presence or the absence of germline and somatic mutations 
in well-known PCC/PGL susceptibility genes (Burnichon et al. 2011). In total, 23 
SDHx, 38 VHL, 30 NF1, 14 RET, 1 TMEM127, 3 MAX, 6 HRAS, 3 MET, 65 sporadic, 
1 NF1/MET, 1 RET/HRAS and 1 TP53/CDKN2A/MET were identified (Castro-Vega et 
al. 2015). HG-U133 Plus 2.0 Affymetrix GeneChip data from this previous study are 
available online as ArrayExpress entry E-MTAB-733 
(http://www.ebi.ac.uk/arrayexpress/) (Castro-Vega et al. 2015). 
Gene expression profiles of imCC and MAF cell lines were assessed in duplicates 
using the GeneChip® Mouse Gene 1.0 ST Array. Data are available as ArrayExpress 
entry E-MTAB-3403.  
 
Immunohistochemistry 
In collaboration with Judith Favier 
6 µM sections cut from 27 paraffin-embedded tumour samples were mounted on 
SuperFrost® Plus slides (ThermoFisher Scientific, 10143560). The following 
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antibodies and a standard procedure were used for immunohistochemistry40 with 
Histogreen as a chromogen: 
Table 2.1 Antibodies employed for Immunohistochemistry staining of pyruvate 
carboxylase and the aspartate-glutamate transporter  
Antibodies Supplier Product Code Dilution Antigen Retrieval 
Anti-PC Abcam Ab115579 1:100 Boil slides in Tris-
EDTA buffer (pH 9.0) 
Anti-
SCL25A13 
Abcam Ab156010 1:50 Boil slides in citrate 
buffer (pH 6.0) 
 
Images were acquired with a Leica DM400B microscope with Leica Application Suite 
software version 2.8.1, and a Leica DFC420C camera (Leica). 
 
RNA Silencing 
In collaboration with Judith Favier 
To assess the knockdown in expression of PC, 5 x 104 cells were seeded onto 12-
well plates in standard culture conditions. After 24 h, cells were transfected following 
manufacturer’s instructions with 150 ng of Silencer Select Pre-designed siRNA 
against PC (Thermo Fisher, siRNA references s71354 and s71355) or Silencer 
Select negative control (Thermo Fisher, 4390843) using Lipofectamine® RNAiMax 
reagent (Thermo Fisher, 13778) as described by the manufacturer. 48 h post 
transfection, cells were passaged and efficiency of gene extinction was evaluated by 
immunofluorescence and RT-qPCR. Passaged cells were re-transfected 24 h later to 
maintain long-term extinction. 
 
Quantitative real-time PCR  
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In collaboration with Judith Favier 
Total RNA was extracted using the mini RNeasy kit (Qiagen, 74104) according to 
manufacturer’s protocol. 500 ng RNA per sample was subjected to reverse 
transcription (RT) using the iScript cDNA Synthesis Kit (Bio-Rad, 1708890). qPCR 
(SybrGreen) was performed with 10 ng of cDNA preparation and the iTaq Universal 
SYBR Green Supermix (Bio-Rad, 172-5120) in a CFX96 Real Time PCR machine 
(Bio-Rad). The following primers and probes were used: 
Table 2.2 Primers for pyruvate carboxylase isoforms 1 and 2 
# Primer Sequence Target Isoform Exon Species Application 
206 Pcx-
E13_F1 
GATCCTG 
CTGTTCC 
TGTGGT 
Pcx 1 and 2 ex13 
(isoform1) 
or ex12 
(isoform2) 
Mouse qPCR 
(SybrGreen) 
207 Pcx-
E14_R1 
TAGGGCG 
CAATCTT 
TTTGAG 
Pcx 1 and 2 ex14 
(isoform1) 
or ex13 
(isoform2) 
Mouse qPCR 
(SybrGreen) 
 
The expression of PC in each sample was normalised to Ubiquitin C as 
housekeeping gene. Comparative analysis across samples was calculated using the 
2-ΔΔCT method. 
 
Immunofluorescence 
In collaboration with Judith Favier 
Cells were seeded at 5 x 104 onto glass coverslips (Thermo Scientific, 1014355) and 
left overnight. Cells were washed in 1x PBS and fixed for 20 min in ice-cold 
paraformaldehyde 4% and permeabilised and blocked in 1% BSA, 0.1% Triton for 30 
min. The following antibodies were used: 
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Table 2.3 Antibodies against pyruvate carboxylase employed in immunofluorescence 
microscopy 
Primary 
antibody 
Anti-PCB 
antibody 
Abcam Ab110314 1:100 Overnight 
incubation at 4oC 
Secondary 
antibody 
Alexa Fluor 488 
Goat anti-mouse 
IgG 
Invitrogen A28175 1:2000 1 h incubation at 
room temperature 
in the dark 
 
Slides were mounted in Vectashield® mounting medium with DAPI, and acquisitions 
were performed using Axioimager ZI Zeiss, with apotome system.  
 
Proliferation 
In collaboration with Judith Favier 
Cells were seeded at 5 x 104 onto 6-well plates under standard culture conditions. 
Cell were transfected 24 h post seeding as described and passaged until confluence 
was reached on 10 cm dishes. Growth curves were established by counting cells 
every 48 h post transfection for a total of 8 days. Experiments were performed three 
times in duplicate.  
 
NMR Spectroscopy 
6 × 106 ImCC and MAF cells were plated onto two 15 cm dishes and cultured in 
standard medium for 24 h, where it was then replaced with fresh DMEM (no glucose) 
supplemented with 1 mM sodium pyruvate and 10 mM [1,2-13C2]- D-glucose (Sigma-
Aldrich, 453188), or DMEM (high glucose with pyruvate and no glutamine) 
supplemented with 2 mM [U-13C5]-L-glutamine (Sigma-Aldrich, 605166) for 24 h. For 
aspartate labelling, cells were cultured in standard medium supplemented with 0.1 
mM [U-13C4]-L-aspartate (Sigma-Aldrich, 604852) for 48 h. 
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Cells were washed with ice-cold PBS and scraped in a pre-chilled acetonitrile-
methanol-water (55:35:10) solution. The cell lysates were vortexed for 15 min at 4°C 
and immediately centrifuged at 15,000 x g for 15 min at 0°C. The polar fraction was 
aliquoted and evaporated to dryness using a SpeedVac concentrator for 5 h at 30oC. 
For the metabolomic extraction of conditioned media, 600 μl of an acetonitrile-
methanol (60:40) solution was added to 200 μl of cell media, and then processed as 
described above. Extraction was performed on 3 different cultures for each labelling 
experiments.  
Dried samples were resuspended in 60 μL 100 mM sodium phosphate buffer 
containing 500 μM TMSP [(3-trimethylsilyl)propionic-(2,2,3,3-d4)-acid sodium salt] 
and 10% D2O, pH 7.0. Samples were vortexed, sonicated (5-15 min) and centrifuged 
briefly (x2), before transferred to 1.7mm NMR tubes using an automatic Gilson 215 
Liquid Handler (Bruker Biospin). 
1D-1H NMR spectra and 2D-1H,13C-HSQC NMR spectra were acquired using a 600-
MHz Bruker Avance III spectrometer (Bruker Biospin, UK) with a TCI 1.7 mm z-PFG 
cryogenic probe at 300 K. Spectral widths were set to 7,812.5 and 24,155 Hz for the 
1H and 13C dimensions, respectively. 16,384 complex data points were acquired for 
the 1D-1H NMR spectra and 512 complex data points were acquired for the 1H 
dimension of 2D-1H,13C-HSQC NMR spectra. An exponentially weighted non-uniform 
sampling scheme was used for the indirect dimension. Here, 30% of 8,192 complex 
data points (2,458) were acquired. 128 transients were recorded for the 1D-1H NMR 
spectra with a relaxation delay of 4 s, and two transients were recorded for the 2D-
1H,13C-HSQC NMR spectra with a relaxation delay of 1.5 s. Each sample was 
automatically tuned, matched and then shimmed (1D-TopShim) to a TMSP line width 
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of <2 Hz prior to acquisition of the first spectrum. Total experiment time was ~15 min 
per sample for 1D-1H NMR spectra and 4.5 h per sample for 2D-1H,13C-HSQC NMR 
spectra. 1D-1H NMR spectra were processed using the MATLAB-based MetaboLab 
software (Ludwig & Günther 2011). All 1D data sets were zero-filled to 131,072 data 
points before Fourier Transformation. The chemical shift was calibrated by 
referencing the TMSP signal to 0 p.p.m. 1D spectra were manually phase corrected. 
Baseline correction was achieved using a spline function (Ludwig & Günther 2011). 
1D-1H NMR spectra were exported into Bruker format for metabolite identification and 
concentration determination using Chenomx 7.0 (ChenomxINC). 2D-1H,13C-HSQC 
NMR spectra were reconstructed using compressed sensing in the MDDNMR and 
NMRpipe software (Delaglio et al. 1995; Kazimierczuk & Orekhov 2011; Orekhov & 
Jaravine 2011). The final spectrum size was 1,024 real data points for the 1H 
dimension and 16,384 real data points for the 13C dimension. Analysis was 
performed using MetaboLab and pyGamma software was used in multiplet 
simulations (Smith et al. 1994). The methyl group of lactate was used to calibrate the 
chemical shift based on its assignment in the human metabolome database (Wishart 
et al. 2013). 
Cell GC-MS 
In collaboration with Christian Metallo 
Cells were seeded onto 6-well plates and cultured in standard medium for 24 h. 
Media was then replaced by DMEM (high glucose with pyruvate, no glutamine) 
supplemented with 2 mM [U-13C5]-L-glutamine (Sigma-Aldrich, 605166) for 72 h. 
At the conclusion of tracer experiments, culture media was aspirated and cells 
washed twice with 0.9% NaCl solution. Cellular metabolites were extracted in 
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methanol (-20oC): water (4oC): chloroform (-20oC), where 1 µg/well DL-norvaline 
(Sigma-Aldrich, N7502) was employed as internal standard in the polar fraction. 
Samples were vortexed at 4oC for 30 min and subsequently centrifuged at 14,000 x g 
for 15 min at 4oC. The polar fraction was aliquoted and dried by speed vacuum 
concentration at 2,000 RPM for 4 h at 30oC. 
Derivatisation of polar metabolites has been previously described (Metallo et al. 
2011; Lewis et al. 2014). Briefly, polar metabolites were derivatised to form 
methoxine-TBDMS (tert-butyldimethylsilyl) derivatives by incubation with 2% 
methoxyamine hydrochloride (Sigma-Aldrich, 226904) dissolved in PierceTM pyridine 
(Thermo Fisher Scientific, 25104) at 37oC for 1-1.5 h followed by addition of 
MTBSTFA (N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide) with 1% TBDMCS 
(tert-butyldimethylchlorosilane) (Sigma-Aldrich, 375934) incubated at 37oC for 30-60 
min.  
Derivatised polar samples were analysed by GC-MS using an Agilent 7890B gas 
chromatograph equipped with a 30 m DB-35MS capillary column (30 m x 0.25 mm 
i.d. x 0.25 µm) connected to an Agilent 5977A mass spectrometer. MIDs were 
determined by integrating metabolite ion fragments and corrected for natural 
abundance as previously described (Fernandez et al. 1996). 
Metabolite ion counts were normalised to norvaline and isoleucine ion counts to 
normalise for varying derivatisation efficiency and cell number, respectively. 
 
Tissue Triple Quadrupole GC-MS/MS 
In collaboration with Judith Favier 
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Six snap-frozen tumour samples (1 SDHD, 2 SDHB, 2 NFI and 1 MAX-mutated) and 
six imCC samples (three WT and three KO) were processed by organic extraction 
with ethylacetate, derivatisation with N,O-bis(trimethylsilyl) trifluoroacetamide with 1% 
trimethylchlorosilane, and analysed by tandem mass GC on a GC-MS triple 
quadrupole (Scion TQ, Bruker Daltonics). Analytes were identified by retention time 
and mass spectrum in selected reaction monitoring mode based on standard spectral 
reference libraries. 
 
Statistical Analysis 
Samples sizes and reproducibility for each figure are denoted in the figure legends. 
Unless otherwise noted, all experiments are representative of at least three 
biologically independent experiments performed in technical triplicate, where error 
bars represent mean +/- S.E.M. Statistical significance was determined by either a 
one-way ANOVA or two-tailed Student’s t-test using GraphPad Prism 6, where *P < 
0.05; **P < 0.01; and ***P < 0.001. 
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Chapter 3 IDH1 MUTATIONS EXHIBIT PSEUDOHYPOXIC PROLINE 
METABOLISM 
 
Introduction 
 
Cytosolic IDH1 catalyses the reversible NADP+-dependent oxidative decarboxylation 
of isocitrate to α-ketoglutarate (αKG). Recurrent heterozygous missense mutations in 
the IDH1 gene have been reported in the majority of LGGs and secondary GBMs, 
where they clinically present in younger patients and are associated with an improved 
prognosis (Parsons et al. 2008). Missense IDH1 mutations occur in the arginine 
residue at codon 132 (R132), which is most commonly replaced by a histidine 
residue (R132H) (Parsons et al., 2008, Yan et al., 2009b, Gravendeel et al., 2010) 
and results in a change of substrate specificity. Instead of the NADP+-coupled 
oxidation of isocitrate to αKG, αKG is reduced to form the oncometabolite (R)-2HG, 
employing NADPH as a cofactor (Dang et al. 2009). The majority of studies have 
concentrated on the biological effects from the significant production of (R)-2HG, 
which has been shown to inhibit a number of αKG dependent dioxygenases, inducing 
changes in DNA and histone methylation (Turcan et al. 2012; Lu et al. 2012; 
Chowdhury et al. 2011; Figueroa et al. 2010) as well as collagen folding and 
maturation (M. Sasaki et al. 2012).  
 
Similar to other cancer-associated mutations in mitochondrial metabolic enzymes, 
IDH mutations have been shown to perturb regulation of the HIF system. While 
mutations in SDH and FH unequivocally result in HIFα stabilisation and the activation 
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of hypoxic pathways despite the presence of oxygen, it is not yet conclusive whether 
IDH mutations promote (Zhao et al. 2009) or suppress (Koivunen et al. 2012) HIFα 
stabilisation, and may be context or cell-specific. Given the highly hypoxic nature of 
gliomas (Evans 2004; Collingridge et al. 1999; Søndergaard et al. 2002), where 
mutations in IDH1 are “selected” for, along with the defined role of wild-type IDH1 in 
hypoxic reductive carboxylation for de novo lipogenesis (Metallo et al. 2011; Wise et 
al. 2011), it remains unclear as to how mutations in IDH1 metabolically affect glioma 
progression. This is likely to be important, as not only does hypoxia itself alter redox, 
but altered substrate specificity by virtue of the IDH mutation also predisposes IDH 
mutated cells to a change in cellular redox. Employing tissue and IDH1 R132H cell 
models, we therefore sought through metabolomics methodologies and stable 
isotope tracers, to investigate how the metabolism of cells harbouring an IDH1 
mutation differ to wild-type, and to address the potential interplay between hypoxia 
and mutant IDH1.  
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Results 
IDH1 mutant gliomas are metabolically distinct from wild-type 
  
To assess whether gliomas with mutated IDH1 exhibit a metabolism different to those 
with wild-type IDH1, an untargeted mass spectrometry analysis was performed on 25 
tumour biopsy samples. The non-polar and polar fractions were analysed by ultra-
high performance liquid chromatography (UHPLC) and GC-MS, respectively, and 
principle component analysis (PCA) was performed for each analytical platform. PCA 
is an unsupervised multivariate method, that compresses data to investigate 
biological significance, and naturally separates the data based on biological variance. 
Tumour tissue samples that are highly clustered therefore represent biologically 
similar tumour types, and those tumour samples that are segregated represent 
biologically distinct tumour types.  
 
Figure 3.1 shows the acquired PCA plot (panel A) and sample number (panel B) for 
the analysis of the tumour samples by GC-MS, wherein each sample number 
corresponds to a different patient tumour sample. Tumour samples 4 and 12 were 
visibly segregated from the remaining tumour samples, distinguishing these samples 
as metabolically different, along with further clustering of two other subgroups in the 
remaining IDH1 wild-type tumour samples. Importantly, the QC samples were highly 
clustered, verifying the conditions of analysis. Reference to patient data confirmed 
the presence of mutant IDH1 in tumour samples 4 and 12 by immunohistochemistry, 
thus establishing this metabolomics methodology as a valid approach for segregating 
tumours based on IDH status. As segregation of IDH1 status was identified by the 
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analysis of the polar fraction by GC-MS, it is also evident that the IDH1 mutations 
significantly affect intracellular metabolism.  
 
  A                                                               B 
 
Figure 3.1 Tissue GC-MS segregates gliomas based on IDH1 status. (A) PCA and (B) 
sample number obtained for tissue GC-MS, which shows the segregation of tumour tissues 
(red triangles) and clustering of quality control (QC) samples (black circles). PC1 is the 
principle component with the most variation, and thus has a higher percentage compared to 
PC2. The PCA shows significant segregation of two IDH mutated tumour tissues, 
corresponding to patient tumour samples 4 and 12, from the remaining samples. The high 
biological variability is further illustrated by high clustering of Quality Control (QC) samples. 
Analysis performed by Warwick Dunn. 
 
To better understand the alterations in tumour metabolism elicited by mutations in 
IDH1, metabolites responsible for the segregation of samples were identified by 
calculating the fold difference between the two IDH1 mutant tumours and the 
remaining wild-type tissue samples, where they were filtered for consistent changes 
of greater than 20% (Figure 3.2). As expected, the greatest change observed was 
elevation of 2HG, which was elevated at 117 and 43 fold in patient number 4 and 12, 
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respectively. In addition, amino acids, organic acids and glycolytic intermediates were 
detected, suggesting diverse metabolic differences between wild-type and mutant 
IDH1 tumours.  
 
Fold difference between IDH1 mutant and wild-type tumour samples
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Figure 3.2 Metabolites responsible for the segregation of gliomas based on IDH1 
status. Metabolites responsible for the segregation between IDH1 mutant and wild-type 
tumour samples were calculated, where the fold difference between IDH1 mutated patient 4 
and 12 tumour samples and remaining wild-type tumour samples were calculated and filtered 
for consistent changes of >20% in both the IDH1 mutant samples. Those metabolites 
indicated twice represent the detection of different fragments. 
 
100	
	
IDH1 mutated cells do not metabolically adapt to hypoxia 
 
The significant production of (R)-2HG in IDH mutant tumours has an ambiguous role 
in HIF biology, with reports claiming that (R)-2HG either causes competition inhibition 
(Zhao et al. 2009), or acts as a co-substrate (Koivunen et al. 2012), for the activity of 
PHDs. Furthermore, the importance of wild-type IDH1 function has been shown in 
hypoxic tumour metabolic remodelling for the provision of carbon in lipid synthesis 
(Metallo et al. 2011). As HIF is a major regulator of metabolism, and mutations in 
IDH1 would be predicted to affect hypoxic metabolic remodelling, we therefore 
sought to investigate the metabolic response of IDH1 mutated cells to conditions of 
low oxygen. To characterise the hypoxic metabolic phenotype of IDH1 mutant-
expressing cells, an untargeted GC-MS analysis was employed using a U87 glioma 
cell line stably transfected with either wild-type IDH1 or IDH1 bearing the R132H 
mutation. Cells were exposed to normoxia or hypoxia for 24 hours, defined as 21% 
and 1% O2 respectively, before extraction and analysis of the polar fraction, from 
which PCA was performed.  
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Figure 3.3 IDH1 R132H are metabolically clustered in hypoxia. PCA shows segregation 
of U87 IDH1 wild-type cell samples in normoxia (21% O2) (light blue diamond) and hypoxia 
(1% O2) (dark blue crosses), and clustering of U87 IDH1 R132H cell samples in normoxia 
(21% O2) (green pluses) and hypoxia (1% O2) (red triangles) where the segregated ellipses 
(dashed lines) are representative of 75% confidence intervals (n=6 technical triplicate per 
sample). Analysis performed by Warwick Dunn. 
 
The PCA plot shown in Figure 3.3. shows clear segregation of normoxic U87 IDH1 
wild-type cell samples from hypoxic U87 IDH1 wild-type cell samples. As stabilisation 
of the HIF transcription factors during hypoxia results in the increased transcription of 
a number of metabolic target genes, this therefore suggests that wild-type IDH1 cell 
samples undergo extensive hypoxic metabolic reprogramming in response to low 
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oxygen. However, U87 IDH1 R132H cell samples are highly clustered, regardless of 
oxygen tension, suggesting that the presence of the IDH1 R132H mutation inhibits 
this adaptation. We hypothesised that this effect could either occur as a result of a 
pre-established “pseudohypoxic” phenotype through HIF stabilisation, or through an 
inability to metabolically adapt to hypoxia.  
 
The ellipse indicating the 75% confidence interval for IDH1 R132H samples 
overlapped with normoxic IDH1 wild-type U87 cells (Figure 3.3), implying a lack of 
metabolic adaptation to hypoxia. However, when expression of HIF was examined, a 
partial stabilisation was observed in IDH1 R132H U87 glioma cells in normoxia, and 
in IDH1 wild-type cells when pre-treated with 5 mM (R)-2HG for 48 hours, although 
the level of stabilisation was not similar to that observed in hypoxia (Figure 3.4A). 
This partial stabilisation of HIF might be expected to lead to a pseudohypoxic 
metabolic phenotype, rather than the inability to metabolically adapt to hypoxia, as 
observed in Figure 3.3. It was therefore investigated whether the observed 
stabilisation of HIF was sufficient to elicit a transcriptional response. Analysis of well-
characterised HIF1 metabolic target genes, pyruvate dehydrogenase kinase 1 
(PDK1), phosphoglycerate kinase 1 (PGK1), lactate dehydrogenase A (LDHA) and 
the facultative glucose transporter 1 (SLC2A1, also known as GLUT1) showed that 
there was indeed a partial transcriptional response in IDH1 mutant cells, that could 
be downstream of HIF1α. However, the increase in target gene expression was not 
uniform across all target genes examined. While PDK1 was up-regulated in IDH1 
R132H cells to levels similar to that of hypoxic IDH1 wild-type cells (Figure 3.4B), 
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only a modest increase was observed in the other target genes in the same 
conditions (Figure 3.4C, D, E). 
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Figure 3.4 IDH1 R132H cells exhibit partial stabilisation of HIF1α. (A) Partial stabilisation 
of HIF1α protein in normoxia in IDH1 R132H and IDH1 wild-type + 5 mM (R)-2HG U87 
glioma cells, along with a corresponding transcriptional increase in HIF1α target genes (B) 
PDK1, (C) PGK1, (D) LDHA and (E) SLC2A1. RT-qPCR performed in technical triplicate, 
with at least four biological replicates. Statistical significance determined using unpaired 
student’s t-test with Welch’s correction. 
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To clarify the nature of the metabolic alteration (or lack of it) induced by hypoxia in 
IDH1 mutant cells, the metabolites responsible for the observed segregation in the 
PCA plot (Figure 3.3) were identified by calculating the fold difference between 
statistically significant metabolites in each sample class (Figure 3.5). Comparison of 
IDH1 wild-type cells in normoxia and hypoxia produced a comprehensive list of 
hypoxia-inducible metabolic changes (Figure 3.5A), consisting of changes in 
intermediates of glycolysis (e.g. sugar derivatives) and the TCA cycle (e.g. malate 
and aspartate). Additional alterations were identified in the levels of some NEAAs, 
including alanine, glycine, glutamate and proline. Interestingly, differences in BCAAs 
valine, leucine and isoleucine were detected. These decreased in hypoxia, which is 
consistent with recent publications to suggest that wild-type IDH1 tumours catabolise 
BCAAs in hypoxia to aid tumour progression (Tönjes et al. 2013). In comparison with 
wild-type cells, IDH1 R132H-expressing cells exhibited very few metabolic changes 
in hypoxia, where only sugar derivatives, aspartate and malate were detected (Figure 
3.5B).  
 
Few metabolic changes were also observed between wild-type and R132H IDH1 
cells in normoxic conditions (Figure 3.5C), including the increase in BCAAs observed 
in wild-type IDH1, and decrease in malate and aspartate observed in R132H IDH1 
U87 cells. The greatest change was the expected production of 2HG in IDH1 R132H 
cells (Figure 3.5C). Consistent with the inability of IDH1 R132H cells to adapt to 
hypoxia, more statistically significant metabolites were differentially detected between 
wild-type and mutant IDH1 in hypoxia (Figure 3.5D), than in normoxia (Figure 3.5C). 
The metabolites identified as being different between IDH1 wild-type and mutant cells 
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in hypoxia include glycolytic intermediates (sugar derivatives, glycerol-3-phosphate 
and pyruvate) and NEAAs (aspartate, glutamate, glycine, and alanine). Many of 
these metabolic changes were similar to those observed between normoxic and 
hypoxic IDH1 wild-type cells (Figure 3.5A). Redox sensitive changes in nicotinamide 
– a precursor to NAD(P+) synthesis in the cell - were consistently detected in both 
tissue (Figure 3.2) and cell models (Figure 3.5A and 3.5D), and found to be 
increased in IDH1 mutant tumours and hypoxic wild-type IDH1 cells.  
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Figure 3.5 Metabolites responsible for the segregation between IDH1 status and 
oxygen tension. Fold difference in significant metabolites between normoxia (21% O2) and 
hypoxia (1% O2) in IDH1 wild-type (A) and IDH1 mutant (B) cell samples and between IDH1 
wild-type and mutant in normoxic (21% O2) (C) and hypoxic (1% O2) (D) conditions identified 
by GC-MS (n=6 technical replicates in total). Those metabolites indicated twice represent the 
detection of different fragments. 
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The data above therefore show that IDH1 R132H U87 glioma cells exhibit very few 
metabolic changes in response to low oxygen. As this would be expected to impact 
their ability to maintain or adapt their phenotype in hypoxia, we wanted to assess 
their growth characteristics in hypoxia. The normoxic proliferation of U87 IDH1 
R132H-expressing cells was observed to be slower than that of U87 IDH1 wild-type 
cells (Figure 3.6), consistent with previously reported data (Bralten et al. 2011). As 
expected, the growth of wild-type cells was indeed markedly reduced in hypoxia 
(~50% decrease; Figure 3.6). However, the hypoxic growth rate for mutant cells did 
not differ to that observed in normoxia until day 3 (72 hours), where there was a 
consistent marked decline in cell number, indicating that these cells are unable to 
continue to proliferate in chronic hypoxia (Figure 3.6). Therefore, despite an initial 
growth advantage, lack of metabolic adaptation appears to render IDH1 mutant cells 
more sensitive to long periods of hypoxic stress and consequently become unable to 
maintain proliferation.  
 
 
Figure 3.6 U87 hypoxic growth curve. Proliferation assay of U87 IDH1 wild-type and U87 
IDH1 R132H cell samples in normoxia (21% O2) and hypoxia (1% O2). Cell counts were 
determined over a time course of 4 days (96 h) (n=3 technical replicates per day, n=5 
biological replicates in total). 
108	
	
Cells with mutated IDH1 sustain oxidative reactions in hypoxia 
 
Whilst being an untargeted tool, and therefore useful for gaining an overview of a 
system, the metabolomic approach offers limited mechanistic information regarding 
pathway activity. To improve our understanding of some of the metabolic differences 
outlined above, we performed a targeted metabolic tracer analysis using stable 
isotope-enriched carbon sources, and employed a cell line derived from a low-grade 
human oligodendroglioma (HOG) as a more biologically relevant model, infected to 
stably overexpress wild-type or R132H mutant IDH1 by lentivirus (Reitman et al. 
2011). Since the majority of metabolites detected in the metabolomics approach 
indicated changes in central carbon metabolism, cells were incubated for 24 hours 
with [U-13C6]-glucose and [U-13C5]-glutamine to probe metabolic differences between 
IDH1 wild-type and mutant cells during the metabolic adaptation to hypoxia. The 
resulting polar extracts were analysed for 13C incorporation by GC-MS.  
 
Production of (R)-2HG in the IDH1 R132H HOG cell model was confirmed (Figure 
3.7A), and shown to increase in hypoxia, consistent with previous reports (Wise et al. 
2011). Pyruvate is an important metabolite, being the end-point of glycolysis, as it 
represents a key metabolic node and a major entry point to the TCA cycle. Changes 
in 13C incorporation into this metabolite can therefore reveal important information 
regarding the metabolic state of the cell (Figure 3.7B). Figure 3.7 shows the 
comparison between the percentage 13C incorporation into pyruvate and its products 
lactate and alanine after incubating cells for 24 hours with [U-13C6]-glucose. 
Increased 13C incorporation in lactate was observed when both cell lines were 
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exposed to hypoxia, suggesting that the majority of lactate is produced from glucose 
in hypoxic conditions (Figure 3.7C). In comparison to lactate, ~50% less 13C 
incorporation was detected in alanine (Figure 3.7D). As the majority of lactate is 
produced in the cytosol, and the majority of alanine is produced in the mitochondria 
(Adeva et al. 2013; Vacanti et al. 2014; Yang et al. 2014; Groen et al. 1982), this 
observation would suggest that the enrichment of the cytosolic and mitochondrial 
pools of pyruvate from glucose are different, whereby the majority of cytosolic 
pyruvate to support lactate production is derived from [U-13C6]-glucose. The 
mitochondrial pool of pyruvate is consequently generated from glucose and another 
source, most likely through glutamine-derived malate. Analysis of 13C incorporation 
into pyruvate revealed significantly reduced 13C incorporation into pyruvate in 
hypoxia, particularly in the IDH1 R132H HOG cells (Figure 3.7E), inferring reduced 
glycolytic carbon entry into the mitochondrion in hypoxia, as expected, and potentially 
an increase in the supply of alternative sources of mitochondrial pyruvate in IDH1 
mutant cells under conditions of low oxygen.  
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Figure 3.7 IDH1 mutant cells exhibit altered pyruvate metabolism. (A) Confirmation of 
2HG production in HOG IDH1 R132H cell model. The ratio of 2HG/glutamate is used to show 
the substantial increase in 2HG production in IDH1 R132H HOG cells. Typically, the ratio of 
2HG to αKG is used (as αKG has the same labelling pattern as 2HG) or norvaline. However, 
αKG was not present in detectable amounts in these samples and norvaline does not 
account for differences in cell number. (B) Schematic of the pyruvate nodes, showing 
differential 13C incorporation into (C) lactate, (D) alanine and (E) pyruvate. Data is in technical 
triplicate, mean +/- S.D. Significance determined using two-tailed unpaired student’s t-test. 
 
When pyruvate enters the mitochondria, it can either be oxidatively decarboxylated 
by PDH to produce acetyl CoA, or carboxylated by PC to form oxaloacetate. As 
carbons in citrate arise from both oxaloacetate and acetyl CoA, the mass 
isotopologue distribution (MID) of citrate can reveal differences regarding the relative 
activity of PDH and PC using [U-13C6]-glucose (Figure 3.8A). Although minimal 
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changes were observed between cell types in normoxic conditions (Figure 3.8B), in 
hypoxia, IDH1 R132H HOG cells preserved a high contribution of the M+2 
isotopologue to the overall pool, indicative of retained PDH activity (Figure 3.8C). In 
contrast, wild-type IDH1 HOG cells exhibited almost 50% less M+2 and increased 
proportions of the M+3 isotopologue, consistent with the expected decrease in 
pyruvate oxidation during hypoxia and a subsequent increase in mitochondrial PC 
activity for continued TCA cycle anaplerosis (Figure 3.8C). Sustained PDH activity in 
IDH1 mutant cells was further exemplified when comparing the relative PDH activity 
by calculating the ratio of M+2 citrate/M+3 alanine (Figure 3.8D), whereby M+3 
alanine represents the labelling of the mitochondrial pyruvate pool. 
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Figure 3.8 IDH1 R132H cells sustain the activity of pyruvate dehydrogenase in 
hypoxia. (A) Schematic to describe mitochondrial pyruvate metabolism by analysing the 
mass isotopologue distribution (MID) of citrate, where M+0, M+1, M+2 etc. mass 
isotopologues correspond to ion fragments containing 0, 1, 2 13C atoms, respectively. 
Pyruvate oxidation by PDH results in M+2 citrate from [U-13C6]-glucose. This is observed in 
both wild-type and mutant IDH1 cells in normoxia (B). As PDH activity is reduced in hypoxia 
through the HIF1α-mediated transcriptional activation of PDK1, an increase in PC activity can 
occur, resulting in the carboxylation of pyruvate to oxaloacetate and giving rise to M+3 citrate 
(C). This is observed in wild-type IDH1 cells only, suggesting that HIF1α transcriptional 
activity is compromised in IDH1 R132H cells. M+4 and M+5 citrate are formed from a second 
round of TCA cycle activity from M+2 and M+3 citrate, respectively. (D) The ratio of M+2 
citrate to M+3 alanine is used to further illustrate this metabolic difference, as a readout of 
PDH-derived citrate from mitochondrial pyruvate. Data is performed in technical triplicate, 
mean +/- S.D. Statistical significance determined using two-tailed unpaired Student’s t-test.	
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HIF-induced up-regulation of PDK1 in hypoxia results in the phosphorylation and 
inactivation of PDH, yet our findings from the metabolic tracer analysis using [U-13C6]-
glucose suggested that IDH1 R132H cells sustain PDH activity in conditions of low 
oxygen. Therefore, our data suggest that HIF1α transcriptional activity could be 
compromised in IDH1 R132H cells in hypoxia. Despite this, a degree of HIF1α 
stabilisation and transcriptional up-regulation of PDK1 was observed in IDH1 R132H 
cells (Figure 3.9A and B), which is increasingly evident at lower oxygen tensions and 
is consistent with findings from the IDH1 U87 glioma model (Figure 3.4), although 
transcriptional activation appears to occur to a lesser extent. Interestingly, analysis of 
HIFα subunit stabilisation in IDH1 R132H HOGs showed increased HIF1α 
stabilisation and blunted HIF2α stabilisation, implying differential regulation in the HIF 
hydroxylases (Figure 3.9A). 
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Figure 3.9 Partial HIF1α stabilisation and transcriptional activity. (A) Increased HIF1α 
protein stabilisation and blunted HIF2α protein stabilisation is observed in IDH1 R132H cells, 
which is particularly emphasised at lower oxygen tensions of 0.3% O2, along with (B) 
increased transcriptional expression of HIF1α target gene PDK1. Data is mean +/- S.E.M. 
Statistical significance determined using unpaired student’s t-test. 
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Analysis of differential 13C incorporation from glucose in IDH1 wild-type and R132H 
mutant cells in the metabolic adaptation to hypoxia indicated perturbed central 
carbon metabolism in IDH1 mutant cells, particularly in the mitochondrial metabolites. 
Glutamine is the other major carbon source to glucose, supplying carbons into the 
TCA cycle in most if not all proliferating cells. To investigate the metabolism of 
glutamine in both IDH1 wild-type and mutant cells in hypoxia, cells were incubated for 
24 hours with [U-13C5]-glutamine. Assessment of 13C label incorporation in citrate can 
be used to determine the relative extent of oxidative and reductive glutamine 
metabolism (Figure 3.10A). Minimal changes in 13C label incorporation were 
observed between cells expressing wild-type IDH1 or the R132H mutant when 
comparing the citrate MID in normoxia (Figure 3.10B). Both cell lines predominately 
exhibit M+4 and M+2 isotopologues, indicative of one and two rounds of glutamine 
oxidation through TCA cycle activity, respectively. However, significant changes were 
observed in 13C incorporation into citrate in hypoxia (Figure 3.10C). Unlike mutant 
IDH1 HOG cells, which exhibit no difference in 13C incorporation in hypoxia, wild-type 
IDH1 cells showed an increase in the proportion of M+5 citrate, consistent with the 
reductive carboxylation of glutamine-derived αKG as previously reported in hypoxic 
cells to support de novo lipogenesis (Metallo et al. 2011; Wise et al. 2011). This 
metabolic change is further exemplified by plotting the ratio of M+3/M+4 aspartate 
(Figure 3.10D) as a measure of relative reductive/oxidative glutamine metabolism, 
where M+3 aspartate is derived from M+5 citrate through the activity of ATP citrate 
lyase (Figure 3.10A).  
 
 
115	
	
	
  A 
 
 B                                                           C 
M+
0
M+
1
M+
2
M+
3
M+
4
M+
5
M+
6
0
5
10
20
40
60
80
100
No. of isotopes per molecule
C
itr
at
e 
M
ID
 
[U
-1
3 C
5]
-g
lu
ta
m
in
e 
(%
)
IDH1 wild-type 
IDH1 R132H
M+
0
M+
1
M+
2
M+
3
M+
4
M+
5
M+
6
0
5
10
20
40
60
80
100
No. of isotopes per molecule
C
itr
at
e 
M
ID
 
[U
-1
3 C
5]
-g
lu
ta
m
in
e 
(%
) IDH1 wild-type 
IDH1 R132H
*
 
 
Figure 3.10 IDH1 mutants have compromised hypoxic reductive glutamine. Comparison 
of the MID in citrate employing a [U-13C5]-glutamine tracer to assess the relative contributions 
of oxidative and reductive TCA activity. In normoxia, glutamine-derived αKG undergoes 
oxidative TCA metabolism producing M+4 citrate from M+4 TCA cycle intermediates. In 
hypoxia, cells increase their reliance on reductive carboxylation of glutamine-derived αKG 
producing M+5 citrate and M+3 aspartate (A). No differences are observed in the citrate MID 
in normoxia (B), but in hypoxia, only IDH1 wild-type cells exhibit an increase in M+5 citrate 
(C), suggesting that IDH1 R132H cells do not increase their reliance on reductive glutamine 
metabolism in hypoxia. 
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Figure 3.10 - IDH1 mutants have compromised hypoxic reductive glutamine, 
continued. This metabolic change is further exemplified by calculating the ratio of M+3/M+4 
aspartate as a measure of reductive/oxidative glutamine metabolism (D). Experiments 
performed in technical triplicate, data is mean +/- S.D. Significance determined using two-
tailed unpaired Student’s t-test. 
 
As reductive glutamine metabolism does not appear to be induced in hypoxic IDH1 
R132H-expressing cells, oxidative metabolism of this amino acid was assessed, 
using the ratio of uniformly 13C labelled succinate and fumarate to glutamate. Wild-
type IDH1 cells present a relative increase in M+4 succinate (Figure 3.11A), along 
with a corresponding decrease in M+4 fumarate in hypoxia (Figure 3.11B), indicative 
of decreased complex II activity and most likely as a result of decreased respiration. 
However, lack of a hypoxia-induced shift in this ratio in IDH1 R132H cells infer that 
they sustain oxidative metabolism in hypoxia unlike their wild-type counterparts, 
which is again consistent with previously reported data (Leonardi et al. 2012; 
Grassian et al. 2014). This data suggests that the decreased label incorporation 
observed in pyruvate from [U-13C6]-glucose in hypoxic IDH1 R132H cells compared 
to wild-type cells (Figure 3.7E) is likely to be a product of the continued oxidation of 
glutamine and synthesis of pyruvate from glutamine-derived malate. Collectively, our 
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results indicate that IDH1 mutations may compromise the capacity of the cell to 
undergo reductive glutamine metabolism, and continue to sustain oxidative 
metabolism despite the low oxygen conditions.  
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Figure 3.11 IDH1 mutants sustain oxidative TCA metabolism in hypoxia. Consistent with 
the lack of reductive carboxylation in IDH1 R132H HOG cells is sustained oxidative 
metabolism, where no relative increase in 13C incorporation in succinate (A) or subsequent 
decrease in fumarate (B) was observed from [U-13C5]-glutamine. Data is presented M+4/M+5 
glutamine to account for differences in anaplerosis. Experiments performed in technical 
triplicate. Data is mean +/- S.D. Statistical significance determined using two-tailed unpaired 
Student’s t-test. 
 
The sustained activity of PDH and oxidative glutamine metabolism exhibited by IDH1 
mutant cells in hypoxia suggest that the presence of the IDH1 R132H mutation 
compromises the metabolic adaptation to hypoxia, despite partial HIF1α stabilisation 
and transcriptional activity. As (R)-2HG production from IDH1 mutant cells has been 
reported to competitively inhibit numerous αKG-dependent enzymes (Zhao et al. 
2009; Xu et al. 2011; Turcan et al. 2012; Lu et al. 2012), the lack of metabolic 
adaptation to HIF-target genes could imply potential inhibition of protein synthesis, as 
translational activity has been recently shown regulated by αKG-dependent 
hydroxylases (Zhuang et al. 2015).  
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IDH1 mutants exhibit pseudohypoxic proline metabolism 
 
Contrary to the number of metabolic findings that argue mutant IDH1 cells do not 
metabolically adapt to hypoxia, there was one observed phenotype to suggest that 
mutant IDH1 cells may display aspects of “pseudohypoxia”. Using a [U-13C5]-
glutamine tracer for 24 hours, our results revealed that hypoxia significantly increases 
glutamine-derived proline biosynthesis in wild-type IDH1 cells (Figure 3.12A). Proline 
is one of many NEAAs synthesised from glutamine (Figure 3.12B). In comparison to 
wild-type IDH1 cells, the presence of the IDH1 R132H mutation, significantly 
increased 13C incorporation from glutamine into proline in both normoxic and hypoxic 
oxygen tensions (Figure 3.12A), with normoxic levels in IDH1 R132H cells being 
analogous to that of wild-type expressing hypoxic cells.  
 
Steady-state concentrations of intracellular proline, as determined by 1D 1H NMR 
spectroscopy, support the observed increase in proline biosynthesis at oxygen 
tensions as low as 0.3% (Figure 3.12C). Approximately twice the amount of proline 
was observed in IDH1 R132H HOG cells compared to wild-type in normoxic 
conditions. Analysis of the culture media confirmed the export of glutamine-derived 
proline out of the cell (Figure 3.12D), which is predicted to permit continued 
intracellular proline synthesis, as the activity of the last enzyme involved in this 
pathway is strongly product inhibited by proline (De Ingeniis et al. 2012). Increased 
export of glutamine-derived proline was observed in the media of hypoxic wild-type 
cells when compared to their normoxic controls and mutant IDH1 HOG cells in 
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normoxia (Figure 3.12D). These data suggest that IDH1 mutant cells synthesise and 
excrete proline in a manner similar to that of hypoxic wild-type IDH1 cells. 
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Figure 3.12 IDH1 R132H HOG cells exhibit hypoxic-like proline metabolism. Proline 
biosynthesis from [U-13C5]-glutamine increases in hypoxia in IDH1 wild-type cells and is 
increased in IDH1 R132H cells at normal oxygen tensions compared to wild-type as identified 
by GC-MS (A) Data is presented M+5 glutamate/M+5 proline to account for differences in 
anaplerosis. Experiments performed in technical triplicate. Data is mean +/- S.D. The 
majority of proline in synthesised from glutamine, where M+5 glutamine gives rise to M+5 
proline (B). Intracellular steady-state concentrations of proline, as determined by 1D 1H-NMR 
Spectroscopy, reflect this increase in pathway usage (C) (n=6 biological replicates, data is 
mean +/- S.E.M). (D) [U-13C5]-proline is exported out of the cell, where increased 13C 
incorporation from [U-13C5]-glutamine is observed in hypoxia (1% and 0.3% O2) and in IDH1 
R132H HOG cells in normoxia. Experiments performed in biological replicate. Data is mean 
+/- S.E.M. Significance determined using two-tailed unpaired Student’s t-test for all graphs.  
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Figure 3.13 IDH1 mutant cells exhibit a blunted transcriptional increase in the proline 
biosynthetic eyzymes. Gene expression of enzymes involved in the biosynthetic pathway 
(A) are increased in wild-type IDH1 HOG cells (B) but blunted in IDH1 R132H HOG cells (C). 
Experiments performed in technical and biological triplicate. Data is mean +/- S.E.M. 
Significance determined by one-way ANOVA. 
 
As metabolic pathway activity can be altered by enzyme expression, relative 
expression of the enzymes shown to be involved in mitochondrial proline 
biosynthesis from glutamine: pyrroline-5-carboxylate synthetase (ALDH18A1), 
pyrroline carboxylate reductase 1 (PYCR1) and 2 (PYCR2) (Figure 3.13A), were 
assessed (De Ingeniis et al. 2012). Consistent with the observed increase in 
glutamine-derived proline biosynthesis in IDH1 wild-type cells in response to low 
oxygen, expression of the proline biosynthetic enzymes were increased in hypoxia 
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(Figure 3.13B), where PYCR2 and ALDH18A1 were the most responsive. However, 
IDH1 R132H HOG cells exhibit a blunted transcriptional response for all three 
transcripts (Figure 3.13C). Importantly, the increase in hypoxic gene expression was 
not reflected at the protein level, where no significant difference between IDH1 status 
or exposure to low oxygen tension (24 hours at 1% or 0.3% O2) was detected (Figure 
3.14A). This reasons that observed changes in proline synthesis are unlikely to be 
due to altered expression of the biosynthetic enzymes.  
 
As previously described, IDH1 mutations result in the accumulation of the 
oncometabolite, (R)-2HG, shown to be the direct mediator of a number of reported 
phenotypes in cells and tissues bearing the IDH1 mutation. To investigate whether 
the proline synthetic phenotype was also due to (R)-2HG accumulation, IDH1 wild-
type cells were treated with (R)-2HG for 48 hours prior to [U-13C5]-glutamine addition. 
Despite the build-up of intracellular 2HG in IDH1 wild-type cells after treatment, no 
change in proline concentration was observed (Figure 3.15B), suggesting that the 
R132H IDH1 mutation elicits this metabolic phenotype through an alternative 
mechanism, likely to occur through a change in redox owing to the presence of the 
IDH1 R132H mutation.  
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Figure 3.14 Increased PYCR1 gene expression may support the increase in proline 
biosynthesis displayed in IDH1 mutants. Immunoblot analysis confirms no difference in 
PYCR1 or PYCR2 protein expression between oxygen tension, or IDH1 status (A). The 
increase in glutamine-derived proline biosynthesis in IDH1 R132H HOG cells is unlikely to 
result from (R)-2HG production (B). Experiments performed in biological triplicate. Data is 
mean +/- S.E.M. PYCR1 gene expression is increased in IDH1 mutated LGG (C) and GBMs 
(D) (data extracted from TCGA cbioportal). 
 
IDH1 mutations are observed in the majority of LGGs and secondary GBM (Parsons 
et al. 2008). Despite no significant difference in the gene expression of any of the 
biosynthetic enzymes between wild-type and mutant IDH1 status in vitro, in vivo 
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analysis of PYCR1 gene expression was significantly increased in IDH1 mutant 
LGGs (Figure 3.15C) and GBMs (Figure 3.15D). 
 
                         A                                                    
 
 
Figure 3.15 Successful knock down of PYCR isoforms. Successful knock down of PYCR 
isoforms 1 and 2 protein was validated for all experimental conditions (A). Immunoblotting 
demonstrates protein knock down 48 h post transfection. 
 
To investigate the biological function of increased proline biosynthesis from glutamine 
in mutant IDH1 R132H cells, knock down of the rate-limiting step - PYCR enzyme 
isoforms 1 and 2 by siRNA was validated and achieved for all experimental 
conditions (Figure 3.15A). Knockdown of both isoforms reduced label incorporation 
from [U-13C5]-glutamine to proline, where knockdown of PYCR1 appeared to have the 
most significant effect regardless of oxygen tension (Figure 3.16A). The effect of 
PYCR2 knock down on 13C incorporation had a greater effect in hypoxia (Figure 
3.16B), consistent with the observed transcriptional increase in PYCR2 gene 
expression in response to low oxygen (Figure 3.13B). Knockdown of either PYCR1 or 
2 decreased intracellular steady-state concentrations of proline by at least 50% in 
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IDH1 wild-type and mutant-expressing cells (Figure 3.16C), concluding that the 
majority of proline in these cells is synthesised by these two isozymes. 
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Figure 3.16 PYCR knockdown reduces proline biosynthesis. Knockdown of PYCR 
isoforms decrease 13C label incorporation from [U-13C5]-glutamine in normoxia (A) and 
hypoxia (B), where siPYCR1 has the most significant effect. Decreased steady-state 
concentrations of intracellular proline also confirm knockdown (C). All data is mean +/- S.D, 
performed in technical triplicate and analysed by GC-MS. Metabolite abundance was 
normalised to d6-glutaric acid and cell number, and then calculated relative to wild-type. 
Significance determined using two-tailed unpaired Student’s t-test. 
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Increased proline biosynthesis maintains redox plasticity 
 
As the synthesis of proline from glutamate is a highly redox regulated pathway, 
requiring 2 molecules of NAD(P)H (Figure 3.13A), it was hypothesised that increased 
proline biosynthesis may be an important means by which cells and tumours bearing 
an IDH1 mutation regulate cellular redox state. Previous reports suggested that IDH1 
mutant cells may have higher levels of oxidative stress than IDH1 wild-type cells 
(Gilbert et al. 2014). To test whether the pathway consumed NADPH, and therefore 
induced this phenotype, cells were treated with H2O2 and assessed for viability after 
24 hours. No difference was observed between the two cell lines, suggesting that this 
pathway is unlikely to be consuming NADPH. Independent knock down of PYCR1 
and 2 before treatment with H2O2, would increase resistance to oxidative stress-
mediated cell death if the pathway were NADPH dependent. Again, no differences 
were detected (Figure 3.17). These data are consistent with reports that PYCR1 and 
2 exhibit a higher specific activity in the presence of NADH compared to NADPH in 
melanoma cells (De Ingeniis et al. 2012).  
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Figure 3.17 Increased mitochondrial proline biosynthesis is unlikely to consume 
NADPH. (A) Dose-response curves to compare and determine IC50 of H2O2 in wild-type and 
R132H IDH1 cells, as determined by SRB assay. (B) SRB assay confirmed no significant 
difference in relative cell viability between wild-type and R132H IDH1 HOG cells in response 
to treatment with 100 µM H2O2. All experiments performed in biological and technical 
triplicate. H2O2 treated cells are normalised to untreated for each condition. Data is mean +/- 
S.E.M. 
 
The majority of mitochondrial NADH is produced by dehydrogenases (PDH, IDH3, 
MDH and αKGDH) to supply electrons to the electron transport chain. If increased 
proline biosynthesis from glutamine were to consume NADH, then knockdown of 
PYCR1 or 2 would be expected to increase the ratio of NADH/NAD+ and result in an 
increase in NADH oxidation by complex I. Confocal microscopy was used to assess 
cellular levels of NAD(P)H (not NAD(P)+), as the reduced forms of these molecules 
autofluoresce when excited with ultra-violet light (Chance & Baltscheffsky 1958). 
NADH is the major autofluorescent signal in cells (Avi-Dor et al. 1962), hence 
confocal microscopy real-time imaging of NADH has been widely employed to detect 
changes in NADH oxidation as a read-out of mitochondrial respiration (Mayevsky 
1984; Mayevsky & Rogatsky 2006). To better evaluate the maximum and minimum 
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NADH levels in the mitochondria, NADH oxidation was blocked with rotenone, an 
inhibitor of complex I, and mitochondria were uncoupled using carbonyl cyanide m-
chlorophenylhydrazone (CCCP) to stimulate maximal NADH oxidation (Figure 3.18A, 
B, C, D). 
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Figure 3.18 Knockdown of PYCR increases NADH availability in IDH1 R132H cells. 
NADH autofluorescence for IDH1 wild-type cells in normoxia (A) and hypoxia (B) and IDH1 
R132H cells in normoxia (C) and hypoxia (D). Addition of CCCP (20  µM) uncouples 
respiration resulting in depleted mitochondrial NADH, whereas addition of rotenone (60  µM) 
inhibits complex I resulting in increased NADH autofluorescence. 
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Figure 3.18 – Knockdown of PYCR increases NADH availability in IDH1 R132H cells, 
continued. Minimal changes in basal NADH are observed between normoxia and hypoxia. 
Rotenone addition in hypoxia increases NADH levels to that of rotenone-treated normoxic 
cell samples. (E) Knockdown of siPYCR1 has no effect on wild-type IDH1 cells but 
increases NADH levels in IDH1 R132H HOG cells, suggesting that proline synthesis 
consumes mitochondrial NADH that would otherwise be available for oxidation by complex 
I. Data subtracted from CCCP, treated subtracted from untreated. Mean is +/- SD, 
Significance determined using one-way ANOVA. 
 
After normalising NADH levels to basal (CCCP-induced), the change in NADH level 
following rotenone treatment was assessed as a measure of the proportion of 
mitochondrial NADH oxidised through complex I activity. No change was observed in 
NADH levels on knockdown of PYCR1 in IDH1 wild-type cells. However, a significant 
increase in NADH was observed in IDH1 R132H cells (Figure 3.18E), suggesting that 
loss of PYCR1 activity results in complex I being responsible for oxidising a greater 
proportion of the mitochondrial NADH. This suggests that the increase in glutamine-
derived proline biosynthesis in IDH1 R132H cells in normoxia uses mitochondrial 
NADH that would otherwise be available for oxidation by complex I. Interestingly, 
comparison of NADH levels between wild-type and IDH1 R132H cells revealed 
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significantly less NADH in IDH1 R132H cells, but were restored to levels similar to 
that of IDH1 wild-type cells on knockdown of PYCR1 (Figure 3.18E). This may 
reason that the increased proline biosynthesis observed in IDH1 R132H cells in 
normoxia oxidises a considerable proportion of mitochondrial NADH.  
 
Based on the results presented in Figure 3.18, it was hypothesised that proline 
synthesis in IDH1 R132H cells was responsible for oxidation of a significant 
proportion of mitochondrial NADH in normoxia, and knockdown of PYCR1 or 2 would 
increase the availability of NADH for electron transfer in the ETC, thereby increasing 
oxygen consumption. To investigate this, the rate of oxygen consumption was 
measured using a Clarke-type oxygen electrode. Comparable oxygen consumption 
rates were observed between wild-type and IDH1 R132H-expressing cells in both 
U87 (Figure 3.19A) and HOG (Figure 3.19B) cell models. Consistent with our NADH 
autofluorescence results, knockdown of both PYCR1 and 2 had no effect on oxygen 
consumption in IDH1 wild-type cells (Figure 3.19C). However, the rate of oxygen 
consumption was significantly increased in IDH1 R132H HOG cells when either 
PYCR1 or 2 were knocked down (Figure 3.19D) This indicates that proline 
biosynthesis oxidises significant NADH in IDH1 mutant-expressing cells, reducing the 
requirement of these cells to consume oxygen, and perhaps making more oxygen 
available for other cellular processes.  
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Figure 3.19 Knockdown of PYCR increases NADH availability for oxygen consumption 
in IDH1 mutant cells. No difference is observed in oxygen consumption measurements 
between IDH1 status in either (A) U87 or (B) HOG cell models in normoxia. Knockdown of 
PYCR 1 and 2 have no effect in oxygen consumption in (C) IDH1 wild-type HOG cells but 
resulted in a significant increase in oxygen consumption in (D) IDH1 R132H HOG cells. 
Experiments performed in technical triplicate. Data is mean +/- S.D. Significance determined 
using one-way ANOVA. 
 
Oxidation of NADH in the mitochondria by a non-ETC reaction, such as proline 
biosynthesis would provide cells the means to continue TCA cycle dehydrogenase 
activity, producing anabolic substrates for continued proliferation in the presence of 
ETC inhibitors, such as rotenone. Indeed, wild-type cells were more sensitive to sub-
maximal concentrations of rotenone than mutant IDH1 cells, and this sensitivity 
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decreased when wild-type cells were exposed to hypoxia (Figure 3.20B). Collectively, 
our findings support the concept that increased proline biosynthesis occurs in 
response to a change of cellular redox elicited by cells expressing the IDH1 R132H 
mutation or those in hypoxia. This alteration in mitochondrial activity may be used as 
a means of regulating mitochondrial redox state, removing the dependency of NADH 
oxidation on oxygen availability, and permitting continued proliferation in an oxygen 
sparing mechanism. 
	
A                                                                              B 
24h Rotenone
0 10 50 100 300 500
0
20
40
60
80
100
R
el
at
iv
e 
C
el
l V
ia
bi
lit
y
[Rotenone] (nM)
IDH1 wildtype
IDH1 R132H
 
WT
 21
%
R1
32
H 
21
%
WT
 1%
0.0
0.2
0.4
0.6
0.8
1.0
R
at
io
 o
f R
ot
en
on
e 
tr
ea
te
d 
/ u
nt
re
at
ed
*
**
 
 
Figure 3.20 IDH1 mutants are less sensitive to complex I inhibition. (A) Dose-response 
curves to compare and determine IC50 of rotenone in wild-type and R132H IDH1 cells, as 
determined by SRB assay. (B) IDH1 R132H HOG cells are less sensitive to complex I 
inhibition when treated with 50 nM rotenone for 72 h, as determined using SRB assay. Data 
performed in technical and biological triplicate, presented as mean +/- S.E.M. Significance 
determined using an unpaired student’s t-test. 
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Discussion 
 
Although mutant IDH1 gliomas are clinically and biologically distinct to those 
expressing wild-type IDH1, unravelling the mechanisms behind this is challenging. 
The nature of the interplay between IDH1 mutations and hypoxia on glioma biology 
and tumour progression remains somewhat elusive. Our results have shown that 
IDH1 mutant gliomas are metabolically distinct to those with wild-type IDH1 (Figure 
3.1 and 3.2), and mutations in IDH1 compromise the metabolic adaptation to hypoxia 
(Figure 3.3), despite observable HIF1α stabilisation (Figure 3.4A and 3.9A). When 
exposed to conditions of low oxygen, IDH1 R132H U87 glioma cells did not exhibit 
the same degree of metabolic adaptation as observed for wild-type cells (Figure 3.3). 
Given the overlapping metabolic profile of IDH1 R132H cells with that of normoxic 
IDH1 wild-type cells (rather than hypoxic wild-type IDH1 cells) in the PCA plot (Figure 
3.3), and the greater number of metabolic differences identified between IDH1 
mutant-expressing cells in both oxygen tensions when compared to hypoxic wild-type 
IDH1 cells (Figure 3.5), our metabolomic data perhaps more strongly suggest that 
IDH1 mutant cells compromise the metabolic adaptation to hypoxia. Indeed, 
sustained activity of PDH (Figure 3.8C and 3.8D) and oxidative glutamine metabolism 
(Figure 3.11) in IDH1 mutant cells in hypoxia, as identified by 13C labelling 
approaches, suggest that these cells are unable to undergo a complete metabolic 
adaptation to hypoxia. Consistent with this theory, was the observation that IDH1 
mutant cells initially maintain proliferation in hypoxia but become more sensitive to 
hypoxic stress over longer periods of time (Figure 3.6).  
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There is overlap in the statistically significant metabolites responsible for the 
segregation of wild-type and mutant IDH1 from the metabolomics analysis of glioma 
tissue and U87 cell samples. This confirms that the cell model used is biologically 
relevant, and would be important should novel therapeutic approaches be designed 
using our results. Many of the metabolic differences identified in tissues and cells 
reveal differences in glycolytic intermediates, organic acid and amino acids – but also 
include redox sensitive changes. Nicotinamide is a redox sensitive change that was 
consistently detected, where it is found to be increased in IDH1 mutant tumour 
tissues (Figure 3.2) and hypoxic IDH1 wild-type cells (Figure 3.5A and 3.5D). 
Changes in nicotinamide is indicative of altered NAD+ metabolism, as it is not only a 
precursor for NAD(P)+ synthesis, but is also a product of de-acetylation through the 
activity of NAD+-dependent sirtuins, and/or a product of poly ADP ribose polymerase 
(PARP) activity. Interestingly, recent reports have suggested that IDH enzymes 
inhibit alkylated DNA repair enzyme alkB homolog (ALKBH) through the production of 
(R)-2HG leading to DNA damage and sensitisation to alkylating agents (Wang et al. 
2015). This would result in high DNA damage that could increase PARP activity, 
utilising (and potentially depleting) NAD+ as a substrate, and regenerating 
nicotinamide. This report could explain the increased nicotinamide observed, and 
may contribute to the susceptibility of IDH1 mutant cancers to NAD+ depletion 
(Tateishi et al. 2015).  
 
The significant production of (R)-2HG in IDH1 mutant cells results in partial HIF1α 
stabilisation and transactivation of target genes in both cell line models studied 
(Figure 3.4 and 3.9), indicative of a pseudohypoxic phenotype common to those 
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observed in SDH and FH deficient cells and tumours. The discrepancies in the extent 
of HIF-target gene transactivation (Figure 3.4) suggest differences in their regulation, 
which could be accounted for by the spectrum of effects HIF signalling has 
depending on its level of stabilisation. Alternatively, these differences may emanate 
from changes beyond the HIF/hypoxic response elicited in the IDH1 mutant cells. For 
example, owing to the effects of mutant IDH1 on cellular epigenetics, or other 
transcription factors.  
 
Despite an increase in the mRNA of PDK1, the regulatory kinase for PDH (Figure 
3.4B and 3.9B), no decrease in PDH activity was observed in our metabolic studies 
(Figure 3.8). This infers that either the increased PDK1 mRNA is not reflected at the 
increased protein expression level, or a compensatory increase in the PDH 
phosphatase 1 (PDP1) allows IDH1 mutant cells to retain PDH activity. If RNAi 
approaches were employed, it may be possible to understand whether the differential 
response in HIF target genes is due to the activity of HIF or by the activity of a 
different transcription factor. Nuclear localisation of HIF, or chromatin 
immunoprecipitation studies may provide additional evidence to prove whether HIF is 
transcriptionally active and binds to the PDK1 promoter. 
 
HIF1 α stabilisation is not reflected in the metabolic profile, as IDH1 mutant cells are 
shown to sustain PDH and oxidative glutamine metabolism in hypoxia. It may 
therefore be possible that 2HG produced by IDH1 mutant-expressing cells directly 
alters mRNA translation. αKG-dependent hydroxylases belong to a large family of 
oxygenase enzymes whose activities are still emerging. Translational hydroxylases 
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involved in protein synthesis are becoming increasingly recognised as an important 
level of gene expression control. To date, three αKG oxygenases have been 
identified as ribosomal protein hydroxylases: OGFOD1, MINA53 and NO66 (Ge et al. 
2012; Loenarz et al. 2014; Singleton et al. 2014). The biological consequences of 
these hydroxylation events remain to be defined. However, MINA53 and NO66 are 
thought to be involved in regulating growth and proliferation (Tsuneoka et al. 2002; 
Sinha et al. 2010). One possible explanation for the partial HIF1α stabilisation and 
transcriptional activity in IDH1 mutant cells, without evidence of metabolic adaptation, 
may be due to the competitive inhibition of αKG-dependent translational 
hydroxylases by the significant production of (R)-2HG, resulting in a block in protein 
translation of HIF1α targets.  
 
Intriguingly, our results also indicate that HIF1α and 2α are differentially stabilised in 
IDH1 R132H and wild-type HOG cells (Figure 3.9A), indicating that different HIF 
prolyl hydroxylases are affected to different degrees by the production of (R)-2HG. 
Increased expression of HIF1α suggests inhibition of PHD2 activity (Berra 2003), yet 
the blunted expression of HIF2α observed in IDH1 R132H cells is indicative that 
PHD1 or PHD3 activity is maintained (Appelhoff et al. 2004). HIF1 and HIF2 are 
capable of eliciting the transcription of different sets of genes, for examples Ca9 and 
PHD3, wherein the former is predominantly HIF1 regulated and the latter HIF2 
regulated, resulting in a differential response between tumour types (Hu et al. 2003; 
Sowter et al. 2003; Raval et al. 2005).  At this stage, it is unclear what the biological 
implications are for this differential HIF regulation in mutant and wild-type IDH1 
tumours. 
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Our results further suggest that increased proline biosynthesis from glutamine 
appears to be a hypoxia-inducible metabolic pathway (Figure 3.12). Increased proline 
is observed in the metabolomics approach in IDH1 wild-type U87 glioma cells when 
exposed to hypoxia (Figure 3.5A), supporting further evidence that proline 
biosynthesis increases in hypoxia. In addition to the significant production of (R)-2HG 
in cells expressing mutant IDH1, it is likely that the change in activity results in an 
alteration in cellular redox state (Dang et al. 2009). Proline biosynthesis from 
glutamine, a highly redox-dependent pathway, is significantly increased in IDH1 
mutant cells regardless of oxygen tension (Figure 3.12). This suggests that IDH1 
mutant cells demonstrate increased proline metabolism, similar to that of hypoxic 
wild-type IDH1 cells. Our results indicate that proline biosynthesis can be used by 
cells as a means to modulate or maintain cellular redox, and in an IDH1-mutant 
background is independent of 2HG production (Figure 3.14B). Increased proline 
biosynthesis is found to decouple TCA cycle activity from the ETC by reducing 
NADH-mediated electron donation to complex I of the respiratory chain (Figure 
3.18E), and is observed through the reduced sensitivity to complex I inhibitors (Figure 
3.20C), and the increased oxygen consumption on inhibition of proline synthesis 
(Figure 3.19D). By providing an alternative mechanism for oxidation of mitochondrial 
NADH, reduced electron flux through the ETC may yield lower ROS generation, and 
decrease oxygen consumption by the mitochondria, perhaps making oxygen more 
available for other metabolic or biological processes. Interestingly, PYCR1 has been 
previously linked to regulation of mitochondrial complex I, mediated through an 
interaction with regulatory protein DJ-1, where knockdown of DJ-1 and PYCR1 
reduced cell viability under conditions of oxidative stress (Yasuda et al. 2013). Such 
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an adaptive redox mechanism could provide a way in which cells regulate oxidative 
metabolism, and therefore oxidative stress in hypoxia (Figure 3.21).  
 
 
Figure 3.21 IDH1 mutations exhibit pseudohypoxic proline metabolism. IDH1 mutations 
increased glutamine derived proline biosynthesis to retain redox plasticity by reducing 
electron donation to complex I of the ETC. Abbreviations: ALDH18A1, pyyroline-5-
carboxylate synthetase; Fum, fumarate; Glu, glutamate; GLDH, glutamate dehydrogenase; a-
KG, α-ketoglutarate; a-KGDH, α-ketoglutarate dehydrogenase; Pro, proline; P5C, pyrroline 
5-carboxylate; PYCR1/2, pyyroline carboxylate reductase 1/2 and Suc, succinate. 
 
Overall, it would appear that IDH1 mutant cells exhibit a “semi-pseudohypoxic” state. 
This results from a lack of adaptation to hypoxia, whereby cells maintain oxidative 
reactions in the absence of oxygen, yet also exhibit hypoxic-like features, such as 
increased glutamine-derived proline biosynthesis in normal oxygen tensions 
(pseudohypoxic proline metabolism). Although the data are not entirely clear, it might 
be inferred that sustained normoxic phenotypes occur as a result of blunted HIF 
transcriptional activity, yet the hypoxic phenotypes occur as a result of hypoxic-like 
redox changes elicited from the presence of the IDH1 mutation. How this benefits the 
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progression of the tumour is unknown. It could be hypothesised that this facilitates 
rapid metabolic plasticity to fluctuating regions of varying oxygen tension and occurs 
from the unstable and chaotic organisation of the tumour-associated neovasculature. 
But, this metabolic plasticity is unsustainable for longer periods of hypoxia, consistent 
with the improved prognosis associated with IDH1 mutant gliomas.  
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Experimental Procedures 
 
Patient information 
The use of patient material was approved by HBRC (Human Biomaterials Resource 
Centre), HTA Research License number 12358, reference for ethical approval 
09/H1010/75 (North West 5 Research Ethics Committee – Haydock Park). GBM 
samples were collected with informed consent from patients at the Queen Elizabeth 
Hospital Birmingham (QEHB) NHS Foundation Trust between 2011 and 2012. 
Immediately following surgical resection, tumour samples were flash frozen and 
stored in liquid nitrogen. All histological diagnoses were confirmed by the Pathology 
department at the QEHB and graded according to 2007 World Health Organisation 
(WHO) classification (Louis et al. 2007).  
 
Cell Lines 
U87 glioma cell line stably transfected with green fluorescent protein (GFP)-tagged 
IDH1 wild-type or R132H mutant were kindly donated by Dr. Pim J. French (Bralten 
et al. 2011). Cells were routinely cultured in DMEM with 10% FBS and 2 mM 
glutamine (all Hyclone Thermo Scientific; SH30081, SV30180.03, and 25030081, 
respectively).  
U87 glioma cell lines were re-selected for the presence of the construct by 
fluorescence activated cells sorting (FACS) to isolate the cells expressing the highest 
GFP levels. For one week following FACS, medium was supplemented to a final 
concentration of 200 units/mL penicillin, 200 µg/mL streptomycin (Thermo Fisher, 
1688253) and 50 µg/mL gentamicin (Sigma-Aldrich, G1397).  
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A cell line derived from a grade III human oligodendroglioma infected with either wild-
type or mutant IDH1 (R132H) by lentivirus, was kindly donated by Professor Hai Yan 
(Reitman et al. 2011). Both HOG IDH1 wild-type and R132H cell lines were cultured 
in high glucose DMEM (Sigma-Aldrich, D5796) supplemented with 10% FBS 
(Hyclone Thermo Scientific, SV30180.03).  
Cell lines were maintained using standard procedures in a 37oC humidified incubator, 
5% CO2 and regularly tested and excluded for mycoplasma contamination using EZ-
PCR Mycoplasma Test Kit, (Geneflow, K1-0210). 
 
Proliferation  
U87 IDH1 wild-type and R132H cells were seeded at 5 x 104 cells in 6-well plates and 
left overnight to adhere to the plate surface under standard conditions. Relevant 
plates were transferred to Don Whitley H35 Hypoxystation set at 1% O2, where the 
media was changed on all wells of all plates. Cell counts were performed 24 h, 48 h, 
72 h and 96 h using Invitrogen Automated Cell Countess®TM (Thermo Fisher, 
C10227).  
 
RNA and Protein Analysis 
Cells were seeded at 1 x 105 onto 6-well plates and left for 24 h. Relevant plates 
were transferred to Don Whitley H35 Hypoxystations set at 1% and 0.3% O2, and left 
for a further 24 h before lysed for protein and RNA to assess gene expression.  
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Quantitative real-time PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, 74104) according to the 
manufacturer’s protocol. 1 µg RNA per sample was subjected to reverse transcription 
using Promega Reverse Transcriptase kits (MMLV-RT, M1701, or AMV-RT, A3500). 
10 µL of the resulting cDNA was used with TaqMan® gene expression master mix 
(AB, 4369016) for quantitative real-time PCR using AB 7500 Real Time PCR System. 
The following primers and probes were purchased from Thermo Fisher Scientific:  
Table 3.1 HIF target genes for quantitative real-time PCR 
Gene Target Product Code 
LDHA (Hs00855332_g1) 
PGK1 (Hs00943178_g1) 
PDK1 (Hs00176853_m1) 
SLC2A1 (Hs00892681_m1) 
PYCR1 (Hs01048016_m1) 
PYCR2 (Hs01016460_gH) 
ALDH18A1 (Hs00913261_m1) 
 
The expression of all genes targets were normalised to beta actin (ACTB) as 
housekeeping gene. Comparative analysis across samples was calculated using the 
2-ΔΔCT method. 
 
Immunoblotting 
Cells were washed with 1x PBS and lysed directly into 100 µL 1x Laemmli buffer 
(Sigma-Aldrich, S3401-1VL), heated at 100oC for 10 min, and loaded on 
polyacrylamide gels for SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel 
electrophoresis). Proteins were separated under reducing denaturing conditions, 
using the mini-PROTEAN Tetra System (BIO-RAD), and transferred 
electrophoretically onto 0.1 µm nitrocellulose membrane (GE Healthcare, 
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10600000) at 100 V for 75-90 min. Blots were blocked in 1x PBS with 0.05% 
Tween-20 (PBST) buffer containing 5% (w/v) non-fat skimmed dry milk powder 
(Marvel) for 1 h, and then incubated with the specific primary antibody of interest 
(table below) diluted in blocking buffer at 4oC overnight (excluding anti-β-actin, 
which was incubated for 1.5 h at room temperature). All antibodies were diluted in 
5% milk with the exception of HIF1α, which was diluted in 1% milk. Membranes 
were washed three times in PBST and incubated with the relevant horseradish 
peroxidase (HRP)-conjugated secondary antibody diluted in 5% milk for 1 h at room 
temperature. Membranes were washed three times and developed using EZ-ECL 
enhanced chemiluminescence detection kit (BI, 20-500-120). Luminescence was 
visualised using Amersham HyperfilmTM (GE HealthCare, 28906836), which was 
subsequently developed (SRX 101A Konica Minolta). All western blots are 
representative of at least two experiments unless otherwise indicated. 
Table 3.2 Primary antibodies employed for immunoblotting 
Primary 
Antibody 
Company  Product 
Code 
Species Dilution Mw 
Anti-β-actin Sigma A4700 Mouse 1:4000 42 kDa 
Anti-IDH1 
R132H 
Dianova DIA-H09 Mouse 1:500 48 kDa 
Anti-HIF1α BD Biosciences, 
UK 
610959 Mouse 1:500 120 kDa 
Anti-HIF2α Novus 
Biologicals 
NB100-122 Mouse 1:500 120 kDa 
Anti-PYCR1 Proteintech 13108-1-AP Rabbit 1:5000 34 kDa 
Anti-PYCR2 Proteintech 17146-1-AP Rabbit 1:1000 34 kDa 
 
Table 3.3 Secondary antibodies employed for immunoblotting 
Secondary Antibody Company Product Code Dilution 
Anti-mouse Cell Signalling #7076 1:4000 
Anti-rabbit Cell Signalling #7074 1:4000 
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RNA Silencing 
To assess the knockdown in expression of PYCR1 and PYCR2, cells were seeded at 
8 x 104 onto 12-well plates in standard culture conditions. After 24 h, cells were 
transfected following manufacturer’s instructions with non-targeting RNA (siNT) and 
siRNA targeting PYCR1 (siPYCR1) and PYCR2 (siPYCR2) (Dharmacon ON-
TARGETplus human siRNA; D-001810-10, L-012349-00 and L-016646-00, 
respectively) at 25 nM using DharmaFECT 1 transfection reagent (Thermo Fisher 
Scientific, T2001-01). 
24 h, 48 h and 72 h post transfection, cells were lysed for protein to evaluate 
efficiency of gene knockdown. All transfections were carried out 24 h post seeding 
and all experiments were subsequently terminated approximately 48 h from 
transfection.  
 
NAD(P)H Autofluorescence 
HOG cells were seeded at 0.2 x 105 onto 8-well chamber slides (Thistle Scientific, IB-
80826) under standard culture conditions and transfected 24 h later with targeting 
and non-targeting siRNA against PYCR1 before NAD(P)H imaging 48 h later using a 
Zeiss UV Axiovert confocal autofluorescence captured at l = 285-470 nm using a 
photomultiplier tube (PMT) (1024 x 1024 pixels; 12-bit). CCCP 20 µM (Sigma-Aldrich, 
C2759) and rotenone 60 µM (Sigma-Aldrich, R8875) were added to each well to 
achieve basal and maximal NAD(P)H autofluorescence, respectively. User-blinded 
offline analysis was performed using Fiji software (http://fiji.sc/) and 48-126 random 
visual fields were considered per experimental condition. To prevent re-oxygenation 
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of hypoxic samples, slices were sealed with parafilm and imaged within 15 min of 
removal from 1% O2. 
 
Oxygen Consumption Measurements 
Cells were seeded at 2 x 105 onto 6-well plates in standard culture conditions and 
were transfected 24 h later with targeting siRNA against PYCR1 and PYCR2. 
Oxygen consumption measurements were made using a Clark-type oxygen electrode 
(Oxytherm, Hansatech Instruments, Norfolk, UK) that measures oxygen 
concentration in a sealed chamber. The cells were harvested and resuspended in 
complete media.  4 x 105 cells in 300 µl were added to the electrode chamber and the 
oxygen consumption rate was measured over a 5 min period using Oxygraph 
software (http://www.hansatech-instruments.com/).  Cells were kept in suspension 
using a stirring bar and the chamber temperature was maintained at 37°C through 
the use of a solid-state heating block. After recording for 5 min, KCN 700 µM (Sigma-
Aldrich, 60178) was added to the electrode chamber to inhibit cellular respiration and 
the oxygen consumption was measured for a further 3 min.  
The final respiration rate was obtained by subtracting the oxygen consumption rate in 
presence of KCN to the oxygen consumption rate in the absence of KCN.  
 
SRB assay 
Cells were fixed in 20% (v/v) ice-cold trichloroacetic acid solution (TCA) (Sigma-
Aldrich, T0699) for 30 min at 4oC. Plate wells were washed with water and once dry, 
intracellular protein was stained using 0.4% (w/v) sulfohodamine B (SRB) (Sigma-
Aldrich, 230162) in 1% acetic acid for 10 min at room temperature. After washing with 
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1% acetic acid to reduce non-specific staining, SRB was dissolved in 50 mM Tris/HCl 
pH 8.8 once dry. 100 µL/well was aliquoted for quantification by absorbance at 495 
nm on FLUOstar Omega (BMG LabTech).  
Final sample absorbance values were determined by calculating the mean blank-
corrected absorbance for each replicate, where 50 mM Tris/HCl pH 8.8 alone was 
used as the blank. 
 
Hydrogen Peroxide 
HOG cells were seeded at 4 x 104 onto 24-well plates in standard culture conditions 
and incubated for 24 h. Cells were dosed with H2O2 concentrations of 10, 50, 100, 
300 and 500 µM and incubated for 24 h to determine the IC50 before fixing using the 
SRB method. 
The effect of H2O2 treatment on cell viability was assessed by dosing the above plate 
format with 100 µM H2O2 24 h post transfection using targeting siRNA against 
PYCR1 and PYCR2. Cells were treated with H2O2 for 24h before fixing using the 
SRB method. 
 
Rotenone  
HOG cells were seeded at 4 x 104 onto 24-well plates in standard culture conditions 
and incubated for 24 h. Cells were dosed with rotenone concentrations of 10, 50, 
100, 300 and 500 nM to determine the IC50 and incubated for 24 h before fixing 
using the SRB method. 
The effect of rotenone treatment on proliferation was assessed by dosing the above 
plate format with 10 nM and 50 nM rotenone 24 h post seeding in normoxia and 
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hypoxia (1% O2). Cells were incubated with rotenone for 24, 48 and 72 h. At each 
time-point, cells were fixed, stained and analysed using the SRB method. 
 
Metabolomics 
In collaboration with Warwick Dunn 
Tissue: ~50 mg (+/-10 mg) tumour tissue was weighed and homogenised using 
Precellys®24 at 6,800 Hz for 2 x 30 s cycles. Metabolites were extracted in 850 µL 
methanol (-20oC): chloroform (-20oC) (1:1) and shaken for 10 min at 4oC, before 
placed on ice for 10 min. 425 µL pre-chilled water was added and left on ice for a 
further 10 min, before centrifugation at 13,500 x g for 15 min. The “sample weight 
normalised” volume of polar and non-polar extract phase was calculated using the 
following formulae:  
“Sample weight normalised volume” = (maximum volume/ minimum weight sample) x 
sample weight. 
QC samples were prepared by mixing ‘sample weight normalised’ volumes for each 
sample. Polar extracts were dried by speed vacuum concentration for 5 h at 35oC. 
Non-polar extracts dried under nitrogen gas stream. 
Cell: U87 IDH1 wild-type and R132H cells were seeded at 1 x 106 in standard culture 
conditions and left overnight. Relevant cell plates were transferred to Don Whitley 
Hypoxystation set at 1% O2 the following day and subjected to 24 h of normoxia or 
hypoxia (n=6 per sample class). Cells were washed x3 with ice-cold 1x PBS and 
scraped in pre-chilled methanol (-20oC), chloroform (-20oC) and water (4oC) in 1:1:1 
ratio. Cell lysates were vortexed for 15 min at 4oC and immediately centrifuged at 
15,000 x g for 15 min at 4oC. The total recoverable volume (550 µL) of the polar 
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extract (after removal of aliquots for QC) was split for analysis by GC-MS. Polar 
extracts were dried by speed vacuum concentration for 6 h at 30oC. 
 GC-MS: Dried polar extracts were derivatised by adding 50  µL of 20 mg/mL solution 
of methoxylamine in pyridine, vortex mixing and heating at 60oC for 30 min. 50 µL of 
N-methyl-N-trifluoroacetamide was added followed by vortex mixing and heating at 
60oC for 30 min. 20 µL retention index marker solution (1 mg/mL C10, C12, C15, C19, 
C22 n-alkanes) was added prior to centrifugation. The resulting supernatant was 
transferred to GC-MS vials for analysis. 
Derivatised polar samples were analysed by GC-MS using an Agilent 6890 gas 
chromatograph (Agilent Technologies, Stockport, U.K.) coupled to a LECO Pegasus 
III (Leco Corp., St. Joseph, MO) electron ionisation time-of-flight mass spectrometry 
(EI-TOF-MS) in a randomised sample order for analysis. Following a derivitisation 
blank, QC samples were analysed for the first two injections and every fourth and fifth 
injection respectively. The GC-MS parameters have been previously described (Dunn 
et al., 2011). 
Data were pre-processed using the ChromaTOF v3.25 software package and 
metabolites assigned, as described in (Armitage et al. 2015). Data were normalised 
to total peak area for each sample followed by statistical analysis applying non-
parametric Mann Whitney U tests or Kruskal-Wallis test. PCA analysis Partial Least 
Squares Discriminate (PLS-DA) in the freely available package MetaboAnalyst (Xia 
et al., 2012). 
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Isotope Tracing 
Basic formulation DMEM media (Sigma, D5030) was supplemented with the relevant 
tracer [U-13C6]-D-glucose (Sigma, 389374) or [U-13C5]-L-glutamine (Sigma, 605166) 
at 10 mM and 2 mM respectively, along with the same concentration of 
corresponding unlabelled glutamine and glucose. All tracing experiments were 
conducted for 24 h and commenced 24 h post seeding.  
 
NMR Spectroscopy 
4 x 106 HOG cells were plated onto 15 cm dishes and cultured in standard medium 
overnight. Relevant cell plates were transferred to Don Whitley Hypoxystations (set at 
both 1% and 0.3% O2) the following morning. Media was replaced with basic 
formulation DMEM (Sigma-Aldrich, D5030) supplemented with 10% FBS, 10 mM [U-
13C6]-D-glucose (Sigma-Aldrich, 389374) or 2mM [U-13C5]-L-glutamine (Sigma-
Aldrich, 605166) for a further 24 h before extraction. 
Cells were washed x3 with ice-cold 0.9% saline solution and scraped in 1.2 mL pre-
chilled methanol (-20oC), water (4oC) and chloroform (-20oC) in a 1:1:1 ratio. Cell 
lysates were vortexed for 15 min at 4oC and immediately centrifuged at 15,000 x g for 
15 min at 4oC. The polar fraction was aliquoted and evaporated to dryness using a 
SpeedVac concentrator for 5h at 30oC. Extraction was performed on three different 
cultures for each labelling experiment.  
Dried samples were resuspended in 60 µL of 100 mM sodium phosphate buffer 
containing 500 µM DSS (4,4-dimethyl-4-silapentane-1-sulphonic acid) and 2 mM 
Imidazole, 10% D2O, pH 7.0. Samples were vortexed, sonicated (5-15 min) and 
149	
	
centrifuged briefly, before transferred to 1.7 mm NMR tubes using an automated 
Gilson 215 Liquid Handler (Bruker Biospin).  
1D-1H NMR spectra and 2D-1H,13C-HSQC NMR spectra were acquired using a 600-
MHz Bruker Avance III spectrometer (Bruker Biospin, UK) with a TCI 1.7 mm z-PFG 
cryogenic probe at 300 K. Spectral widths were set to 7,812.5 and 24,155 Hz for the 
1H and 13C dimensions, respectively. 16,384 complex data points were acquired for 
the 1D-NMR spectra and 512 complex data points were acquired for the 1H 
dimension of 2D-1H,13C-HSQC NMR spectra. An exponentially weighted non-uniform 
sampling scheme was used for the indirect dimension. Here, 30% of 8,192 complex 
data points (2,458) were acquired. 128 transients were recorded for the 1D-NMR 
spectra with a relaxation delay of 4 s, and two transients were recorded for the 2D-
1H,13C-HSQC NMR spectra with a relaxation delay of 1.5 s. Each sample was 
automatically tuned, matched and then shimmed (1D-TopShim) to a DSS line width 
of <2 Hz prior to acquisition of the first spectrum. Total experiment time was ~15 min 
per sample for 1D-1H NMR spectra and 4.5 h per sample for 2D-1H,13C-HSQC NMR 
spectra. 1D-1H NMR spectra were processed using the MATLAB-based MetaboLab 
software (Ludwig & Günther 2011). All 1D data sets were zero-filled to 131,072 data 
points before Fourier Transformation. The chemical shift was calibrated by 
referencing the DSS signal to 0 p.p.m. 1D-spectra were manually phase corrected. 
Baseline correction was achieved using a spline function (Ludwig & Günther 2011). 
1D-1H NMR spectra were exported into Bruker format for metabolite identification and 
concentration determination using Chenomx 7.0 (ChenomxINC). 2D-1H,13C-HSQC 
NMR spectra were reconstructed using compressed sensing in the MDDNMR and 
NMRpipe software (Delaglio et al. 1995; Kazimierczuk & Orekhov 2011; Orekhov & 
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Jaravine 2011). The final spectrum size was 1,024 real data points for the 1H 
dimension and 16,384 real data points for the 13C dimension. Analysis was 
performed using MetaboLab and pyGamma software was used in multiplet 
simulations (Smith et al. 1994). The methyl group of lactate was used to calibrate the 
chemical shift based on its assignment in the human metabolome database (Wishart 
et al. 2013). 
GC-MS  
GC-MS analysis in collaboration with Christian Metallo 
HOG cells were seeded at 1 x 105 in 6-well plates and cultured in standard medium 
overnight. Hypoxic plates were transferred to Don Whitley Hypoxystation set at 1% 
O2 the following morning. 24 h post seeding, cells were cultured for a further 24 h, in 
either normoxia and hypoxia, in glucose or glutamine free DMEM (Sigma-Aldrich, 
D5030) containing 10% FBS and supplemented with the appropriate tracer - 10mM 
[U-13C6]-D-glucose (Sigma-Aldrich, 389374) or 2mM [U-13C5]-L-glutamine (Sigma-
Aldrich, 605166).  
At the conclusion of tracer experiments, culture media was aspirated and cells 
washed twice with 0.9% NaCl saline solution. Cellular metabolites were extracted in 
methanol (-20oC): water (4oC): chloroform (-20oC), where 1 µg/well DL-norvaline 
(Sigma-Aldrich, N7502) was employed as internal standard in the polar fraction. 
Samples were vortexed at 4oC for 30 min and subsequently centrifuged at 14,000 x g 
for 15 min at 4oC. The polar fraction was aliquoted and dried by speed vacuum 
concentration at 2,000 RPM for 4h at 30oC.  
Polar metabolites were derivatised to form methoxine-TBDMS derivatives by 
incubation with 2% methoxyamine hydrochloride (Sigma-Aldrich, 226904) dissolved 
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in PierceTM pyridine (Thermo Fisher Scientific, 25104) at 37oC for 1-1.5 h followed by 
addition of MTBSTFA with 1% TBDMCS (Sigma-Aldrich, 375934) incubated at 37oC 
for 30-60 min (Metallo et al. 2011)(Lewis et al. 2014). 
Derivatised polar samples were analysed by GC-MS using an Agilent 7890B gas 
chromatograph equipped with a 30 m DB-35MS capillary column (30 m x 0.25 mm 
internal diameter x 0.25 µm) connected to an Agilent 5977A mass spectrometer. 
MIDs were determined by integrating metabolite ion fragments and corrected for 
natural abundance (Fernandez et al. 1996).  
Metabolite ion counts were normalised to norvaline and cell number to normalise for 
varying derivatisation efficiency and varying metabolite concentrations, respectively. 
 
GC-MS analysis in collaboration with Karsten Hiller 
HOG cells were seeded at 2 x 105 onto 6-well plates in standard culture conditions. 
After 24 h, cells were transfected with 25 nM non-targeting RNA (siNT) and siRNA 
targeting PYCR1 (siPYCR1) and PYCR2 (siPYCR2). After overnight incubation, 
relevant plates were transferred to hypoxia (1 % and 0.3% O2), where 24 h post 
transfection, media was changed to basic formulation DMEM (Sigma-Aldrich, D5030) 
containing 10% FBS and supplemented with 2mM [U-13C5]-L-glutamine (Sigma-
Aldrich, 605166) for a further 24 h. 
At the conclusion of tracer experiments, culture media was aspirated and cells 
washed twice with ice-cold 0.9% NaCl solution. Cellular metabolites were extracted in 
methanol (-20oC): water (4oC) containing 1 µg/mL d6-glutaric acid (C/D/N ISOTOPES 
INC, D-5227): chloroform (-20oC). Extracts were shaken at 1,400 rpm for 20 min at 
4oC and centrifuged at 16,000 x g for 5 min at 4oC. The polar fraction was aliquoted 
152	
	
and evaporated in GC glass vials under vacuum at -4oC using a refrigerated 
CentriVap Concentrator (Labconco). 
Metabolite derivatisation was performed using an Agilent autosampler. Dried polar 
metabolites were dissolved in 2% methoxyamine hydrochloride (Sigma-Aldrich, 
226904) dissolved in pyridine (Thermo Fisher Scientific, 25104) at 45oC. After 1 h, an 
equal volume of MSTFA (N-methyl-N-(trimethylsilyl)trifluoroacetamide) + 1% TMCS 
(chloro-trimethyl-silane) (ThermoFisher Scientific, TS-48915) was added and 
metabolites were incubated for 30 min at 45oC.  
Derivatised polar extracts were analysed by GC-MS using an Agilent 6890 gas 
chromatograph equipped with a 30 m DB-35MS capillary column (30 m x 0.25 mm 
internal diameter x 0.25 µm). The gas chromatograph was connected to an Agilent 
5975C mass spectrometer. For MID determination, spectra were corrected for natural 
isotope abundance. Data processing from raw spectra to MID correction and 
determination was performed using MetaboliteDetector software (Hiller et al. 2009). 
Metabolite ion counts were normalised to d6-glutaric acid and cell number to 
normalise for varying derivatisation and varying metabolite concentrations, 
respectively. 
Statistical Analysis 
Samples sizes and reproducibility for each figure are denoted in the figure legends. 
Unless otherwise noted, all experiments are representative of at least three 
biologically independent experiments performed in technical triplicate. All error bars 
represent mean +/- S.E.M. Statistical significance was determined by either a one-
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way ANOVA or two-tailed Student’s t-test using GraphPad Prism 6, where *P < 0.05; 
**P < 0.01; and ***P < 0.001. 
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Chapter 4 DISCUSSION 
 
Cancer cells reprogram their energy metabolism to enable rapid proliferation and to 
adapt to changes in their microenvironment. The identification of mutations in 
metabolic enzymes SDH, FH and IDH have not only shown that malignant 
transformation can occur as a direct result to changes in normal metabolism, but 
have emphasised the importance of hypoxia-induced metabolic reprogramming in 
driving this malignancy. Further understanding of how mutations in SDH, FH and IDH 
control metabolism, and how metabolism changes in response to hypoxic stimuli, 
may therefore elicit the design of new selective therapies.  
 
The research presented highlights novel mechanisms whereby cancer cells with 
mutations in metabolic enzymes SDH and IDH rewire their metabolism to support 
both the demands of cellular anabolism and the maintenance of redox homeostasis 
for proliferation and viability. In particular, it reveals a metabolic vulnerability relevant 
in SDH-deficient cells that could be efficacious for the treatment of other tumours 
harbouring these mutations. It additionally characterises a novel, redox-sensitive 
metabolic pathway common to both pseudohypoxic IDH1 and SDHB mutated cells 
that plays a critical role in maintaining metabolic plasticity. 
 
Pyruvate carboxylase is a metabolic vulnerability associated with SDH 
deficiency  
A key question this thesis addresses is how cells deficient in SDHB maintain 
proliferation and viability in PGL/PCC. Our published results (see Appendix - 
D)(Lussey-Lepoutre et al. 2015), along with another recent publication (Cardaci et al. 
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2015), demonstrate that loss of SDH activity results in an increased dependency on 
PC for endogenous aspartate synthesis. With limited means by which these cells can 
make aspartate in the absence of a fully functional TCA cycle, the proliferation-driven 
demand for aspartate exceeds supply. Aspartate is required for the synthesis of two 
major classes of macromolecules: proteins and polynucleosides. In addition to its 
obvious contribution to protein synthesis, it is required for the de novo synthesis of 
arginine and asparagine, the conversion of inosine monophosphate (IMP) to 
adenosine monophosphate (AMP) in de novo purine synthesis and the carbon 
backbone for de novo pyrimidine synthesis. Owing to a block in TCA cycle activity, 
PC-mediated aspartate biosynthesis is likely to determine the anabolic and 
proliferative state of the cell. Dysregulation of PC activity has been shown to extend 
to other disease areas, such as renal cancer (Cardaci et al. 2015), non-small lung 
cancer (Sellers et al. 2015) and diabetes (Kumashiro et al. 2013), and may be 
compatible with mutations in other TCA cycle intermediates, as predicted to be the 
case with loss of FH activity (Frezza et al. 2011).  
 
Inhibiting PC-mediated de novo aspartate biosynthesis in SDH-mutated 
tumours 
Increased PC activity highlights a metabolic vulnerability specific to SDH-mutated 
tumours and thus represents a valid therapeutic target. PC is an enzyme that is 
amenable to a number of different approaches for inhibitor design. Examples include; 
disrupting the interaction with biotin, use of carboxyphosphate or ATP analogues, 
employing pyruvate structural analogues, or decreasing the availability of positive 
allosteric regulators such as acetyl CoA (Jitrapakdee et al. 2008). However, a 
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problem with all the above drug design approaches is the ubiquitous nature of PC, 
leading to theoretical selectivity arguments with other metabolic pathways, and 
resulting in numerous off-target effects. This makes PC in itself a difficult therapeutic 
target. As SDH deficient tumours are dependent upon endogenous production of 
aspartate for nucleotide synthesis, it could be feasible to target other aspects of the 
aspartate biosynthetic pathway. Our results demonstrate that SDH-mutated PCC also 
significantly up-regulates expression of the glutamate-aspartate antiporter, as well as 
the transaminase responsible for converting oxaloacetate to aspartate in the 
mitochondria (GOT2) (data not shown). The low levels of aspartate detected in SDH-
mutated tumours, may imply that mild inhibition of aspartate aminotransferases, such 
as GOT2, may be more effective in limiting proliferation.  
 
Increased malignancy of mutations in SDHB and use of the serine synthesis 
pathway 
The potential phenotypic similarities and differences in cancer cells harbouring 
mutations in other SDH subunits has not yet been investigated. Furthermore, results 
do not yet indicate why mutations in SDHB are associated with increased malignancy 
when compared to other SDHx mutated tumours. The basis for increased malignancy 
with loss of SDHB has previously been speculated by several groups. One of the few 
studies to examine the differential effects of deficiencies in the various SDH subunits 
suggested that RNAi-mediated reduction in the expression of SDHB led to increased 
mitochondrial ROS production (Guzy et al. 2008) and is perhaps is the basis for 
increased malignancy associated with mutated SDHB tumours. A subsequent study 
reported significantly greater hypermethylation in SDHB tumours when compared to 
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mutations in other SDH subunits, resulting in greater epigenetic silencing of genes 
involved in neuroendocrine differentiation and epithelial-mesenchymal transition 
(EMT) (Letouzé et al. 2013). It therefore poses an interesting speculation as to 
whether mutations in other SDH subunits show the same increase in de novo serine 
synthesis from glucose and subsequent catabolism, as high activity within this 
pathway has been recently associated with metastasis (Piskounova et al. 2015), and 
could be used to support the demand for mitochondrial NADPH and/or one-carbon 
groups for DNA and histone methylation. 
 
Proline biosynthesis maintains cellular redox plasticity in tumours 
A significant finding consistent for both SDH and IDH1 mutations was the increased 
biosynthesis of proline from glutamine, which also appeared to be a feature of 
hypoxic cells. The catabolism of glucose and glutamine in cancer cells is used not 
only for cellular anabolism, but also to maintain redox homeostasis. Well-
characterised examples of metabolic pathways that support cellular redox include i) 
increased lactate production to regenerate NAD+, which is reused by GAPDH to 
sustain glycolysis, cytosolic NADPH production, either by ii) the recycling of glucose 
through the PPP, and/or iii) the activity of cytosolic ME, which uses glutamine carbon 
to form pyruvate from malate. Thus, other less explored biosynthetic pathways could 
affect the reducing potential in cancer cells, such as the redox sensitive biosynthesis 
of proline from glutamine. However, this biosynthetic pathway has not as yet been 
characterised as having a role in maintaining cellular redox plasticity in cancer cells.  
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Our results demonstrate that proline anabolism increases in response to redox stress 
in hypoxic environments and in conditions of pseudohypoxia experienced by cells 
harbouring mutations in either SDH or IDH1. An increased ratio of NADH/NAD+ is 
likely to increase proline biosynthesis in order to maintain redox homeostasis by 
oxidising mitochondrial NADH, which would otherwise be oxidised by the ETC to 
ultimately reduce oxygen to water. As the activity of the ETC impacts cellular 
processes such as apoptosis and levels of ROS in cells, increased proline 
biosynthesis may therefore modulate/regulate these activities. Furthermore, use of 
this pathway could make more oxygen available for other biological purposes, which 
would benefit cells in environments where oxygen supply is limited. Our findings may 
therefore demonstrate a novel redox-sensitive mechanism by which mutations in 
metabolic enzymes promote tumorigenesis.  
 
Other tumour suppressors and oncogenes have been shown to regulate proline 
metabolism. For example, oncogenic MYC stimulates glutamine-derived proline 
biosynthesis by coordinating the increased expression of GLS and proline 
biosynthetic enzymes P5C synthetase (P5CS) and the PYCRs, in addition to 
suppressing the enzymes involved in proline catabolism, proline dehydrogenase 
(PRODH) and P5C dehydrogenase (P5CDH) (Liu et al. 2012). Interestingly, PRODH, 
the first enzyme in proline catabolism, is regulated by tumour suppressor p53 to block 
cell cycle progression and induce apoptosis through the generation of mitochondrial 
ROS (Donald et al. 2001). As PRODH is usually down-regulated in tumours (Liu et al. 
2009), the increased PYCR activity exhibited in SDH and IDH mutated cells is likely 
to result in production of proline, consistent with increased concentrations of 
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intracellular (Figure 3.12C) and extracellular (Figure 2.16B and 3.12D) proline. It may 
also be possible that PYCR1 is the major enzyme involved in proline biosynthesis, 
since PYCR2 is most product-inhibited (De Ingeniis et al. 2012). Indeed, PYCR1 
gene expression is significantly increased in SDH-mutated PCC (Figure 2.17) and 
IDH1 LGG and GBMs (Figure 3.14C and 3.14D). Increased PYCR1 has also been 
identified in prostate cancer (Ernst et al. 2002), melanoma (De Ingeniis et al. 2012) 
and breast carcinoma (Possemato et al. 2011).  
 
Previous reports have suggested that cells expressing mutant IDH1 are more 
sensitive to pharmacological inhibitors of complex I in the ETC (Grassian et al. 2014). 
Our results may contradict these findings, as the increased anabolism of proline 
observed in IDH1 mutant cells reduced NADH availability for complex I of the ETC, 
rendering these cells less sensitive to treatment with rotenone (Figure 3.20C). Given 
our results suggesting the role of increased proline biosynthesis in IDH1 mutant cells 
to promote redox plasticity, targeting aspects of this pathway, such as the PYCR 
isozymes, could be more therapeutically efficacious.  
 
IDH1 mutations induce a “semi-pesudohypoxic” state 
Consistent with these previous reports, we observe that IDH1 mutated cells maintain 
oxidative reactions in low oxygen environments (Grassian et al. 2014), in addition to 
hypoxic-like proline metabolism. Although the data are not entirely clear thus far, we 
suggest that the sustained oxidative phenotypes in IDH1 mutant cells in hypoxia 
occur as a result of blunted HIF transcriptional activity, yet the hypoxic-like 
biosynthesis of proline occurs as a consequence of hypoxic-like redox changes due 
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to the expression of the mutated IDH1 protein. How this benefits the progression of 
the tumour is yet unknown. It could be possible that this facilitates rapid metabolic 
plasticity to fluctuating regions of varying oxygen tension, which occur as a result of 
the unstable and chaotic organisation of the tumour-associated neovasculature, but 
are unsustainable for longer periods of hypoxia. Indeed, IDH mutations occur at high 
frequency in LGGs which lack hypoxia-induced necrosis and microvascular 
proliferation (Svensson et al. 2011; Rong et al. 2006). The partial lack of metabolic 
adaptation and inability to survive longer periods of hypoxia may account for the 
improved prognosis observed in these tumour types (Parsons et al. 2008).  
 
In hypoxia, the suspected increase in mitochondrial NADH/NAD+ is thought to arise 
as a result of decreased ETC activity. Whilst this may be the case for SDH deficient 
cells, our results show that IDH1 mutant cells retain a similar oxygen consumption 
rate to their wild-type counterparts in normoxia, suggesting that this putative increase 
in NADH/NAD+ is influenced by pathways that deplete NAD+ rather than affect the 
rate at which NADH is oxidised. Such examples include the activity of NAD+-
dependent sirtuins and/or poly ADP ribose polymerases (PARP), which may be 
further supported by the significant changes of nicotinamide levels detected between 
in wild-type and IDH1 mutant cells and tissues, as identified from the metabolomics 
approach (Figure 3.2 and 3.5). 
 
The differential role of oncometabolites in HIF biology 
Unlike SDH and FH deficient tumours, where the accumulation of succinate and 
fumarate unambiguously result in HIFα stabilisation and the subsequent 
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development of a pseduohypoxic phenotype, the effect of (R)-2HG production in 
IDH1 mutant gliomas appears to have an ambiguous yet intriguing effect. To date, it 
has been shown that the oncometabolites succinate and fumarate inhibit all αKG-
dependent dioxygenases studied. However, opposing reports exist in the literature 
regarding the role of (R)-2HG, particularly in the regulation of the HIF hydroxylases 
(Zhao et al. 2009; Koivunen et al. 2012). Our data highlights differential stabilisation 
of HIF1α and HIF2α in IDH1 R132H-expressing oligodendroglioma cells, which imply 
that (R)-2HG differently affects HIF hydroxylase activity. Despite observable HIF1α 
stabilisation in IDH1 mutant cells, the presence of the IDH1 R132H mutation appears 
to partially compromise the metabolic adaptation to hypoxia, possibly indicative of a 
block in protein translation accounted for by inhibition of αKG-dependent translational 
hydroxylases. As αKG-dependent dioxygenases belong to a large family of 
hydroxylases involved in multiple biological processes, there may therefore be a 
plethora of differential effects caused by the accumulation of (R)-2HG, which are yet 
to be explored. There remains much to be derived from the role of (R)-2HG in HIF 
biology, which could extend to further αKG-dependent dioxygenases, and the 
implications for these in cancers in which IDH1 mutations are present.  
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